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ABSTRACT 
 
Epstein-Barr virus (EBV) is associated with B- and epithelial cell malignancies.  It is also 
associated with lymphoproliferations and malignancies of T- and natural killer (NK) cells.  The 
global impact of these conditions is significant, and although rare, they are aggressive and are 
often resistant to treatment.  Diagnosis is often delayed, and evidence-based treatment 
strategies are limited due to their rarity.   
Viral gene expression in extranodal T- and NK-cell lymphoma (ENKTL), chronic active Epstein-
Barr virus (CAEBV) and haemophagocytic lymphohistiocytosis (HLH) is limited.  The viral latent 
membrane proteins LMP1, LMP2A and LMP2B have growth-transforming properties in B- and 
epithelial cells.  Their effects on cellular gene expression in primary NK cells include pathways 
involved in cell cycle and stress responses.  LMP1 and LMP2B expression by ENKTL and CAEBV 
cell lines is associated with increased survival in the absence of relevant growth factors, but also 
with increased susceptibility to apoptosis.  This cannot be fully explained by variation in the 
expression of proteins involved in the intrinsic apoptotic pathway. 
Finally, we describe PrimeFlow RNA, a new protocol for identification of the EBV-infected 
lymphocyte subset.  Importantly, this technique means that we can begin to identify druggable 
targets on the EBV-infected cells directly from patient blood samples. 
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CHAPTER 1 - INTRODUCTION 
 
1.1  Epstein Barr virus 
 
Epstein-Barr virus (EBV), a member of the gammaherpes virus subfamily, is characterised by 
high prevalence (>95%) within the adult human population, lifelong asymptomatic infection, 
low pathogenicity in the majority of infections and oncogenicity in a minority of cases.  It is 
associated with a wide range of conditions ranging from the relatively benign (infectious 
mononucleosis), to association with at least 9 human malignancies.  As well as cancer, EBV can 
play a driving role in the inflammatory conditions haemophagocytic lymphohistiocytosis (HLH) 
and chronic active EBV (CAEBV), and is associated with multiple sclerosis (MS) and chronic 
fatigue syndrome. 
 
The history of EBV 
The story of the discovery of EBV has passed into folklore as an example of serendipity in 
science.  Denis Burkitt, a young Irish surgeon working in Uganda, described a childhood tumour, 
Burkitt lymphoma (BL), predominantly affecting the jaw.  In an attempt to map its distribution 
within the country, he surveyed medical units throughout Africa and determined that the 
disease was not seen at altitudes above 5000 feet.  In order to further clarify the situation, he 
toured the hospitals at the south-eastern tail of the tumour distribution – his famous “tumour 
safari” - and determined that the critical environmental variable for the tumour was 
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temperature, rather than altitude, as the “safe” altitude diminished as they travelled further 
from the equator (1), as shown in figure 1-1. 
 
Figure 1-1 - A. Distribution of endemic Burkitt lymphoma in Africa (from (1)) B. Distribution of holoendemic malaria in Africa 
(2).  
This raised the possibility of an arthropod-borne disease, and it is now known that endemic BL is 
associated with holoendemic malaria, although the precise mechanism for the association 
remains unclear.  However, during the quest for the infectious agent, in 1961 Anthony Epstein, 
an enthusiastic young pathologist, listened to a lecture by Burkitt and became intrigued by the 
as-yet-unknown virus.  He was first able to see the virus by electron microscopy in cultured cell 
lines derived from Burkitt lymphoma (BL) biopsies (3).  The presence of a transmissible 
oncogenic agent was demonstrated when co-culture with irradiated Burkitt cells resulted in the 
immortalisation of primary lymphocytes (4).  Finally, viral DNA was demonstrated in fresh 
tumour tissue (5), confirming its presence in the tumour in vivo. 
 
A B 
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Structure of the virus 
EBV is a member of the herpesvirus family, which is subdivided into α, β and γ subclasses; EBV 
together with Kaposi Sarcoma herpesvirus (KSHV) belong to the latter group. 
 
 
 
Figure 1-2 – Schematic diagram of the structure of the EBV virion.  The viral genetic material is wound around a protein core; 
this is surrounded by a nucleocapsid, then a tegument, and the whole is contained within a virus envelope studded with 
glycoproteins.  
The core of the virus is composed of a doughnut-shaped protein core containing the viral 
genetic material, linear double-stranded 184 kilobase pair (kbp) DNA (dsDNA).  The DNA is 
contained within a nucleocapsid made of 162 capsomers surrounded by a protein tegument and 
all contained within the virus envelope (6).  The envelope is derived from the plasma membrane 
of the infected cell and is embedded with the glycoproteins gp350, gp42, gH/gL and gB (7) (see 
figure 1-2).  At each end of the linear DNA is a terminal repeat (TR) region consisting of 4-12 
copies of a 500bp tandem, reiterated sequence.  When the viral DNA enters the target cell 
    
 
 
 
 
 
 
 
 
  
  
DNA core 
Glycoproteins 
Capsid 
Tegument 
Envelope 
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nucleus, the DNA circularises by recombination of these terminal repeats generating the 
characteristic episomal viral DNA with subtly different sizes of terminal repeats (see figure 1-3) 
(8, 9).  When infected cells replicate, the episome is also faithfully replicated so that each 
daughter cell will contain identical episomes (10); this can be exploited to demonstrate clonality 
of the infected cells.  This is particularly useful when considering EBV-associated malignancies, 
(see section 1.2). 
 
Figure 1-3 - Structure of the EBV genome.Capital letters are used to designate BamH1 fragments, small arrows represent 
transcription promoters, solid boxes represent latent gene coding sequences and the grey box represents the TR segment.  
Reproduced by permission of Prof M. Rowe.  
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EBV was the first herpes virus to be sequenced in its entirety.  A first map of the virus was 
produced by analysing restriction enzyme fragments of the B95-8 strain (11).  It was 
subsequently sequenced by sequencing EcoR1 or BamHI restricted cloned fragments (12).  As a 
result, the virus is still organised by BamHI fragments, which are named alphabetically by size.  
There are 2 major strains of the virus, EBV-1 and -2 (or -A and –B).  Type 1 is much more 
common except in equatorial Africa and Papua New Guinea, which are interestingly the areas 
where BL is endemic (13).  The main differences between the virus strains are observed in the 
DNA sequences of EBNA-2 and EBNA 3A/B/C (14).  The majority of the viral DNA sequence is 
otherwise generally well-conserved, although there are numerous polymorphisms which have 
revealed geographical variation of the viruses (15).  In general, patients with EBV-associated 
cancers have the same virus strains as their healthy counterparts; no mutations have been 
identified which correlate with disease or cancer (16-18). 
 
Cell entry 
EBV efficiently infects B-cells following the interaction between the viral envelope glycoproteins 
gp350 and gp42 with the B cell specific CD21 and HLA class II, respectively.  This interaction 
triggers recruitment of gH/gL to the binding complex and then endocytosis of the virus, 
whereupon the fusion protein gB interacts with an unknown receptor to trigger fusion between 
the viral envelope and the endosomal membrane, releasing the capsid into the cytoplasm.  In 
epithelial cells, which lack CD21, virus is transferred from the surface of B-cells via a B 
lymphocyte: epithelial cell synapse which creates a very close interaction between the two cells, 
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thereby enabling transfer of the virus from the B cell to the epithelial cell (19).  Binding to the 
epithelial cells occurs through the interaction of gH/gL with the integrins v5, v6 and v8. 
This triggers recruitment of gB and fusion of the viral envelope with the plasma membrane (20).  
In T- and NK-cells, which also lack CD21, it is not clear how infection occurs in vivo, and despite 
isolated reports to the contrary (21), it has, until recently, been considered impossible in vitro.   
A recent publication has suggested that type 2 EBV may be able to infect CD8+ T-cells in vitro 
resulting in cell proliferation and aggregation, viral gene expression and dysregulated cytokine 
release (22).  However, there are several criticisms to be made of this study.  Firstly, there is no 
evidence that type 2 EBV infects T-cells in vivo; all of the cases published or studied by our 
group involve type 1 virus.  Secondly, the methods used by the authors involved concentrating 
large volumes of cell culture supernatant by centrifugation; this inevitably results in 
contamination of the cell culture with debris and is likely to be sufficient to activate T-cells 
independent of any virus activity.  The authors show LMP1 expression by Western blot at 24 
hours; this seems implausibly early to represent true latent infection. 
Occasional EBV-positive T- and NK cells are seen in the blood (23), tonsils (24, 25) and lymph 
nodes (26) of infectious mononucleosis patients, although the significance of this is not clear.  
 
Life cycle 
Despite 50 years of intensive research, there is still considerable uncertainty surrounding the 
details of the virus life cycle, primarily because initial infection by EBV is usually asymptomatic.   
7 
 
It is known that primary infection is often a result of ingestion of infected cells, or cell-free virus, 
in saliva, and as such either occurs in infancy due to sharing utensils and toys, or in adolescence 
due to early romantic liaisons.  The virus is also found in genital secretions, but it is unlikely that 
direct sexual transmission occurs in the absence of salivary contact (27).  Once it has entered 
the host little is known about how the virus infects the B-lymphocyte population and two main 
theories prevail: firstly, EBV may directly access B-cells in the lymphoid-rich oropharynx across 
gaps in the single-cell thick epithelial cells, such as in the tonsillar crypts (28).  Secondly, EBV 
may directly infect oropharyngeal epithelial cells, replicate and infect underlying B-cells with 
new progeny virus (25, 29).  In either case, it is thought that the infected naïve B-cells, which 
express the viral latency-associated proteins, enter the circulation where the majority are 
eliminated by the innate immune system (6).  The virus establishes a life-long persistence in 
memory B-cells. 
There are two possible pathways by which the infected B-cells establish a pool of virus in 
memory B-cells.  The “germinal centre”  model (30) suggests that the remaining infected naïve B 
cells, together with their uninfected counterparts, are trafficked to the germinal centres of 
lymph nodes and there undergo class switching and somatic hypermutation to become memory 
cells – the normal process of B-cell maturation.  At this stage, B-cells without surface 
immunoglobulin (Ig) with a high-affinity for antigen would usually undergo apoptosis; the viral 
proteins LMP1 and LMP2 can rescue infected B-cells (31), however, and allow them to 
differentiate into memory cells and return to the circulation, providing a pool of virus within the 
blood – approximately one in 105-6 peripheral blood B-cells.  In healthy, EBV-positive patients 
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the virus is found almost exclusively in the memory cell compartment.  No viral proteins are 
expressed in the majority of these cells which makes them poor targets for the immune system 
(6, 32).  In the “direct infection” model, it is postulated that the virus infects memory B-cells, 
which have already undergone the germinal centre reaction, and drives their proliferation. 
There are, however, problems with both of these models.  EBV can be found in non-isotype 
switched B-cells (33), suggesting a germinal-centre-independent route of infection; this is 
highlighted in the case of XLP where germinal centre formation is absent and yet the virus 
persists in non-switched memory cells (34).  This suggests that EBV may be able to make B-cells 
into memory cells itself without the need for the germinal centre. 
In order to infect new hosts and to maintain the pool of infected B-cells, the virus must be 
stimulated to enter productive (lytic) replication.  Viral lytic replication can occur in both B-cells 
and the oropharyngeal epithelial cells.  In B-cells, lytic reactivation is thought to be stimulated 
by memory B-cell differentiation into plasma cells (35).  However, in the oropharynx, EBV 
undergoes lytic reactivation in the differentiated epithelial cells (36), where virus is shed into 
the saliva and is thereby passed onto new, susceptible hosts.   
 
Transformation of B-cells 
When primary B-cells are infected with EBV, they become growth-transformed and, as 
lymphoblastic cell lines (LCLs), can grow indefinitely in culture.  The value of this to the study of 
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EBV virology has been immense, and as a result it is a particularly well-documented 
phenomenon. 
Once the virus has entered the B-cell, transcription of the viral genome is initiated by host RNA-
polymerase from the Wp promoter (see figure 1-3), resulting in the expression of the viral 
proteins Epstein-Barr Nuclear Antigens Leader Protein (EBNA-LP) and EBNA-2, which reach the 
levels seen in a mature LCL by 24-36 hours after initial infection (37).  Promoter use is switched 
from Wp to Cp by EBNA-2 (see figure 1-3), and it has recently been shown that by 36 hours after 
the initial infection both the Wp and Cp promoters are active (38).  From the Cp promoter the 
virus is able to express the 6 nuclear proteins EBNA-1, -2, -3A, -3B, -3C and –LP.  EBNA-2 also 
acts to upregulate expression of the viral Latent Membrane Proteins LMP1 (39), LMP2A and 
LMP2B (40) – these, along with the EBNA proteins, complete the nine viral proteins expressed in 
the “latency III” pattern (41).  By 72 hours the majority of the infected B-cells have divided.  In 
order for transformation to take place, the viral proteins LMP1 (42, 43), EBNA-2 (44), EBNA-3A 
and EBNA-3C (45) are essential.  Expression of the EBNA proteins from the Cp and Wp 
promoters is only seen in B-cells (46, 47); in other cell types the Q promoter (Qp) is responsible 
for latent EBNA expression, and apparently only EBNA-1 is expressed (6, 48-50).  
Epstein Barr Virus Latency 
The ability to sustain a latent infection in a host is an important survival feature of human 
herpes viruses.  As the name suggests, the virus is maintained in the infected cell in a ‘dormant’ 
state; thus proliferation and de-novo virus production have ceased.  What have become known 
as the EBV latency gene expression profiles were identified in EBV-associated malignancies and 
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EBV-transformed B-cell lines; in these scenarios, whilst the virus is not undergoing lytic 
replication, a limited number of “latent” genes are expressed consistent with the proliferative 
states of the malignant or transformed cells.   The virus employs its different promoters to 
express different patterns of gene expression; these profiles can be classified as latency I, II and 
III (see figure 1-4).  Different EBV-positive malignancies have been shown to be associated with 
different latency states (see table 1-1); however, this model should be considered as a 
framework rather than a prescriptive list.  To illustrate this point, extranodal NK/T lymphoma 
(ENKTL) is considered a latency II tumour, yet LMP1 is not expressed in every case (51).  
Furthermore, even within LMP1-positive tumours, LMP1 may be expressed in only a subset of 
malignant cells (52).  Despite this, the latency I/II/III nomenclature is widely used and has 
proved useful. 
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Figure 1-4 – Schematic of how different viral latency patterns arise.  The EBV genome is shown in the top panel. Open boxes 
indicate reading frames for latent genes.  Small arrows indicate viral promoters, open arrow heads show non-translated RNA, 
closed arrowheads show translated gene products. Redrawn from (69).   
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Table 1-1 - Latency patterns seen in various EBV-associated malignancies.
 Latency pattern Cell of origin Malignancy Viral proteins expressed 
I B cell 
 
BL EBNA-1 
I/II Epithelial cell Gastric carcinoma EBNA-1, LMP2 
II B cell 
 
 
T/NK cell 
 
 
NK 
 
 
Epithelial cell 
HL 
DLBCL of the elderly 
 
ENKTL 
Angioimmunoblastic 
T-cell lymphoma  
Aggressive NK 
leukaemia 
 
Nasopharyngeal 
carcinoma 
EBNA-1, LMP1,2 
EBNA-1, LMP1,2 
 
EBNA-1, LMP2, LMP1 (+/-) 
EBNA-1, LMP2, LMP1 (in B-cells) 
 
EBNA-1, LMP1, LMP2 
 
 
EBNA-1, LMP2, LMP1 (+/-) 
 
III B cell 
 
B cell 
PTLD 
 
DLBCL 
EBNA-1, -2, -3a, 3b, 3c, -LP; LMP1, LMP2 
EBNA-1, -2, -3a, 3b, 3c, -LP; LMP1, LMP2 
 
This list is not exhaustive but demonstrates the range of viral proteins expressed. Hodgkin lymphoma (HL), diffuse large B-cell 
lymphoma (DLBCL), extranasal NK/T-cell lymphoma (ENKTL), EBV-encoded RNA (EBER). 
 
The maintenance of EBV in B-cells is achieved by carefully balancing the need to limit viral gene 
expression in order to reduce immunogenicity of the infected cells, and the need for the virus to 
replicate and maintain its cellular presence.  In memory B-cells in vivo, the virus gene expression 
is limited to the EBERs; no viral proteins are expressed. This is now termed latency 0 (6, 53).   
In contrast, Latency III (discussed above) is not only observed in transformed B-cells (LCLs) 
following infection in vitro, but it is also observed in vivo, in post-transplantation 
lymphoproliferative disorder (PTLD) (54) and infectious mononucleosis (IM) (55).  By its nature, 
PTLD affects immunocompromised patients, and the initial treatment is always, where possible, 
to reduce immunosuppression (56); this is effective as so many viral genes are expressed that 
the infected cells are highly immunogenic.  Most EBV-associated malignancies, however, rely on 
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restricting their viral gene expression to slip under the radar of the host immunological 
response.  This is possible because changes in cellular gene expression make it unnecessary for 
the full complement of latent genes to be expressed.   
The Latency I pattern of viral gene expression is characterised by the expression of EBNA-1 from 
the Qp, the EBERs and miRNAs plus the silencing of the Wp, Cp and LMP promoters.  Latency I is 
consistently observed in endemic BL.  However, cell lines adapted from endemic BL are 
frequently observed to “drift” towards a Latency III phenotype, with expression of EBNA-2 and 
LMP1, suggesting that Latency III is the default viral expression pattern in B-cells in the absence 
of host immune control.  
Latency II is an intermediate pattern of EBV gene expression and was originally identified in 
undifferentiated nasopharyngeal carcinoma (NPC); it is now considered to include the viral gene 
expression pattern observed in ENKTL, Hodgkin lymphoma (HL) and gastric carcinoma.  Like 
latency I, latency II is characterised by the expression of EBNA-1 from the Qp promoter plus the 
EBERs and viral micro RNAs (miRNAs).  Additionally, the latent membrane proteins LMP1, 
LMP2A and LMP2B are expressed.  However, as stated above, there is considerable 
heterogeneity in expression of the LMPs, both between and within tumours of the same type 
(52, 57). 
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EBV Latency-Associated Proteins 
The vast majority of our knowledge of the role of EBV proteins comes from work on either B-
lymphocytes or epithelial cells – the “natural” hosts of the virus.  There is some evidence that at 
least some of the effects of the proteins are different according to the cell background (58), and 
this must be borne in mind when considering the following descriptions.  Transformation of B-
cells, as discussed, requires the co-operative action of at least 5 latent genes, and loss of any 
one of these will result in substantial impairment to the transformation process.  Similarly, EBV-
associated malignancies generally express characteristic subsets of latent genes that may reflect 
either the cell of origin of the tumour, or alternatively the specific pathogenesis of this disease.  
Cellular mutations associated with each type of malignancy may substitute for some EBV 
transforming functions, thus allowing a more restricted pattern of viral gene expression in the 
established tumour (with the immunological advantage that this presents).  For example, in BL 
the overexpression of the oncogene myc along with other cell-cycle genes is thought to be the 
prime proliferative driver in the established tumour, and the continued presence of EBV may 
only be required to provide a survival advantage, thus allowing the virus to express a more 
restricted number of genes and gain a useful immunological advantage. 
 
EBNA-1 
The primary function of EBNA-1, which is expressed in every EBV-associated malignancy, is to 
facilitate replication of the circularised EBV episome during cell division to ensure efficient 
transmission to progeny cells (59).  It contains a glycine-alanine repeat region which inhibits its 
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degradation and reduces its presentation by host cell MHC class I molecules thereby reducing its 
immunogenicity (60, 61).  Potential oncogenic actions include protection from p53-mediated 
apoptosis (62) and contribution to cellular genomic instability via the induction of reactive 
oxygen species; the resulting DNA damage may explain in part how EBV contributes to 
malignant transformation of cells (63). 
 
EBNA-2, -3 and –LP 
EBNA-2 and EBNA-LP are the first proteins expressed by the virus in latent infection of B-cells.  
EBNA-2 is vital for EBV-mediated growth transformation, and it is speculated that the 
differences in EBNA-2 may explain why the EBV type 2 strain is less efficient at transforming 
lymphocytes in vitro (44).  EBNA-2 activates transcription of the cellular proteins CD23, CD21 
and CMYC (6, 37, 39, 64-67).  EBNA-LP augments the actions of EBNA-2 on the promoters of 
LMP1 and LMP2B, and is important for transformation (68). 
There are 3 members of the EBNA-3 family, designated EBNA-3A, EBNA-3B and EBNA-3C.  The 
EBNA-3A/B/C family of proteins is particularly interesting as it is highly immunogenic and is a 
potent target for cytotoxic T-lymphocytes (CTLs) (69, 70).  EBNA-3A and 3C are important for B-
cell transformation into LCLs (45, 71).  In contrast, EBNA-3B is dispensable for transformation 
but seems to act as a tumour suppressor gene by attracting host T-cells to the tumour (72). 
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LMP1 
Latent Membrane Protein 1 (LMP1) is considered the key protein in EBV-induced cellular 
transformation.  It is critical for EBV-induced B-cell transformation (42) and functions as a 
classical oncogene in rodent fibroblast models (6, 73); LMP1 expression under the control of the 
Ig promoter in transgenic models is associated with the development of lymphoma (74).  LMP1 
can inhibit cellular differentiation in epithelial cells (75) and can cause the downregulation of 
CD10 and upregulation of CD11a, CD23, CD40 and CD54 – similar to the changes seen in the cell 
surface phenotype upon EBV infection of B-cells (76-78).  It acts as a constitutively active 
tumour necrosis factor receptor (TNFR), resembles CD40 functionally, and provides growth and 
differentiation signals to B-cells.  It is a key modulator of cell signalling via the NFκB (79) and JNK 
(80) pathways and induces expression of a number of anti-apoptotic proteins, including BCL2 
and A20 (TNFAIP3) (81, 82), as well as adhesion and activation proteins. 
First described in 1984 (83), LMP1 is a 63 kDa protein with a short amino and long carboxy 
terminal spanning 6 transmembrane domains, which oligomerises in the plasma membrane 
independent of any ligand binding, enabling it to be constitutively active (84, 85) (see figure 1-
5).  The amino terminal is necessary to tether the protein in the plasma membrane (86), and the 
transmembrane loops are required for oligomerisation.  The cytoplasmic tail is necessary for the 
transforming properties of the protein (87). 
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Figure 1-5  Schematic representation of the structure of LMP1.  The protein has 6 transmembrane segments and a long 
cytoplasmic tail.  The two C-terminal activating regions (CTARs) can activate downstream signalling via the NFκB, STAT and 
MAPK pathways. From (88). 
The cytoplasmic C-terminal contains two “C-terminal activating regions” (CTAR1 and 2), which 
are vital for the recruitment of factors which stimulate various intracellular signalling pathways 
(79).  Between them they can activate the canonical and non-canonical nuclear factor κ B (NFκB) 
pathway, which is important in multiple cellular processes including apoptosis, differentiation 
and proliferation, and there is evidence that blocking it may remove the ability of EBV to 
transform B-cells (89).  In EBV-infected cells, NFκB is responsible for upregulating cytokines, 
antiapoptotic proteins and cell surface antigens such as CD40 (88).  High-throughput RNA 
sequencing of the effects of CTAR1 in C33 epithelial cells showed enrichment in growth, 
survival, migration and proliferation pathways (90). 
Other cellular signalling cascades are also activated by LMP1.  The mitogen-activated protein 
kinase (MAPK) pathway (91) is important in mediating cellular responses to external stimuli.  
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The Janus kinase/Signal Transducers and Activators of Transcription (JAK/STAT) pathway is a 
major pathway for the transduction of signals from cytokine and growth factor receptors (92) 
and was thought to be activated by LMP1, although it is not clear whether this is a direct effect 
(93). 
The interferon regulatory factor IRF7 pathway is also likely to be important.  IRF7 is expressed in 
lymphoid cells (94); it is both induced by and induces LMP1 (95), is co-expressed in some EBV-
positive lymphomas and acts to enhance its effect on growth transformation of fibroblasts (96).  
LMP1 has been shown to activate the c-Jun N-terminal kinase (JNK) pathway, known to be 
important in cellular proliferation and differentiation, via the CTAR2 pathway; this is 
independent of the NFκB pathway (80) and has an important role in LMP1-induced lymphocyte 
transformation (97). 
 
LMP2A and B 
Transcripts for the Latent Membrane Proteins LMP2A and LMP2B-TR share the majority of their 
sequence but are generated by transcription from different viral promoters ( see figure 1-4) 
(98).  Interestingly, the transcripts span the TR section of the genome; this suggests that the 
virus must have assumed its circular form before transcription can take place (99).  The first 
exon of LMP2A encodes 119 amino acids whereas the first exon of LMP2B is non-coding; they 
then share the remaining 8 exons after the TR (98).  In structure, they are characterised by 12 
membrane-spanning domains with a cytosolic C-terminal domain.  Although these proteins 
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facilitate immortalisation (100) and lytic cycle, they are not essential for B cell transformation in 
vitro.  LMP2A can act as a “surrogate” B-cell receptor to drive the proliferation and survival of B-
cells (101) via constitutive activation of the Ras/PI3K/Akt pathway (102), such that its expression 
can rescue B-cells with crippled Ig genes from apoptosis (103).  Its expression is vital for the 
survival and proliferation of infected B-cells in culture, and also for their early activation and 
proliferation (104).  LMP2A can also activate the Ras/PI3K/Akt pathway in epithelial cells (105). 
Multiple cell signalling pathways have been hypothesised to be influenced by expression of 
LMP2A and B (see (106) for review).  LMP2A can modulate signalling by the B-cell receptor (BCR) 
by blocking its phosphorylation after cross-linking (107); amongst other things this prevents the 
BCR-induced switch from latent to lytic cycle (108).  LMP2A and 2B co-localise in B-cells, and 
LMP2B antagonises the effects of LMP2A by impairing the phosphorylation of its N-terminus, 
and thus prevents its effect on BCR signalling (109) and facilitates the switch to lytic cycle (108).  
It appears that LMP2B is not important in long-term growth of EBV-infected B-cells in vitro, and 
has no major role in their activation, proliferation or survival in the early stages of viral infection 
(104). 
In epithelial cells, LMP2A and 2B can increase cell spreading and motility, and in contrast to the 
situation in B-cells, seem to have similar roles (110, 111).  They are both also involved in limiting 
the response of epithelial cells to interferons α and γ by increasing the turnover of their 
receptors (112).  There are very little data available on the roles of LMP2A or LMP2B in T- or NK 
cells. 
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EBERs 
EBER transcripts are double-stranded RNA molecules that are the most highly expressed viral 
gene products in EBV-transformed cells.  This abundance has proven to be particularly useful in 
the detection of EBV in tissue samples, with in situ hybridisation providing a sensitive and 
specific assay in fixed and fresh tissues.  They are predicted to form a double stranded structure 
and associate with the cellular protein La (113).  
The function of EBERs in B-cells remains enigmatic.  There is some evidence to suggest that 
EBER expression can protect cells from apoptosis and contribute to cell transformation and 
proliferation (114, 115).  EBER1 transcripts are detected in the culture supernatant of BL and 
LCLs, and in the serum of patients with EBV-associated inflammatory disorders including 
haemophagocytic lymphohistiocytosis (HLH), chronic active EBV (CAEBV) and infectious 
mononucleosis (IM) patients (116).  The transcript can act via the toll-like receptor 3 to induce 
the release of inflammatory cytokines from cell lines, as well as inducing the activation of 
dendritic cells in culture.  This leads to a model whereby EBER1 could be responsible for the 
marked and often overwhelming immune response to EBV infection seen in these conditions 
(116).  La is present in exosomes produced by epithelial cells, suggesting that EBER1 may be 
actively secreted in combination with the protein (117).  EBER2 is seen at much lower levels but 
is probably transcribed at similar rates at least in cell lines; it has a much shorter half-life, which 
may explain the lower levels (118). 
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miRNA 
MicroRNA (miRNA) describes a non-coding RNA which acts to regulate translation of messenger 
RNA by binding it and either preventing translation or accelerating its degradation (119).  There 
are at least 700 human miRNAs described to date, of which many have been implicated in 
oncogenesis (120).  EBV itself encodes at least 44 miRNAs from 25 precursors (120), with 
potential targets including cell cycle control, apoptosis and transcription (121).  EBV miRs are 
clustered within 2 areas of the viral genome, the BART (BamH1-Associated Rightward 
Transcripts) and the BHRF1 cluster (see figure 1-4).  In general, the BHRF1 cluster miRs are only 
expressed during latency III or lytic cycle, and thus are not seen in either HLH or ENKTL, whereas 
BARTs are expressed at low levels in all forms of lytic and latent infection (6).  The expression 
and function of the BART miRNAs in nasopharyngeal carcinoma, another EBV-associated 
malignancy with a ‘latency II’ pattern of EBV gene products, have been more comprehensively 
studied and are implicated in apoptosis protection (122) (123) and immune evasion; they also 
inhibit the expression of LMP1 (124, 125) and act to maintain viral latency by inhibiting EBNA-2 
(126) (see (127) for review). 
 
BHRF1 and BALF1 
BHRF1 and BALF1 are viral homologues of BCL2, an anti-apoptotic protein (discussed in detail 
below).  BHRF1 (128) protects B-cells from apoptosis; BALF1 has a more ambiguous role.  In 
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some cells lines it has been suggested that it may provide apoptosis protection, or it may act by 
regulating the activity of BHRF1 (129, 130).  They are highly expressed in lytic cycle and are 
thought to prevent apoptosis in response to viral infection, allowing time for more virus to be 
produced (131).  The fact that two BCL2 homologues are expressed suggests the importance of 
this pathway in the EBV life cycle. 
It has recently been shown, however, that BHRF1 is present in latent infection as well – at low 
levels in LCLs and at very high levels in the context of Wp-restricted Burkitt lymphoma – a 
subset of the disease where the virus has a mutation resulting in the loss of EBNA-2.  
Furthermore, the EBNA-2 deletion results in the constitutive expression of the BHRF1 from the 
Wp promoter, thereby providing the high levels observed.  In this latter case BHRF1 is 
responsible for the marked apoptosis-resistance of these cells in culture (132).   
 
1.2  EBV-associated diseases. 
B-cell disorders 
Infectious mononucleosis 
When primary EBV infection occurs during adolescence there is a risk of between 25 and 70% of 
developing clinical IM (133-136), an immune-driven, self-limiting illness characterized by 
lymphadenopathy, sore throat and fever as well as profound fatigue.  Large, activated CD8+ 
lymphocytes can be seen on blood film examination, and are thought to drive the clinical 
manifestations of the disease as well as giving it its name.  Although other primary infections, 
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notably cytomegalovirus and toxoplasmosis, may cause a similar clinical picture, 90% will be 
attributable to primary EBV infection. 
The association of EBV with (IM) was uncovered when a technician in an EBV research group 
contracted the condition.  She had previously donated cells and serum for laboratory 
experiments, but it was noted that when she returned to work with IM symptoms she had 
evidence of EBV infection (137).  The link between EBV and IM was then confirmed on various 
further populations, including army cadets at West Point (138).  Of particular charm in this latter 
study, the peak incidence of IM amongst the young soldiers was in February, 6 weeks after their 
return from their first Christmas break.  Presumably their new haircuts and developing 
physiques were appreciated by the young women of their home towns. 
However, primary infection during adolescence can also be asymptomatic, and it is not clear 
what determines whether or not IM will develop.  One theory is that the size of the viral 
inoculum may be significant, using for evidence the increased risk of IM in sexually active 
students, and postulating that deep kissing at the time of intercourse is likely to be the mode of 
transmission as although the virus is present in genital secretions, the levels are much lower 
than that seen in saliva (27, 134, 135).  HLA type is also important, with polymorphisms at the 
HLA class I site associated with an increased risk of IM (133), and this, combined with the 
evidence that prior IM is also associated with the development of Hodgkin lymphoma (139) and 
multiple sclerosis (140) suggests that the development of IM may reflect a poorer ability by the 
individual to control the virus (141).  This is corroborated by the fact that HLA class I 
polymorphisms are associated with both IM (133) and EBV-positive Hodgkin lymphoma (142). 
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X-linked lymphoproliferative disorder (XLP) 
The X-linked lymphoproliferative disorders are characterised by excessive and often fatal 
inflammatory responses to infectious triggers (see (143) for review).  XLP1 results from a 
mutation in the SAP gene, which is expressed in NK, NKT, CD4+ and CD8+ cells.  Amongst its 
other functions, SAP is necessary for NK- and CD8+ T-cell cytotoxicity of EBV-infected B-cells.  It 
is likely that this results in prolonged activation of the cytotoxic cells, and hyperinflammation.  
When affected boys are infected with EBV they are unable to control the infection and it may 
prove fatal; if they survive they may progress to lymphoma or dysgammaglobulinaemia.  XLP2 is 
caused by a defect in the XIAP/BIRC4 gene. 
 
Burkitt lymphoma 
As discussed earlier, the association of BL with EBV was made early on in the course of its 
investigation.  However, as it became clear that EBV-infection was nearly universal, the 
temperature-sensitive, presumably arthropod-borne cofactor was sought.  Although by then 
cases had been reported from all over the world, Burkitt and his team focused on Papua New 
Guinea, the only area outside Africa where the disease was commonly seen, and suggested that 
common factors between these two locations should be sought (144).  Holoendemic malaria 
(i.e. infection occurring throughout the year) had been postulated for some time to be a 
common feature in the BL areas, and in 1970 it was accepted that the co-operation between 
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EBV and high malarial parasite loads was necessary for endemic BL(145).  It had initially been 
observed in 1964 that the distribution of BL mirrored that of holoendemic malaria (146) and as 
EBV showed no evidence of being vector-borne, mosquito-borne malaria infection was seriously 
considered as the vector-borne co-factor for BL pathogenesis (147).  The evidence for the 
association is still primarily epidemiological, but it has been shown that there is a positive 
correlation between BL incidence and malarial transmission intensity (148), that the distribution 
of endemic BL distribution mimics that of holoendemic malaria, and that reducing malarial 
burden reduces the incidence of BL in endemic areas (149) 
As mentioned above, cases of BL are seen, albeit at much lower frequencies, all over the world.  
These sporadic BL cases are less strongly associated with EBV (only about 15% are EBV positive 
(150, 151) compared to close to 100% in endemic BL (152)). 
A defining characteristic of BL, regardless of its origin or EBV status, is the presence of a genetic 
translocation moving the c-myc gene from chromosome 8 into the influence of an 
immunoglobulin promoter region, either on chromosome 14 (Ig heavy chain), 2 (κ) or 22 (λ) 
(153).  The resulting overexpression of c-myc is necessary for the development of BL, and is 
sufficient to transform an LCL culture into an EBNA-2-independent, Burkitt-like cell line (154, 
155).    
EBV-positive BL classically has a “latency I” pattern of infection, with only EBNA-1, EBERs and 
BARTS transcribed.  Transcription of EBNA-1 is initiated from the Qp promoter.  However, a 
subset of BL samples (15%) was shown to carry both the wild-type and an EBNA-2-deleted virus 
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and exhibited an unusually high resistance to apoptosis (156, 157).  These cells do not express 
EBNA-1 from the Q-promoter, but alternatively use the Wp promoter and express the EBNA-1, 
EBNA-3A, -B, -C and -LP proteins and the BCL2 homologue BHRF1 (132).  This pattern of latency 
is termed “Wp” restricted BL.  Interestingly, in these cases EBNA-2 is deleted, presumably due to 
its antagonistic effect on c-myc (156), and consequently the latent membrane proteins are not 
expressed either. 
EBV is likely to be important in BL pathogenesis.  This is evidenced by its ubiquitous association 
with endemic cases, frequent association with sporadic cases and stereotyped pattern of viral 
gene expression.  Loss of the viral genome from cultured BL lines results in the loss of 
transferrable tumorigenicity and increased sensitivity to apoptosis (158); restoring the virus 
reversed these changes (159).  These, along with other studies, suggest that the virus is playing 
an important role in lymphomagenesis.  However, it is still not at all clear exactly how the virus, 
with its limited viral expression, can contribute to the disease pathogenesis. 
 
Hodgkin Lymphoma (HL) 
Hodgkin lymphoma (HL) is a lymphoma of B-cells, characterised by the presence of large, 
malignant Hodgkin-Reed-Sternberg (HRS) cells in a reactive infiltrate of inflammatory cells (160).  
It has a bimodal age distribution, with peaks occurring in the twenties and fifties in the West, 
although the early peak is somewhat earlier in less economically developed countries.  It has a 
slight male preponderance (161).  Modern classification defines two subtypes, classical HL and 
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nodular lymphocyte-predominant HL (162); the latter is likely to present earlier, has a more 
favourable clinical course and is much rarer than the former (163).  Although it has generally 
been considered to have no association with EBV, this dogma has recently been challenged 
(164). 
EBV was first demonstrated in HL samples in 1987 (165).  It is seen in about 40% of HL cases, 
with an increased prevalence in tumours from children from lower income countries and in 
males; there are also high incidences in tumours from patients of Asian and Hispanic origin 
(166).  There is a significant association of HL with IM in young adult cases, particularly in EBV 
positive disease (OR 2.94) , and it is suggested that a late first exposure to EBV (i.e. in teens or 
early adulthood) may increase the risk of developing EBV+ HL in higher-income countries (167); 
this is mirrored by a peak in the disease in childhood in lower-income countries, where initial 
EBV infection is earlier (168).  EBV-positive disease in older adults might reflect virus 
reactivation.  However, interestingly IM is also associated with EBV-negative disease, suggesting 
a shared lifestyle factor between IM and a possible aetiological agent in EBV-negative disease.  
Virus is demonstrable in the HRS cells and shows a latency II pattern (6).  The virus, specifically 
LMP2A, is thought to “rescue” cells with crippling immunoglobulin gene receptor 
rearrangements allowing their progression into Hodgkin Reed-Sternberg (HRS) cells (31, 169).  
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PTLD 
Post-transplant lymphoproliferative disorder (PTLD) encompasses a range of conditions 
affecting immunosuppressed patients who have undergone either a solid organ or 
haematopoietic stem cell transplant (HSCT).  The phenomenon was first described in 1969 (170) 
and 90% are associated with EBV, with the majority showing a latency III pattern of infection 
(171).  The current model for the disease is that primary infection or viral reactivation is able to 
proliferate uncontrolled due to the incompetent T-cell response resulting from iatrogenic 
immunosuppression.  In allogeneic HSCT recipients the incidence is highest between 1 and 5 
months after transplantation and falls rapidly after a year; this coincides with the period of 
maximal T-cell impairment and B-cell regeneration.  These epidemiological data, however, 
precedes the use of Alemtuzamab in conditioning regimens, and may no longer be accurate 
(172).  Overall incidence of PTLD in HSCT recipients is about 1% but if T-cell depletion or anti-T-
cell immunotherapy is used this can rise significantly (173), reflecting the vital importance of T-
cells in controlling the virus.  After solid organ transplant the risk of PTLD varies with which 
organ was transplanted, but the incidence is highest in the first year regardless, and is increased 
if the recipient was EBV seronegative at the time of transplantation (171). 
The World Health Organisation (WHO) divides PTLD into 4 pathological categories; early lesions, 
polymorphic PTLD, monomorphic and classical HL-type PTLD (174).  Monitoring of EBV viral 
loads may detect viral reactivation before PTLD develops; the reduction of immunosuppression 
(where possible) with anti-B-cell antibodies such as Rituximab to target the virus-containing B-
cells is routinely used in these situations and has been shown to reduce the risk of developing 
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PTLD (175).  In established disease, conventional chemotherapy is used and, if available, in HSCT 
recipients donor T-cell infusions may be useful (176).   
The malignant cells, particularly in early and polymorphic PTLD, often show a latency III pattern 
of gene expression, which makes them a very attractive target for infused EBV-specific T-cells, 
as they express the immunogenic EBNA-3s.  There is also evidence that lytic replication may be 
significant in PTLD, which suggests the possibility of using the immunogenic lytic antigens, 
particularly BZLF1, as immunotherapeutical targets (177).  This is a very promising future 
direction, and may eventually replace conventional chemotherapy, particularly in bone marrow 
transplant recipients; however, in monomorphic lesions the expression of viral proteins is often 
more restricted (178) and immunotherapy is therefore less likely to be successful (179). 
 
Non-B-cell disorders 
CAEBV 
CAEBV is characterised by recurrent or chronic IM-like symptoms, with high virus loads and 
unusual serological responses with no previous immunological deficit (180).  It was first 
described in 1978 (181).  Early reports of a chronic symptomatic EBV infection (182) relied upon 
clinical symptoms for more than a year and unusual serological responses with no anti-EBNA, in 
the background of a previously normal immune system.  About 40% of patients have an initial 
IM-like illness (180). 
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Intriguingly, in CAEBV cases in Japan, EBV is most commonly found in CD4+ T and NK cells (23, 
183-185), whereas in the USA the virus is more usually found in B-cells (186).  This is especially 
interesting when we consider that ENKTL, another EBV-associated NK-cell disorder, is also more 
prevalent in Asia than the West, which suggests a genetic or environmental predisposition for 
non-B-cell infection.  The mean age of onset is 19 years in the USA but is younger for T-cell 
disease (7 years) than B-cell (23 years) when they are considered separately (186).  In Japan the 
median age of onset is 14 years, and B-cell disease is very rare (187).  Symptoms include fever, 
lymphadenopathy, splenomegaly, thrombocytopenia and hypersensitivity to mosquito bites; 
less commonly uveitis, hepatomegaly, pancytopenia, haemophagocytosis, skin rash, oral ulcers, 
coronary artery aneurysm, interstitial pneumonitis and lymphoma occur (180, 188).  The disease 
is predominantly clonal (187).  T-cell CAEBV seems to carry a worse prognosis than NK-cell 
disease, and is characterised by more prominent fever, lymphadenopathy and anaemia, 
whereas NK disease has more large granular lymphocytosis and high IgE levels (187-189).   
Treatment is difficult in both B- and non-B-cell disease – initial responses to steroids, 
immunosuppression, chemotherapy and cytotoxic T-cell therapy are not durable and 
haematopoietic stem cell transplant seems to offer the only chance of cure (186).  The 
prognosis is worse if older than 8 years, if thrombocytopenia is present at presentation and in T-
cell disease (187). 
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Haemophagocytic lymphohistiocytosis 
Haemophagocytic lymphohistiocytosis (HLH) describes a clinical syndrome of macrophage 
activation, cytokine release and haemophagocytosis.  It was first described as “histiocytic 
medullary reticulosis” in 1939 (190).  The authors described a syndrome of “asthenia, 
emaciation and a profound general intoxication” as well as hepatomegaly, splenomegaly, 
lymphadenopathy, cytopenia and erythrophagocytosis seen on histological examination.  Until 
the first formal international guidelines were published in 1991 (see table 1-2) (191) this 
remained the only framework for diagnosing the condition.  The diagnostic guidelines were 
revised in 2004 to include hyperferritinaemia, elevated sCD25 and reduced NK cell activity (192).  
HLH is often insidious and atypical, and clinical features may fluctuate during the course of the 
illness (193), further complicating the process of diagnosis.  It is also useful to think of HLH as 
the “extreme end of the spectrum of inflammatory reactions “ (194) as the published diagnostic 
criteria are not specific to HLH and will be seen, to some extent, in all patients undergoing a 
systemic inflammatory response. 
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Table 1-2.  HLH-2004 diagnostic guidelines (193).  
5 of the following 8 diagnostic criteria  
Fever*  
Splenomegaly*  
Cytopenias affecting ≥2 of 3 lineages in the 
peripheral blood* 
Hb <9.0 g/dL (10.0 g/dL in infants less than 4 
weeks old) 
Platelets < 100 x 109/L 
Neutrophils < 1.0 x 109/L 
Hypertriglyceridaemia * (fasting triglycerides ≥ 3mmol/L) 
 and/or hypofibrinogenaemia (fibrinogen ≤ 1.5 
g/L)* 
Low or absent NK activity  
Haemophagocytosis in BM, spleen, lymph nodes 
or liver 
 
Ferritin ≥ 500mg/L  
Soluble CD25 ≥ 2400 U/ml  
Other supporting evidence 
 
Spinal fluid pleocytosis &/or raised spinal fluid 
protein 
Chronic persistent hepatitis on liver histology 
Cerebromeningeal symptoms, 
lymphadenopathy, jaundice, oedema, rash, 
deranged liver enzymes, hypoproteinaemia, 
hyponatraemia, raised VLDL, low HDL 
 
Primary, or familial, HLH is classically associated with X-linked lymphoproliferative disorder (XLP) 
as well as with other congenital immunodeficiencies such as Chediak-Higashi syndrome.  The 
genetic mutations associated with HLH to date all involve perforin-mediated cytotoxicity (see 
table 1-3).  Cytotoxic T-cells, NK and NKT cells are able to induce apoptosis in virus-infected or 
malignant cells by forming an immunological synapse and releasing the contents of their 
secretory granules into the cytoplasm of the target cell; mutations in this pathway are 
associated with familial HLH including perforin (195), Munc13-4 which is necessary for required 
for cytolytic granule exocytosis (196), syntaxin 11 (197) and Munc18-2(198) which are needed 
for vesicle trafficking. 
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Table 1-3 - Genetic mutations associated with familial HLH. 
Syndrome Gene Encoded protein Chromosomal 
location 
Reference 
FHL-1 Unknown Unknown 9q21.3-q22 Ohadi et al (199) 
FHL-2 PFR1 Perforin 10q21-q22 Stepp et al (195) 
FHL-3 UNC13D Munc13-4 
(required for 
cytolytic granule 
exocytosis) 
17q25 Feldmann et al 
(196) 
FHL-4 STX11 Syntaxin11 (vesicle 
trafficking) 
6q24 zur Stadt et al 
(197) 
FHL-5 STXBP2/UNC18B Munc18-2 (co 
localises with 
syntaxin 11 and 
may be necessary 
for its function) 
19p13.2-3 zur Stadt et al 
(198) 
Chediak-Higashi CHS/LYST Lyst 1q42.1-q42.2 Barbosa et al 
(200), Nagle et al 
(201) 
Griscelli RAB27a Rab27a 15q21 Menasche et al 
(202) 
XLP1 SH2D1A SAP xq25 Filipovich et al 
(143) 
XLP2 BIRC4 XIAP xq25 Filipovich et al 
(143) 
 
The most comprehensive international study of HLH to date, the HLH-94 trial, showed a median 
age of onset of 8 months, and a slight male preponderance, which is postulated to represent 
undiagnosed X-linked immunodeficiencies (203).  The geographical distribution of HLH is similar 
to that of ENKTL.  It predominantly affects young children, with mortality rates around 30%.  
Immunosuppressive treatment may lead to a complete response and relapse is rare in the West, 
although possibly more common in Asian countries (204). 
The syndrome of HLH can be seen in response to many diverse insults and is seen in both 
immunodeficient and immunocompetent patients.  The triggers include infection, malignancy 
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and autoimmune diseases (see (205) for review).  Infectious associations include leishmaniasis, 
influenza, parvovirus and hepatitis A (206-208), as well as EBV. 
The first coherent suggestion of HLH as a consequence of herpes viral infection was in 1979 
(209), when an increase in EBV-specific IgM, consistent with primary infection, was 
demonstrated in 2 cases of HLH.  EBV-associated HLH, which accounts for up to 60% of cases, is 
now defined as the association of EBV-positivity with the diagnostic criteria above (210),  but 
there is no consensus on how this should be defined which limits its usefulness in the clinical 
setting.  Molecular detection of EBV-DNA in peripheral blood by PCR is commonly used to 
determine viral load, but variation between laboratories, tests and limits of detection means 
that there is no consensus on the lower limit of viral DNA necessary to diagnose EBV-HLH.  The 
wide range of reported viral loads in the literature is somewhat concerning, as a low level of 
detectable EBV-DNA may reflect a “high-normal” virus load, or low-level reactivation as a result 
of HLH-induced immune dysregulation.  In these cases the virus is unlikely to be driving the 
disease and other explanations should be sought. 
Unlike classical EBV infection, where the virus shows complete tropism for B-cells, T-cell 
infections, particularly CD8+ and NK cell infections, are seen in HLH.  T-cell infection was first 
reported in 1993 (211), and has been confirmed in small studies (23) and case reports in various 
geographical populations since (see (212) for review).   NK cell infection in the context of HLH 
was first reported in 1995 (213) and has since been confirmed in an adult series in the UK (214), 
however, it seems to be less common than in T-cells.  These observations may provide a useful 
tool for defining EBV-HLH, whereby non-B-cell infection could become a diagnostic requirement. 
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As with some EBV-associated cancers, it is not clear how the virus is contributing to the 
pathogenesis of HLH.  EBV infection of T-cells experimentally has been shown to result in the 
secretion of tumour necrosis factor α (TNFα); culture supernatant from these cells resulted in 
the activation of a macrophage cell line (215).  However, the same group reports that these 
effects can be attributed to LMP1 (216, 217), and there is evidence that EBERs are the only EBV 
genes significantly expressed in EBV-associated HLH, at least in adults (218). 
HLH in adults is rare, but probably under-reported due to the combination of non-specific 
symptoms, low diagnostic suspicion and often rapid fatality.  This makes the true incidence 
difficult to estimate, but a recent study in Los Angeles estimated that 0.9 cases per million per 
year were diagnosed in the region (219). 
A humanised mouse model of EBV-driven HLH has recently been developed, and offers exciting 
possibilities to study this condition in more depth (220).  However, EBV is not seen in T- or NK-
cells in these mice and so does not exactly mirror the situation in humans, although HLH with 
the EBV in the B-cell population has been described in XLP patients (221). 
 
Extra-nodal NK/T lymphoma 
Extranodal NK/T-cell lymphoma (ENKTL) is a rare malignancy usually affecting the upper 
aerodigestive tract and consistently associated with the presence of EBV in the malignant cells.  
Early descriptions of destructive nasal tumours, suggestive of ENKTL, date back over 100 years 
(222-224), and have been defined variously as “lethal midline granuloma”, “rhinitis gangrenosa 
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progressive”, “polymorphic reticulosis” or “malignant midline reticulosis”.  The 1994 Revised 
European and American Lymphoma (REAL) classification suggested the term “angiocentric 
lymphoma” (225), but it was not until the World Health Organisation (WHO) publication of 1999 
that the disease reached its modern name and description (174).  The malignant cells were 
shown to react to anti-T-cell sera in 1982 (226); subsequently, the development of antibodies 
against the CD56 antigen questioned the T-cell phenotype of the malignant cells (227-229) and 
it is now considered likely that polyclonal anti-CD3 antibodies in the T-cell sera reacted to the 
cytoplasmic ε-chain of the CD3 molecule in formalin-fixed, paraffin-embedded (FFPE) material in 
the original study (230).  The discovery that the malignant cells had germline T-cell receptor 
(TCR) gene configurations supported the idea that, at least in the majority of cases, the cell of 
origin was a natural killer (NK) cell, rather than a T-cell (229, 231). 
The characteristic phenotype of ENKTL, as defined by the WHO, consists of CD2+, CD56+, surface 
CD3- (as demonstrated on fresh/frozen tissue), cytoplasmic CD3ε (as demonstrated on FFPE 
tissues), together with expression of EBERs.  A recent review by the International T cell project 
of 136 ENKTL cases confirmed an NK phenotype and genotype in the majority of cases but also 
showed a cytotoxic CD8+ phenotype in 14% of the tumours (232). 
 
Epidemiology and clinical features of ENKTL 
An aggressive malignancy, ENKTL is very rare in the West, comprising approximately 0.5% of all 
non-Hodgkin lymphoma (NHL), or 4% of all NK and T-cell lymphomas (233).  It is, however, much 
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more common in East Asia and Central and South America (233, 234).  In East Asia in particular 
it accounts for 4-6% of all NHL and about one third of mature T and NK cell cancers (235, 236).  
It is not clear why there is such a marked disparity between continents, although, as will be 
seen, it is similar to that seen in other EBV-associated T- and NK-cell disorders.  EBV infection is, 
however, nearly ubiquitous in the adult population worldwide, so it seems likely that genetic or 
environmental factors may be implicated. 
Within East Asia, where the relative frequency of the disorder allows for more accurate 
characterisation of patient series, the median age at presentation is 45-50 with a male: female 
ratio of 2-3:1 (233).  Although there are reports of cases in immunosuppressed patients (237-
239), the majority are immunocompetent. 
ENKTL usually affects the upper aero-digestive tract, characteristically the nasal cavity, and 
presents with localised symptoms such as a mass, pain or bleeding (240).  Extranasal disease 
may account for up to a quarter of all cases, including adrenal glands (241), uterus (242), skin 
(243, 244), heart (245) and brain (246), although it is important to bear in mind that there may 
be co-existing occult nasal disease, and naso-endoscopy and biopsy are recommended even in 
the absence of macroscopic pathology (233).  Primary lymph node involvement is rare in the 
absence of extranodal disease, but has been described (247).  Staging investigations should 
involve bone marrow examination, although involvement is probably rare (248).  
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Current treatment 
The rarity of ENKTL, even in high-risk populations, means that large-scale studies on treatment 
options are scarce.  Disease is often localised at presentation, leading to an initial vogue for 
involved-field radiotherapy as a single treatment modality; however, despite initially promising 
responses, the majority of patients relapse with either local or systemic disease (249).  The 
tumour cells are thought to be inherently chemoresistant due to frequent expression of the P-
glycoprotein efflux pump (250, 251), which actively extrudes chemotherapy drugs from the cell 
(252), and success rates with conventional chemotherapy regimens such as CHOP 
(cyclophosphamide, doxorubicin, vincristine and prednisolone) are poor (253).  However, it has 
been suggested that the P-glycoprotein expressed by NK cells may differ from the conventional 
form, and possibly P-glycoprotein expression should not be taken as a reason to abandon 
anthracycline chemotherapy (254). 
With localized disease, impressive results have been reported with upfront radiotherapy 
combined with concurrent cisplatin as a radiosensitiser, followed by chemotherapy with 
ifosfamide and methotrexate which are unaffected by the P-glycoprotein pump (255).  This 
group reported an 86% 3 year overall survival, which represents a great improvement on that 
reported previously.   
With disseminated disease at presentation, treatment is much more difficult and response rates 
are significantly poorer.  L-asparaginase, which acts by depleting the milieu of available 
asparagine, has shown early promise in trials, but outcomes still remain poor (256-258). 
39 
 
 
Prognosis 
A variety of factors have been shown to have prognostic relevance in ENKTL, including serum 
β2-microglobin (β2m) levels (259), bone marrow involvement (248, 260), low lymphocyte count 
(261), ki67 overexpression (262) and p53 gene mutation status (263).  The Korean International 
Prognostic Index was developed as a means of determining prognosis in ENKTL, and relies upon 
stage, performance status, extranodal involvement and non-nasal origin (264).  A Japanese 
group has a similar scoring system that includes “B” symptoms, stage, lactate dehydrogenase 
(LDH) level and lymph node involvement (265).  Most interestingly, a recent study shows that 
circulating EBV levels act as a marker for tumour mass at diagnosis, and also their fluctuation 
during the course of treatment is the most significant prognostic factor in patients treated with 
modern chemotherapy regimens (266). 
 
Pathogenesis and role of EBV in ENKTL 
Cellular genetic lesions 
Macroscopically, ENKTL lesions are often destructive and ulcerated and, as a result, biopsy 
specimens tend to be necrotic.  Repeated biopsies are often required for diagnosis (267) and, 
accordingly, availability of unfixed tissue for molecular genetic studies has historically been 
limited.  To date, no disease-defining translocation events have been confirmed although 
genetic complexity is common (268-270).  Deletions of the long arm of chromosome 6 are seen 
both with conventional karyotyping and with comparative genomic hybridisation (271), 
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implicating tumour suppressor genes within these regions in the pathogenesis of ENKTL (269, 
272). 
Comparative genomic hybridization of NK cell lines and primary tumours showed three 
candidate genes within the common region of deletion in chromosome 6q21 - PRDM1, ATG5 
and AIM1 - and identified PRDM1 as an important target gene by functional studies in cell lines 
(273).  However, another study showed heterogeneity in PRDM1 and suggested alternative 
candidate genes such as HACE1, a tumour suppressor gene (272).  The limitations of poor-
quality and scarce biopsy material, with a reliance on cell lines for molecular studies, means that 
much more work is needed in this area before these results can be extrapolated to the clinical 
situation.  The JAK/STAT pathway is another promising target as it is constitutively activated in 
some ENKTL cell lines, and in tumour samples, and is associated with proliferation and 
migration; the expansion in small molecule inhibitors may make this a promising clinical target 
(274-276).  Interestingly, a single nucleotide polymorphism (SNP) in the gene encoding perforin 
has recently been described in a series of Caucasian ENKTL patients (277) – as will be discussed 
later.  Perforin mutations are associated with X-linked lymphoproliferative disorder (XLP) which 
is characterised by overwhelming and often fatal EBV infection. 
 
The role of EBV in T- and NK- lymphomagenesis 
The first serious evidence that EBV could be implicated in the development of T and NK 
lymphomas arose from the observation of 3 patients who went on to develop T-cell lymphoma 
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after a diagnosis of chronic active EBV (CAEBV)(183).  On closer examination, their tumour cells 
were found to contain clonal copies of the virus, as determined by analysis of the terminal 
repeat sequence.  This suggested that EBV infection of the cell had occurred before its clonal 
expansion.  Subsequently, EBV genomes and/or EBV-encoded RNAs (EBERs) were demonstrated 
within the tumour cells of both nasal and extra-nasal T and NK lymphomas arising in children 
and adults (185, 231, 278).  The most robust association with EBV was seen in extra-nodal 
lymphomas and those arising in the nasopharynx (279). 
 
There is compelling evidence that EBV infection of the NK or T-cell is an early event in 
lymphomagenesis.  Firstly, the virus is seen in virtually all cases regardless of patient ethnicity 
(233, 280), such that the absence of EBV from tumour cells is highly suggestive of an alternative 
diagnosis (174).  Secondly, the virus within the tumour is clonal and EBV genomes are seen in 
every tumour cell within the lesion (281, 282).  Interestingly, a case of ENKTL was recently 
reported to have lost the viral episome – this coincided with its dissemination to the skin, which 
might suggest that EBV-loss clones have a metastatic advantage(283).  Thirdly, the virus within 
the tumour cells is expressing transcripts and proteins such as LMP1 and EBNA-1 (52, 282, 284) 
that have been shown to be important in the growth-transformation of B-cells in vitro and in 
vivo(285). 
Typically there are no more than 20 EBV genome copies per cell.  As will be discussed later, this 
relatively low number suggests latent episomal infection, although higher loads are seen on 
occasion and may have prognostic relevance (286).  Evidence of active lytic cycle within tumour 
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tissue is relatively rare and limited to only occasional cells (52).  It has been proposed that 
quantification or monitoring of EBV genome copy numbers in serum or whole blood may predict 
treatment outcome in both advanced and limited stage ENKTL (256, 287-290).  However, this is 
limited by the fact that most qPCR assays will detect both encapsidated virions and cell-free EBV 
DNA, so high EBV loads in the circulation may simply reflect tumour bulk and necrosis rather 
than virus replication – although as a surrogate marker for tumour bulk it may have some 
significance.  EBV-containing T- or NK cells are sometimes seen (291), although this has not been 
systematically examined.  In particular, the frequency and significance of EBV-harbouring NK 
and/or T cells in the peripheral blood at diagnosis and follow-up has not been adequately 
studied.   
What is not at all clear at present is how such a relatively small number of EBV genes can be 
responsible for the phenotype of ENKTL.  Even LMP1, a well-characterised oncogene, has 
functions that are obscure in T and NK cells.  Interestingly, a recent retrospective study 
examined EBV-gene expression in a cohort of ENKTL patients and found LMP1 expression in only 
22 out of the 30 cases studied; the authors also suggest that in these patients, clinical outcomes 
were superior (51).  This has, as yet, not been confirmed in a prospective series, but it may be 
that the ability to proliferate independent of LMP1 reflects a more damaged cellular genome.  
There is evidence that LMP1 renders cells more susceptible to DNA damage in response to 
radiation and chemotherapy, which might confer an improved prognosis (292).  It may also be 
possible that this reflects the known ability of LMP1 to render cells more immunogenic by 
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upregulating HLA class I (76, 293) as these authors report a cytotoxic infiltrate in one of the 
LMP1-positive biopsies. 
Despite this, however, it is not clear how LMP1 is contributing to the pathogenesis of T- and NK-
cell disorders.  Interestingly, immunohistochemical studies suggest that LMP1 is only expressed 
by a subpopulation of ENKTL cells within the tumour (52), and that the proportion of cells 
expressing the protein can vary between tumours (57).  Of course, this could represent 
fluctuations in expression over time, as seen in LCLs (294), but there is as yet no evidence for 
this.  It is also clear that environmental factors are important since IL-2 deprivation of ENKTL 
lines results in a fall in LMP1 expression, and IL10, IL15 and IFNγ can all increase it (295, 296).  
Interestingly, IL-2 is a potent activator of the JAK/STAT pathway in NK cells (297).  In contrast to 
B-cells where LMP1 expression is regulated by EBNA-2s, in the latency II state in ENKTL where 
EBNA-2 is not expressed, LMP1 transcription initiates from an alternate promoter in the 
terminal repeat region that is not regulated by EBNA-2 (298, 299).  Both the classical EBNA-2-
responsive LMP1 promoter, ED1, and the alternate TP1 promoter are responsive to the 
activation of the JAK/STAT pathway via STAT-binding motifs present in each promoter (300).  As 
discussed above, the JAK/STAT pathway is likely to be an important target in ENKTL, and more 
work is needed to uncover the connection between LMP1 and STAT in vivo (276).  In T-cells 
LMP1 has been shown to upregulate tumour necrosis factor α (TNFα) (216).  LMP1 also acts, in 
B-cells, to inhibit apoptosis by increasing BCL2 levels as well as other anti-apoptotic genes such 
as BFL1 (301), A20 (302) and Mcl-1 (303).  Expression of LMP1 in Jurkat, an EBV-negative T-cell 
leukaemia cell line, resulted in the induction of BCL3 (304) and downregulation of c-myc (305).  
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However, in EBV-positive NK lymphoma cell lines, reducing LMP1 expression did not seem to 
have the same negative effect on proliferation, BCL2 levels and survival that it did in B-cells, and 
more work is needed to try to unravel the different functions in different cells (58). 
LMP2A, and a novel LMP2B-TR transcript, have been shown to be expressed in ENKTL (306).  
However there is little information available on their function in T- and NK-cells.  It is also 
extremely difficult to reliably demonstrate LMP2 protein expression in ENKTL.  Although LMP2A 
can be detected in paraffin sections using antibodies to the N-terminus, there are no reliable 
antibodies for LMP2B.   Conventional, non-quantitative PCR studies suggested low or absent 
levels of both LMP2A and 2B in primary tissue (52, 284).  Notwithstanding this, adoptive T-cell 
preparations containing LMP2-specificities were shown to induce meaningful clinical responses 
in ENKTL patients (307), and LMP2-specific cytotoxic T-lymphocytes (CTLs) can recognise and kill 
ENKTL cell lines.  These findings led to the discovery of a novel LMP2 transcript (306), which 
lacks the first coding and non-coding exons respectively, of the classical LMP2A and LMP2B 
transcripts.  This alternative transcript is therefore not detected by commonly-used PCR primers 
designed to selectively detect LMP2A or LMP2B, but is predicted to encode a protein identical to 
LMP2B.  Expression in primary tissue is variable but can be high, suggesting a role in the 
initiation or potentiation of T/NK lymphomagenesis. 
When we come to consider other EBV genes that are expressed in ENKTL, the literature is 
particularly scanty.  With regard to expression, BZLF1 is seen in a small proportion of ENKTL cells 
(51).  There is no significant expression of BHRF1 miRNAs, but BART miRNAs, particularly miR-
BART9, are increased (308).  The functions of these in the ENKTL setting are not clear.  The only 
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evidence to date of EBNA-1’s role in NK cells comes from a report in which partial silencing in an 
EBV-positive NK cell line reduced proliferation (309).  Yang et al, with an ingenious selectable 
recombinant EBV, managed to infect a few cells of a human T-cell line in vitro and showed that 
EBERs were responsible for inducing IL9 (310), which is postulated to act as an autocrine growth 
factor for ENKTL (311).  The BART miRNAs seem to influence LMP1 expression and cell growth, 
suggesting that they may be significant in lymphomagenesis (308).     
In summary, there is very little solid evidence about the role of EBV in ENKT lymphomagenesis, 
due in part to the relative rarity of the disease, but also to the difficulty in experimentally 
infecting T and NK cells in vitro.  The ubiquitous presence of the virus within the tumour, the 
fact that infection occurs early in lymphomagenesis, and the known oncogenic potential of the 
virus make it seem inevitable that it has an important part to play. 
 
Aggressive NK-cell Leukaemia (ANKL) 
Defined by the WHO as “a systemic proliferation of NK-cells almost always associated with EBV 
and an aggressive clinical course” (174), aggressive NK-cell leukaemia (ANKL) is a rare but 
extraordinarily dangerous disorder.  Its scarcity means that epidemiological data are based of 
necessity on a small series, but it appears that the median age of onset is 42 years, and that the 
male: female incidence is roughly equal (312).  As with the other EBV-associated T- and NK-cell 
disorders, it is more common in Asia than in the West (313).  Occasionally it is preceded by a 
chronic NK-cell lymphoproliferation.  There are no characteristic chromosomal abnormalities 
(312).   
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The commonest presenting symptoms are fever, B-symptoms, disseminated intravascular 
coagulation and haemophagocytosis (313, 314).  Extramedullary infiltration is common, 
particularly involving liver, spleen, lymph nodes and skin (312, 313).  Central nervous system 
and gut involvement are also seen (313).  EBV genomes are seen within the cells in the vast 
majority of cases and are clonal, again suggesting EBV infection as an early event in 
leukaemogenesis (174, 185).  There is very little published literature investigating EBV gene 
expression, although one study suggests the cells are LMP1-negative (315).   
Median survival is 58 days from diagnosis (312).  There is no consensus on treatment although 
L-asparaginase seems to have an effect on overall survival (316).  Allogeneic bone marrow 
transplantation is also likely to represent the only current possibility for long-term remission 
(316).  
 
1.3  Apoptosis 
Apoptosis, or programmed cell death, is a vital biological process.  Its name, from the Greek 
word for the process of shedding leaves from a tree, reflects its non-inflammatory, controlled 
nature, which allows the division of the embryonic fingers, the deletion of autoreactive T-cells, 
and the removal of damaged cells before they can make a cancer, as well as countless other 
processes.  Although its presence was suspected as a counter-balance to the readily-
demonstrable mitosis seen within tissues, it was first named and described microscopically in 
1972 in Aberdeen (317).  It is characterised microscopically by rounding of the cells followed by 
blebbing of the cell membrane with the formation of apoptotic bodies, and condensation and 
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fragmentation of the nucleus.  Widespread proteolytic cleavage takes place as a result of 
activation of the caspase cascade, and the result in vivo is removal of the cell by phagocytes. 
Apoptosis is particularly interesting in regard to cancers – which can be regarded, at some level, 
as a failure of apoptosis leading to uncontrolled proliferation of damaged and malignant cells.  
The process by which cancerous cells are able to escape normal apoptotic triggers, as well as 
how chemotherapy and radiotherapy affect apoptotic pathways, is currently the subject of 
intense scrutiny. 
It is useful to consider the situations in which apoptosis should normally take place.  Firstly, it is 
a vital process in embryogenesis, which I will not discuss in this thesis.  Secondly, it must be able 
to be induced by immune cells in response to intracellular infection.  Thirdly, cells must be able 
to trigger their own apoptosis in response to stresses such as DNA damage and cytokine or 
hormone withdrawal.  As will be discussed, the various external and internal apoptotic stimuli 
converge upon an evolutionarily-conserved pathway which results in the conversion of a live cell 
into a dead one, which can be taken up and degraded by phagocytic cells (318). 
 
Apoptosis pathways 
Although described here separately, the three main apoptosis pathways are closely entwined 
and show substantial areas of overlap (see figure 1-6).  They all converge on the final execution 
pathway. 
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Figure 1-6  - The interaction between apoptosis pathways.  There are 3 main apoptosis pathways, which converge upon the 
activation of the cellular caspase cascade.  The perforin pathway is initiated in response to cytotoxic T- and NK-cells; the 
resultant activation of granzymes A and B results in caspase activation and DNA cleavage.  The extrinsic pathway is ligation of 
cell surface death receptors.  Caspase 8 is activated, which in turn activates both caspase 3 and stimulates the conversion of BID 
to its active form, allowing the activation of the mitochondrial pathway.  Intrinsic pathway activation is a result of intrinsic 
stimuli and results in activation of the mitochondrial pathway.  Although a simplification, this figure highlights some of the 
important proteins in cellular apoptosis.  
 
Execution pathway 
Caspases are a family of cysteine-dependent aspartate-specific proteases which are the central 
regulators of apoptosis.  This family includes the initiator caspases (including caspase 2, 8, 9, 10, 
11 and 12) which are closely coupled to and activated by proapoptotic signals such as DNA 
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damage, ligation of FAS and withdrawal of growth factors.  Once activated, these initiator 
caspases cleave and activate the downstream effector or “executioner” caspases 3, 6 and 7. 
These caspases trigger apoptosis by cleaving cellular proteins (319). 
The different initiator caspases are coupled to specific pro-apoptotic signals (see figure 1-6).  
Activation of FAS by FAS-ligand or TNFR by TNF activates caspases 8 and 10.  Alternatively, DNA 
damage induces the expression of PIDD, which binds RAIDD and caspase 2, resulting in the 
activation of caspase 2.  Cytochrome c released from the mitochondria activates caspase 9; pro-
inflammatory cytokines activate caspase 11; ER stress activates caspase 12 and 7.   
Regardless of the initial trigger, all apoptotic pathways described to date converge on a 
common execution pathway characterised by the activation of caspases-3, -6 and -7.  These 
exist in healthy cells as zymogen precursors, and their cleavage sets in motion the process which 
will usually end with the death of the cell.  In total, caspases have several hundred known 
substrates in human cells alone, and this number is continually increasing (320).  The cleavage 
of cytoskeletal proteins results in the rounding of the cell and membrane blebbing (321).  The 
nuclear membrane is also attacked, resulting in fragmentation (322), and the destruction of cell-
matrix interaction sites allows the dying cell to withdraw from its surroundings.  Cellular 
organelles are fragmented and DNAse enzymes are activated to degrade nuclear material (323).   
Mitochondrial fragmentation is a result of the action of the effector BCL2 family members – BAX 
and BAK.  These permeabilise the mitochondrial outer membrane and permit the release of 
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mitochondrial intermembrane contents, such as cytochrome c, into the cytoplasm (324).  This 
will be discussed later. 
 
Perforin/Granzyme pathway 
Although cytotoxic T-cells can act via the Fas pathway, they can also induce apoptosis by the 
perforin/granzyme pathway.  Here, granules containing perforin and granzyme proteases are 
released by exocytosis into a tight immunological synapse (325); the perforin, as its name 
suggests, can polymerise in the cell membrane of the target cell and produce a pore through 
which the granzymes, as well as water and salts from the extracellular environment, can enter 
the cell (326).  These locate to the nucleus and result in the activation of the apoptotic caspase 
cascade by the initial cleavage of BID (327).  Caspase inhibition will prevent perforin-mediated 
apoptosis, highlighting the importance of the caspases as final pathways (328). 
The importance of the perforin pathway is shown very elegantly by the case of familial HLH, as 
discussed above.  Here, mutations in the pathway proteins result in disease and death within 
the first few years of life. 
 
Intrinsic pathway 
The mitochondrial or intrinsic pathway of apoptosis is initiated by numerous cytotoxic stimuli 
and pro-apoptotic signal-transducing molecules which act in concert to induce mitochondrial 
outer membrane permeabilisation (MOMP).  This is the common response to a variety of stimuli 
which can be either negative (for example the withdrawal of a hormone) or positive, including 
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DNA damage.  The increased permeability of the mitochondrial membrane allows the release of 
pro-apoptotic proteins such as cytochrome c, SMAC/DIABLO and endonuclease G from the 
mitochondrial intermembrane space into the cytoplasm (329, 330).  These proteins then trigger 
the caspase execution pathway or act as caspase-independent death-effectors.  
 
The BCL2 proteins 
The intrinsic apoptosis pathway is mediated to a great extent by a group of structurally related 
proteins.  Named BCL2 proteins after the founding member of the family, they can be divided 
into 3 groups: the pro-apoptotic BH3-only group, the multidomain anti-apoptotic BCL2 group, 
and the multidomain pro-apoptotic effector proteins (see figure 1-7).  
 
Figure 1-7.  The BCL2 family proteins.These can be divided by function and by structure.  The multidomain anti-apoptotic group 
members each contain 4 α-helical BH domains (BH1-4) and a transmembrane (TM) domain.  The multidomain pro-apoptotic 
group have a similar structure but without the fourth BH domain.  The BH3-only group, as implied by their name, consist of the 
BH3 domain only – they can be further subdivided by their function into activators or sensitisers. 
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BCL2, the founding member of the BCL2 family, was first discovered in 1985.  A translocation 
between chromosomes 14 and 18, which is strongly associated with follicular lymphoma, was 
shown to put the gene encoding BCL2 into the region of influence of the Ig heavy chain 
promoter, resulting in its overexpression (331).  Introduction into cell lines showed that it 
promoted cell survival, and could thus contribute to oncogenesis (332). 
The structure of the BCL2 family members is highly conserved.  The BCL2 and effector protein 
groups all share four BCL2 homology (BH) domains (BH1-3) whereas the BH3 group have only 
BH3.  BH1, 2 and 3 form a globular structure with a hydrophobic groove which interacts with the 
BH3 domain of the BH3-only group.  This interaction occurs predominantly on the mitochondrial 
outer membrane (333).  Whether a cell lives or dies depends upon the relative balance between 
the pro- and anti-apoptotic proteins present, and so disruption of this, either by pathology or 
pharmacology, is important in both the development and treatment of cancer. 
 
The effector proteins 
Both the pro- and anti-apoptotic groups exert their effects predominantly through the pro-
apoptotic effector groups, which are essential for apoptosis to take place (334).  The effector 
proteins are kept inactive in cells by association with the anti-apoptotic BCL2 family members.  
The pro-survival actions of the BCL2 proteins are reliant on their ability to bind and neutralise 
the effector proteins BAX and BAK.  When levels of BH3-only pro-apoptotic proteins rise, the 
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BCL2 proteins are displaced from BAX and BAK, and apoptosis can take place.  When activated, 
BAK and BAX oligomerise and can form pores in the mitochondrial outer membrane (335) – 
causing MOMP. 
 
The pro-apoptotic BH3 group 
BH3 proteins act by activating the effector proteins and by binding and neutralising the anti-
apoptotic group members.  Synthetic peptides corresponding to the BH3 domains have been 
shown to mimic the function of the naturally-occurring proteins (334, 336).  There is a degree of 
heterogeneity in their function, with some able to bind BAK and BAX directly (for example, BID 
and BIM – the activator proteins), and some acting purely through their effects on the BCL2 
group members (derepressor or sensitiser proteins) to release sequestered BAK and BAX (324).  
Similarly, some are selective for which BCL2 protein they bind whereas others are more 
promiscuous (see figure 1-8) (335).  However, it is necessary for one of the direct activator 
proteins (i.e. BID or BIM) to be present for apoptosis to take place – the derepressor and 
sensitisers, which act by inhibiting the anti-apoptotic effects of the BCL2 family, will not suffice 
on their own (334, 337). 
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Figure 1-8.  Binding profiles for the BH3 proteins and BCL2 family.As can be seen, some are selective for one target whereas 
others can bind more than one BCL2 family member.  Redrawn from (260) 
 
There are two current models for how BH3 proteins are able to contribute to apoptosis, 
although the situation in vivo is likely to represent a combination of these (338).  The “direct 
activation” model assigns them two roles – as sensitisers and as direct activators.  The sensitiser 
proteins (BAD, BMF, NOXA, HRK, BIK) interact only with the anti-apoptotic group and neutralise 
them, allowing the activation of the effector proteins.  The direct activator group (BIM, PUMA, 
BID) can not only neutralise the anti-apoptotic proteins but can also directly activate BAX and 
BAK (324).  In contrast, the “indirect activation” model suggests that BAX and BAK are 
spontaneously activated, and the role of the pro-apoptotic proteins is simply to release them 
from the control of the BCL2 family (339).   
BID is inactive in its full length form as the BH3 domain is hidden; its activation requires cleavage 
by caspase-8, caspase-2 or granzyme B (340, 341); it is also enhanced by N-myristoylation (342).  
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The active t-BID moves to the mitochondrion and mediates mitochondrial outer membrane 
permeabilisation. 
Sensitiser proteins act by binding to anti-apoptotic proteins and preventing them inhibiting the 
direct activators in response to stress.  For example, cellular stress may induce the expression of 
BIM.  If BCL2 is expressed the BIM will be sequestered, but if PUMA is also present then the 
BCL2 is neutralised and the BIM can activate the effector proteins.  In de-repression, the 
antiapoptotic protein which is binding and neutralising an effector protein is displaced from that 
interaction and so apoptosis can take place (335). 
The pro-apoptotic BH3 family members are also important in cellular response to 
chemotherapy.  For example, PUMA, NOXA and BIM expression are required for maximal 
lymphoma toxicity by DNA damaging agents (343), and PUMA and BIM are important in 
mediating cell death in response to glucocorticoids or radiation (344) (see figure 1-9). 
 
The anti-apoptotic proteins 
BCL2, after its early identification as an important protein in lymphomagenesis (see above), was 
shown to protect cells from apoptosis induced by cellular stress and, in combination with CMYC, 
to contribute to lymphomagenesis (332).  It, and the other family members, sequester the 
activator proteins and prevent them initiating apoptosis.  Overexpression of BCL2 is seen not 
only in follicular lymphoma but also in chronic lymphocytic leukaemia (CLL), where it 
corresponds to poorer prognosis (345), myeloma (346) and other B- and T-cell malignancies 
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(reviewed in (347)).  BCL2 overexpression can contribute to a failure of the cell to undergo 
apoptosis in response to stress (348).  Malignant cells are described as being addicted to anti-
apoptotic proteins, meaning they are reliant upon them to survive – it follows that by targeting 
these proteins we would expect to be able to induce apoptosis in these cells, a new and 
important direction for cancer chemotherapy. 
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Figure 1-9 - The interaction between the BCL2 family members in the control of cellular apoptosis (from (333)).  Usually the 
effector proteins BAX and BAK are kept neutralised by the anti-apoptotic BCL2 proteins.  A pro-apoptotic stimulus, either from 
the intrinsic or extrinsic pathway, results in the activation of the BH3-only proteins with resulting inhibition of the anti-apoptotic 
BCL2 family members and activation of BAX and BAK effector proteins.  These associate in the mitochondrial outer membrane 
and result in MOMP. 
 
BH3 mimetics 
In the quest to exploit the intrinsic apoptosis pathway for therapeutic ends, highly-specific small 
molecules have been designed to bind into the hydrophobic groove of the BCL2 family proteins 
58 
 
to inhibit the interactions between the proteins.  These molecules are known as BH3 mimetics, 
and are currently under close scrutiny to assess their effectiveness in treating malignancies.  The 
first to show effectiveness, ABT-737, inhibits BCL2, BCL-XL and BCL-w, and was shown to cause 
cell death in lymphoma particularly CLL and small-cell lung cancer cells, and to enhance 
sensitivity to chemotherapeutic agents and radiation in other tumours (349).  It binds to BCL2 
with a higher affinity than to BCL-XL or BCL-w in cells (350). 
Unfortunately a side effect of ABT-737 mediated BCL-XL inhibition is dose-limiting 
thrombocytopenia, therefore ABT-199 was engineered to be a specific BCL2 inhibitor.  It can 
induce apoptosis in cell lines dependent on BCL2, and has activity in vivo (351).  Clinical trials are 
still underway but it has shown impressive activity against CLL in particular, even in the 
presence of adverse prognostic features (see (347) for review and preliminary data).  Although 
obatoclax (GX15-070) was initially thought to be a specific inhibitor of MCL1 (352), it has 
recently be shown to cause cell death in a manner independent of BAX, BAK and caspase 9, 
suggesting that its cytotoxicity is not related to the intrinsic apoptotic pathway. 
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AIMS OF THE THESIS 
 
1. The T- and NK-cell EBV-associated malignancies express the viral proteins LMP1, LMP2A 
and LMP2B, the functions of which are poorly defined.  Therefore, our first aim is to 
investigate their modulation of cellular genes in primary NK cells, and compare this to 
the effects previously observed in other cell backgrounds. 
2. ENKTL and CAEBV are highly resistant to conventional chemotherapies.  However, the 
role of the virus in this resistance is currently unknown.  Our second aim, therefore, is to 
investigate the role of the viral proteins, particularly LMP1, on the growth, proliferation 
and survival of CAEBV and ENKTL cell lines. 
3. EBV-associated non-B-cell disorders are rare and diagnosis is often difficult.  Our third 
aim is, therefore, to develop an assay which can quickly and reliably determine the 
identity of the infected lymphocyte subsets directly on peripheral blood samples. 
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 CHAPTER 2 - MATERIALS AND METHODS 
 
2.1  Donors and Patients 
Ethical approval for this work was provided from the West Midlands Research Ethics Committee 
(REC: 07/H1208/62).  Patients were recruited from clinical centres with probable or confirmed 
diagnoses of T- or NK-cell EBV infection; after giving informed consent, blood or bone marrow 
samples were taken.  Samples received from non-study centres were sent for diagnostic 
purposes, with anonymised clinical data provided subsequently.  Healthy donors were recruited 
from departmental staff; blood samples were taken after informed consent and according to 
local protocols. 
 
2.2  Cell culture methods 
Maintenance of cell lines 
T and NK cell lines 
All cells were grown at 37°C in 5% CO2.  T and NK cell lines were grown in NK medium - CellGro° 
SCGM (stem cell growth medium - CellGenix™) supplemented with 10% v/v heat-inactivated, 
sterile-filtered human serum (Sigma), 50 U/ml penicillin/streptomycin, 6 mM L-glutamine 
(Invitrogen), 1 mM sodium pyruvate (Sigma), 0.13 mg/ml oxalacetic acid (Sigma) and 700 U/ml 
IL-2 (Novartis).  Human serum was heat-inactivated by heating to 56°C for 30 minutes, cooling 
to 4°C then centrifuging at 3000 rpm in a Heraeus™ Megafuge™ 40 centrifuge for 30 minutes.  
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The serum was finally filtered through a 0.2 µm syringe filter.  It was then either used 
immediately or frozen at -20°C.  Of note, the ability of the serum to support NK growth was 
batch-sensitive. 
The T and NK cell lines (table 2.1) were obtained from Professor Shimizu (Tokyo Medical and 
Dental University, Japan).  MEC04 (276), SNK1, 6 and 10, and SNT8 and 16 were cultured in 
25cm2 flasks (Corning, Sigma-Aldrich, Germany) in NK medium.  SNT13 and 15 were cultured in 
12 well plates (Iwaki).  Cells were split approximately twice a week, aiming for a cell density of 
approximately 1x106 cells/ml.  In practice this usually resulted from splitting 1:3. 
Table 2-1 - T- and NK-cell lines used in this study.  
Name Lineage Underlying disease Reference 
SNK1 NK ENKTL with CAEBV (353) 
SNK6 NK ENKTL (354) 
SNT8 γδT ENKTL (354) 
SNK10 NK CAEBV (353) 
SNT13 γδT ENKTL (355) 
SNT15 γδT ENKTL (355) 
SNT16 αβT CAEBV (353) 
MEC04 NK ENKTL (276) 
 
 
Primary NK cells 
Primary NK cells were cultured in 24 well plates in NK medium, as described above.  Following 
entry into exponential growth phase, usually about a week after isolation, the cells were split to 
maintain a density of approximately 1x106cells/ml; in practice this resulted in splitting 1:2 every 
4 days. 
62 
 
 
B-cells 
Primary B-cells and B-cell lines were grown in cell culture medium consisting of RPMI 1640 
(Sigma) supplemented with 10% v/v fetal calf serum (Gibco), 50 U/ml penicillin/streptomycin 
and 6 mM L-glutamine (Invitrogen).  Primary B-cells, after infection with EBV, were cultured in 
12 well plates, B-cell lines in 25 cm2 flasks. 
 
Epithelial cells 
293FT (Invitrogen) cells were grown in 10 cm plates (Corning) in cell culture medium consisting 
of RPMI 1640 (Sigma) supplemented with 10% v/v heat-inactivated bovine calf serum, 50 U/ml 
penicillin/streptomycin, 6 mM L-glutamine (Invitrogen) plus 500 μg/ml G418 (Life Technologies).  
The serum was inactivated by heating to 56°C for one hour.  Cells were split 1:4 when they were 
approximately 90% confluent using 1 ml 10% trypsin solution (Sigma) per 10 cm plate to detach 
them.  The trypsin was inactivated in growth medium and then the cells were passaged onto 
fresh plates.  For lentiviral production, 293-FT cells were used up to passage 15 before being 
discarded. 
 
Cell cryopreservation 
Up to 1x107 viable primary lymphocytes and up to 5x105 cells from cultured lines were 
cryopreserved as follows: cell lines were initially centrifuged at 1200 rpm in a Heraeus™ 
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Megafuge™ 40 centrifuge for 5 minutes then resuspended in 1 ml of the cell-specific culture 
medium supplemented with 10% v/v of DMSO and a further 10% v/v of serum.  Primary 
lymphocytes isolated from the blood were resuspended in 1 ml heat-inactivated human serum 
supplemented with 10% v/v DMSO.  After initial slow freezing at -80° in a “Mr Frosty” 
isopropanol-filled container for at least 4 hours they were transferred to the vapour phase of a 
liquid nitrogen freezer for long-term storage at -180°C.  
 
Recovery of cells from liquid nitrogen 
Cell recovery was undertaken by quickly defrosting the vial of cells in a 37°C water bath then 
immediately adding the contents to 40 ml prewarmed culture medium in order to dilute the 
DMSO.  The cells were centrifuged at 1200 rpm in a Heraeus™ Megafuge™ 40 centrifuge then 
resuspended in appropriate cell-specific medium. 
 
Isolating PBMCs from whole blood or aphaeresis cones 
Peripheral blood mononuclear cells (PBMCs) were obtained either from healthy volunteers 
working within the School of Cancer Sciences, or from aphaeresis leukocyte-depletion “cones” 
obtained from the National Blood Service.   
UK-based patients with ENKTL, CAEBV or HLH were recruited as part of our ongoing study “EBV 
associated NK/T cell malignancies” (UKCRN ID: 5098).  Samples of blood or bone marrow were 
received. 
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Samples were diluted 1:2 (fresh blood) or 1:5 (aphaeresis cone) with phosphate buffered saline 
(PBS) and layered onto LymphoPrep (Axis Shield, Oslo, Norway) in 50 ml polypropylene tubes.  
LymphoPrep has a density of 1.077 +/- 0.001 g/ml whereas PBMCs are generally less dense.  
When centrifuged at 1800 rpm in a Heraeus™ Megafuge™ 40 centrifuge for 30 minutes with no 
brake the PBMC compartment forms a visible layer at the interface between the plasma and the 
LymphoPrep.  This layer was removed with a transfer pipette.  Sequential centrifugation in a 
Heraeus™ Megafuge™ 40 centrifuge at decreasing velocities was performed to remove residual 
LymphoPrep and platelets; these centrifugation steps were typically 1600 rpm for 10 minutes, 
followed by 1200 and 1000 rpm for 5 minutes each.  All washes were performed in 50 ml PBS. 
 
Isolating primary NK cells 
Primary NK cells were isolated from the PBMC suspension using the Dynabeads° Untouched™ 
Human NK Cells kit (Life Technologies, UK).  Briefly, the PBMCs were resuspended in PBS with 
2% fetal calf serum and 1 mM EDTA.  They were then incubated at 4°C with a cocktail containing 
biotinylated monoclonal antibodies against CD3, CD14, CD36, HLA Class II, CD123 and CD235a, 
with heat-inactivated FCS to block non-specific binding.  After washing, pre-washed 
streptavidin-conjugated Dynabeads, which bind to the biotinylated-antibody-coated cells, were 
added to the cells and incubated at room temperature with agitation for 15 minutes.  The 
suspension was placed inside a magnetic isolator (DynaMag-15, Life Sciences) causing the bead-
bound non-NK cells to be removed from suspension thereby allowing the recovery of the 
untouched NK-cells.  The cells were washed and placed in the isolator for a second time to 
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recover the maximum number of non-NK cells.  The isolated 95% pure NK cells were then spun 
down and resuspended in NK medium for culture.  Primary NK cells were grown in 24 well plates 
at approximately 1x106 cells per well.  Once proliferating, cells were split approximately 1:2 
twice a week. 
 
Isolating primary B-cells 
Primary B-cells were positively isolated from a PBMC suspension as prepared above.  PBMCs 
were incubated with CD19-conjugated magnetic DynaBeads™ (Invitrogen) at a ratio of 4 beads 
per cell for 30 minutes at 4°C with continual agitation.  The bead-coated B-cells were then 
removed from the non-B-cells by exposure to a magnet followed by five sequential washes and 
magnet exposure to purify the B-cells.  The magnetic beads were then removed from the B-cells 
by incubation with CD19 DetachaBead™ (Invitrogen) for 45 minutes at room temperature 
followed by magnet exposure.  The resulting B cell preparation was at least 98% pure.  
B-cell infection with EBV and generation of lymphoblastoid cell lines 
 
Primary B-cells were pelleted by centrifugation at 12000 rpm for 5 minutes in an Heraeus™ 
Megafuge™ 40 centrifuge and were resuspended in titrated viral supernatant at a sufficient 
volume to give a multiplicity of infection (MOI) of at least 10 virus particles per cell.  After 2 
hours incubation at 37°C the viral supernatant was removed by centrifugation and resuspension 
of the cells in B-cell medium in 24-well plates at 2x106 cells/ml.  The cells were inspected daily 
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and fed with fresh medium as required.  As cell numbers increased the cultures were 
transferred to larger wells or flasks for ongoing culture. 
 
Growth assays 
Cells were counted and plated in triplicate into 24 well plates with 0.5 x 106 cells per well in 2 ml 
appropriate medium.  On each day the cells were resuspended and thoroughly mixed and 10 μl 
of the cell suspension was combined with an equal volume of 0.4% Trypan Blue (Sigma).  A 10 μl 
sample of this suspension was inserted into one well of a cell counter slide and the cells were 
counted on the BioRad TC20 automated cell counter.  Total and live cells were counted and an 
average of the three wells was taken.  Every day, half of the medium in the remaining wells was 
removed and replaced with fresh medium.  Cells were split 1:2 when they reached 80% 
confluence. 
 
Apoptosis assays 
Cells were seeded into 96-well, flat-bottomed plates at 5x104 cells per well in 100 μl of the 
appropriate medium supplemented with the apoptosis-inducing drugs etoposide, ionomycin, 
camptothecin, ABT199 and ABT737 (described in detail in chapter 3).  The cells were treated for 
48 hours then harvested, washed and stained for Annexin V and PE using the eBiosciences 
Annexin V PE kit.  This involved suspending the cells at 1x106cells/ml in the Binding Buffer 
supplied and staining at room temperature with fluorochrome-conjugated Annexin V, which 
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binds to phosphatidylserine (PS).  Usually located on the inner leaflet of the plasma membrane, 
in apoptotic cells it is translocated to the outer membrane and so can be bound by Annexin V.  
Propidium iodide, which is actively excluded from live and early apoptotic cells, was then added 
(to an end concentration of 1%) immediately before analysis.  Live cells were analysed by flow 
cytometry on the Becton Dickinson Accuri flow cytometer. 
 
2.3  Molecular Biology Techniques 
In order to minimise sample degradation or contamination, DNAse and RNAse-free water and 
plasticware were used for all molecular biology procedures. 
 
RNA extraction from less than 1x106 cells 
In order to preserve the cellular RNA, cells were sorted by fluorescence-activated cell sorting 
(FACS) into DEPC-treated phosphate buffered saline (Ambion) in RNAse-free Eppendorf tubes, 
and were kept on ice.  RNA extraction from < 1x106 cells for use in the Microarray studies was 
performed using the RNeasy Micro centrifuge-column kit (Qiagen, Germany) according to the 
manufacturer’s instructions.  ExpressArt NucleoGuard (Amsbio, Spain), a universal nuclease 
inhibitor, was added to the cell lysis buffer.  An additional on-column DNAse digestion was 
undertaken to minimise DNA contamination.  The resultant RNA was frozen immediately at -
80°C.  Analysis of RNA quality and quantity was undertaken using the Eukaryote Total RNA Pico 
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Series II Bioanalyser chip (Agilent) for microarray purposes, or using the 
NanoDrop Fluorospectrometer (Thermo Scientific). 
 
RNA extraction from more than 1x106 cells 
For RNA extraction from more than 1x106 cells the NucleoSpin° RNA kit (Macherey-Nagel) was 
used as per the manufacturer’s protocol.  Briefly, the cells were lysed in a lysis buffer with 
added  β-mercaptoethanol.  The lysate was filtered then ethanol was added before the RNA was 
bound to a column.  This was washed, then after an on-column DNAse digestion step, eluted 
into DEPC-treated water.  The resulting RNA was quantified using the NanoDrop  
Fluorospectrometer (Thermo Scientific). 
 
DNAse digestion of RNA 
To minimise contamination of RNA with cellular DNA, a further DNAse digestion step was 
performed upon the extracted RNA using the DNA-free kit (Ambion).  Briefly, 1 μg of RNA was 
treated with 1 μl of rDNase for 30 minutes at 37C, then inactivated during a 2 minute 
incubation with 5 μl DNAse Inactivation Reagent.  Following a brief centrifugation, the purified 
RNA was removed to a fresh tube and used to generate cDNA. 
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Generation of cDNA from RNA using reverse transcriptase 
cDNA was made from the extracted RNA using QScript cDNA Supermix (Quanta Biosciences, 
USA) as per the manufacturer’s protocol.  Briefly, 400 ng of RNA was incubated with 4 μl of 
QScript cDNA Supermix (containing reverse transcriptase and random primers) in a total 
reaction volume of 20 μl for 5 minutes at 25C, 30 minutes at 42C and 5 minutes at 85C.  In 
order to control for the presence of genomic DNA contamination of the RNA, controls lacking 
the reverse transcriptase enzyme were prepared in exactly the same way. 
 
DNA extraction from cells 
DNA was extracted from cells using the DNEasy Blood & Tissue Kit (Qiagen) according to the 
manufacturer’s instructions. 
 
Conventional reverse-transcriptase PCR (RT-PCR) 
In order to amplify specific cDNA sequences for subsequent cloning, primers were designed to 
correspond to the beginning and end of the gene of interest.  PCRs were performed in a 50 µl 
reaction volume containing 100 ng of cDNA, 1x Expand High Fidelity buffer, 5 µl of dNTPs (2 
mM), 5 µl of the forward and reverse primers (10 µM) and 1 µl of Expand High Fidelity Taq 
Enzyme (Invitrogen).  The enzyme was added after an initial denaturation at 90°C for 1 minute.  
The PCR reaction consisted of denaturation at 94˚C for 5 minutes followed by 35 cycles of 94˚C 
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denaturation for 1 minute, 55˚C annealing for 1 minute and 72˚C extension for 2 minutes in an 
Eppendorf Thermocycler.  Products were separated by agarose gel electrophoresis. 
 
Agarose gel electrophoresis 
The DNA PCR product was mixed 6:1 v/v with gel sample loading buffer (0.25% xylene cyanol, 
0.25% bromophenol blue, 30% glycerol) and loaded onto a 0.6% agarose TAE gel (40 mM Tris-
acetate, 1 mM EDTA) (Eurogentec) in 1 x TAE buffer containing 5 µg/ml ethidium bromide.  A “1 
kb DNA ladder” (Promega) was loaded into one lane to determine PCR product size.  DNA bands 
were visualised using UV transillumination; the correct-sized PCR amplicon was excised and 
extracted from the gel using the QIAquick Gel Extraction Kit (Qiagen, Germany) and 
resuspended in a total volume of 50 µl, according to the manufacturer’s instructions.   
 
Phenol-chloroform purification and ethanol precipitation 
The gel-extracted PCR amplicon was purified by phenol-chloroform purification and ethanol 
precipitation as follows.  An equal volume (50 µl) of phenol-chloroform was added to the gel-
extracted PCR amplicon and mixed thoroughly.  This was then centrifuged at 13000 rpm in a 
Hereaus™ Pico™ microfuge for 5 minutes, the supernatant (aqueous layer) removed and mixed 
with 2.5 (v/v) x 100% ethanol and 0.1 (v/v) x 3 M sodium acetate then incubated at -20˚C for 30-
60 minutes to precipitate the DNA.  This was then centrifuged at 13000 rpm in a Hereaus™ 
Pico™ microfuge at 4°C for 30 minutes to pellet the DNA.  The supernatant was discarded; the 
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pellet was washed in 200 µl 70% ethanol then air-dried and resuspended in 50 µl DEPC-treated 
water. 
 
Digestion of DNA with restriction endonucleases 
In order to insert DNA sequences specifically into plasmid vectors and to verify insertion it is 
possible to exploit the specificity of different restriction endonucleases for specific DNA 
sequences.  One microgram of plasmid DNA (for cloning) or up to 500 ng plasmid DNA (for 
verification purposes) was digested by addition of 1 μl of the selected enzyme in a 50 μl reaction 
in the appropriate buffer.  The digests were generally incubated at 37°C for at least an hour, and 
the products separated by agarose gel electrophoresis as described above. 
 
2.4  Bacteriology 
DH5α and Stbl3 competent E.coli bacteria were purchased from Life Technologies and grown in 
either sterile Lennox Broth (LB) medium or on LB agar plates.  Ampicillin was added to both at a 
final concentration of 100 μg/ml to prevent non-specific growth. 
 
DNA ligation reactions 
The gene of interest was ligated into the appropriate plasmids by incubation of the relevant 
segment of DNA (either from a PCR reaction or from restriction digestion of plasmid DNA) with a 
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plasmid which had been pre-digested with the appropriate restriction endonuclease.  After 
digestion, plasmids were treated with 0.5µl of calf alkaline phosphatase (CAP) per 10 µl of 
reaction volume to remove the phosphate thereby preventing religation of the plasmid DNA to 
itself at 37˚C; after 30 minutes a further 0.5 µl CAP per 10 µl reaction volume was added and 
incubated for a further 30 minutes at 37˚C.  The CAP was then inactivated by heating to 80˚C for 
5 minutes.  Approximately 50 ng of phenol chloroform-purified LMP2A or LMP2B-TR gene 
sequence was incubated with a 1:1, 2:1 or 3:1 molar ratio of the plasmid vector and 1 µl (400 
units) T4 DNA ligase in 1 x T4 buffer in a 20 µl reaction volume for 18 hours at 4C.  The entire 
ligation reaction was then transformed into competent E.coli by heat-shock, as described below. 
 
Transformation of competent bacteria 
Plasmid DNA or ligation reactions were transformed into competent E. coli cells as follows.  
Twenty ng of plasmid DNA or entire ligation reactions were initially incubated with 100 µl of 
DH5α or Stbl3 on ice for 20 minutes.  The bacteria were heat shocked at 42˚C for 90 seconds 
then incubated at 37˚C for 1 hour in 1 ml of LB broth with agitation.  The bacteria were then 
centrifuged at 3000 rpm in a Hereaus™ Pico™ microfuge for 2 minutes, the majority of the 
supernatant discarded and the cells resuspended in the remainder. This was spread on pre-
warmed ampicillin-containing (100 μg/ml) LB agar plates.  Colonies were picked after incubation 
at 37°C for 18 hours. 
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Preparation of plasmid DNA 
A 4 ml culture of LB broth containing 100 μg/ml ampicillin inoculated with a single bacterial 
colony from an agar plate was incubated for 18 hours in a 37˚C shaking incubator.  The bacterial 
DNA was then extracted using the QIAprep Spin Miniprep Kit (Qiagen, Germany).  The correct 
insert was verified by restriction enzyme digestion and sequencing.  In order to amplify the 
correct plasmid, 200 ml of ampicillin-containing LB broth was inoculated with a 4 ml day culture 
of the correct bacterial clone and incubated at 37°C overnight in a shaking incubator.  The 
plasmid DNA was isolated using the QIAprep Spin Maxiprep Kit (Qiagen, Germany), according to 
the manufacturer’s instructions.  The resulting DNA pellet was air-dried and resuspended in 
DEPC-treated water at 1 μg/μl and stored at -20°C in small aliquots. 
 
2.5  Lentiviral vectors 
The lentiviral expression system 
The lentiviral vector system used here was designed by Dr Marco Herold (356) and was kindly 
donated by him.  It constitutively expresses GFP from a ubiquitin promoter, allowing 
identification of successfully transduced cells, but has the gene of interest under tetracycline 
repression.  Introduction of doxycycline, a stable tetracycline analogue, allows the repressor to 
dissociate from the promoter sequence and thus gene expression can take place (see figure 2-
1). 
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Figure 2-1 - The FH1T inducible vector showing doxycycline-induced dissociation of the Tet repressor from the genome.From 
Herold et al (356).  In the absence of the antibiotic, the tetracycline repressor protein (TetR) is associated with the gene 
promoter at the tetO sequence and the gene is silenced.  When doxycycline is added, the repressor protein is dissociated from 
the promoter and gene expression, a shRNA in this example, can take place.  Green-fluorescent protein (eGFP) is expressed 
regardless of the presence of doxycycline which allows identification of successfully transduced cells.  
 
PCR amplification of the relevant EBV gene 
ENKTL, although rare, is proportionally much more common in Asia and South America (233, 
234).  EBV strains also show some geographical variation, the significance of which is not always 
clear (16, 17),  For this reason SNK6, a Japanese ENKTL line (354), was used as the source of the 
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viral sequence for the LMP1 and LMP2B-TR.  As LMP2A, however, is not expressed in any ENKTL 
line, the B95.8 sequence was used for this.  There is, as yet, no reliable antibody to detect 
LMP2B.  The LMP2B was therefore cloned with a carboxyl-haemagglutinin (HA) tag to enable 
detection by anti-HA antibodies for Western blot analysis.  
RNA was extracted from B95.8 and SNK6 cells, which have high expression of LMP2A or LMP2B-
TR as described in chapter 1.  cDNA was generated from 1 µg of total cellular RNA by reverse 
transcription using the Qscript cDNA Supermix (Quanta Biosciences, USA) as per the 
manufacturer’s protocol.  LMP2A and LMP2B were amplified from the cDNA by Polymerase 
chain reaction (PCR).  Primers corresponding to the beginning and end of the gene were 
designed using Primer Express software v2.0, and were manufactured by Alta Biosciences UK 
(see table 2-2).  The forward primer incorporated a Kozak sequence (ACCATG) to maximise 
expression.  The reverse primers incorporated a BglII (LMP2A) or BamH1 (LMP2B) restriction site 
to facilitate cloning into plasmids.  The Expand High Fidelity PCR system (Roche, Switzerland), 
incorporating a proofreading DNA polymerase enzyme, was used to minimise PCR-induced 
sequence error.  
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Table 2-2 - Primers used in the initial PCR reaction 
 Forward Reverse 
LMP
2A 
5’-
GCGCAGATCTACCATGGGGTCCCTAGAAATG
GT-3' 
5’ -
GCGCGGATCCTACAGTGTTGCGATATGGGGTCGGTG
GGCG -3’  
LMP
2B 
5’-
GCGCGGATCCAACCATGAATCCAGTATGCCT
GCCTGTAATTGTTGCGCCCTACCT-3’ 
5’ - 
GCGCAGATCTTACAGTGTTGCGATATGGGGTCGGTG
GGCG - 3’ 
 
 
Cloning into pGEM°-T Easy Vector system 
 
The cloning strategies are summarised in figures 2-2 and 2-3.  The PCR product was initially 
cloned into the pGEM°-T Easy Vector (Promega, USA).  Briefly, 1 µl purified LMP2A or LMP2B 
PCR amplicon was incubated with 1 µl pGEM-T vector and 1 µl T4 ligase in 1 x T4 buffer in a 20 µl 
reaction volume for 18 hours at 4C.  The ligase reaction was then transformed into competent 
DH5α E. coli cells as described.  The transformed cells were plated onto ampicillin-containing 
agar plates pre-treated with X-galactose and Isopropyl β-D-1-thiogalactopyranoside (IPTG).  The 
agarose plates were incubated overnight at 37˚C and white colonies, indicating that the 
incorporated fragment has inactivated β-galactosidase, were picked.  The correct insert was 
confirmed by restriction enzyme digestion and sequencing. 
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Generating the FTGW-HA plasmid 
A B 
C 
 
 
Figure 2-2.  LMP1 cloning schematic.The LMP1 sequence was inserted into the FTGW plasmid (panel A) using BAMH1 and EcoR1 
(panel B), then excised, with the promoter, and inserted into the FH1T vector using PacI (panel C). 
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A B 
C D 
Figure 2-3 - LMP2 cloning schematic.The HA linker sequence was inserted into the FTGW intermediate plasmid (panels A & B).  
The LMP2 sequence, isolated from the SNK6 cell line, was inserted into the same FTGW plasmid (panel C); the protein:HA 
sequence, with the promoter, was then cut out using PacI and inserted into the final vector (panel D). 
 
In order to generate an LMP2A and LMP2B protein with an HA tag, a linker sequence small scale 
oligonucleotide was synthesized by Alta Biosystems.  The sequences were generated using 
MacVector software to incorporate the HA tag sequence (TACCCATACGATGTTCCAGATTACGCT), 
with a Bam HI restriction site at the 5’ end, and a stop codon, a Pac1 site then an Eco R1 site at 
the 3’ end (figure 2-3).  The linker sequences are shown in table 2-3. 
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Table 2-3 - Sequences of the HA tag linkers. 
HA tag linker forward 5’ - GATCCTACCCATACGATGTTCCAGATTACGCTTAATTAATTAAG - 3’ 
HA tag linker reverse 5’ - AATTCTTAATTAATTAAGCGTAATCTGGAACATCGTATGGGTAG - 3’ 
 
Two μl of each of the forward and reverse linker sequences (100 μg/ml) were incubated with 46 
µl of Roche restriction buffer B at 90°C for 3 minutes, and then left to anneal at 24°C for 2 hours.  
2 μg of FTGW plasmid DNA was digested with 2 µl of BamH1 and 2 µl of Eco R1, in a total 
volume of 100 µl in 1 x Buffer B.  This was incubated at 37°C for 3 hours.  The annealed HA 
linkers were ligated into the digested FTGW plasmid in a 20 µl total reaction volume, with a 
200:1 molar ratio of insert to vector.  Thus, 60 ng of digested FTGW vector and 50 ng of 
annealed HA linkers were incubated at 4°C overnight with 1 µl of T4 DNA ligase in 1 x T4 DNA 
ligation buffer.  The HA DNA was replaced by water for a negative control.  5 μl of the ligation 
reaction was transformed into 50 µl competent Stbl3 cells by heat-shock; the resulting colonies 
were picked and screened by restriction digest to select clones containing the HA tag. 
 
Cloning LMP2A and LMP2B into the FTGW-HA plasmid 
The LMP2A- and LMP2B-pGEM-T vectors and the FTGW-HA vector were all digested with 
BamH1 (LMP2B), or BamH1 and Bgl-II (LMP2A) in order to clone the LMP2A/B into the FTGW-
HA.  Briefly, 2 µg of DNA was digested with 2 µl of the appropriate restriction enzyme(s) in the 
relevant buffer.  The digested DNA was separated by electrophoresis on a 0.8% agarose gel.  The 
correct size fragment was excised, gel-purified and phenol-purified as described previously.  The 
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viral genes were ligated into FTGW-HA at a 3:1 insert:vector ratio using T4 DNA ligase at 4˚C for 
18 hours.  As previously described, the ligation mix was transformed into 100 µl of competent 
Stbl3 cells.  The Stbl3 cells were grown on ampicillin LB agar plates overnight, DNA was 
extracted and the correct clones identified by restriction digestion.  Plasmid DNA was then 
extracted from 200 ml bulk preparations.  
 
Cloning into FH1T. 
The correct LMP2-HA fragment was excised from the FTGW vector by Pac1 digestion, excised 
from a 0.8% agarose gel, gel purified and phenol purified as previously described.  Similarly, the 
FH1T plasmid was also digested with Pac1 then directly dephosphorylated by incubation with 
calf alkaline phosphatase (CAP).  The LMP2-HA fragment was then ligated into the Pac1-digested 
FH1T with T4 DNA ligase, transformed into Stbl3 cells and the resultant clones analysed for the 
presence of the correct insert.  A correct clone was picked and a 400 ml bulk culture made for 
large scale plasmid preparation for use in making lentiviruses.  Figures 2-2 and 2-3 show the 
cloning strategy used. 
 
Lentivirus packaging and synthesis 
Transfection of the 293FT cells to induce production of lentivirus particles required a 70% 
confluent monolayer; this was achieved by splitting a 90% confluent plate 1:2 the preceding 
day.  On the day of transfection, the culture medium was changed for 10 ml fresh, pre-warmed 
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293FT medium without G418 for 2 hours before transfection.  Care was taken not to disrupt the 
semi-adherent cell layer.  For each 10 cm plate to be transfected, 36 µl of Lipofectamine 2000 
(Life Technologies) was added to 1.5 ml OptiMEM (Life Technologies).  In a separate tube, a 
further 1.5 ml of Optimem was incubated with 4 µg of the plasmid containing the gene of 
interest, 6 µg of packaging plasmid PAX-2 and 2 µg of VSV-G envelope protein-containing 
plasmid (kindly provided by Dr Marco Herold).  These were incubated at room temperature for 
5 minutes before they were combined and incubated for a further 20 minutes at room 
temperature.  The 3 ml transfection mix was then added to the 10 ml of medium in each plate 
and the cells incubated overnight at 37°C.  After 16 hours the medium was carefully replaced 
with fresh 293FT medium without G418.  The virus-containing supernatant was harvested after 
a further 3 days, spun at 1400 rpm in a Heraeus™ Megafuge™ 40 centrifuge to pellet cells, 
filtered through a 4.5 µm filter and either used immediately or frozen at -80°C. 
 
Transduction of primary NK cells with lentivirus 
Primary NK cells were isolated as described above and cultured for 7 days to ensure that the 
cells had entered exponential growth phase.  60 ml of lentivirus was concentrated by 
ultracentrifugation (Beckman Ultracentrifuge) at 19,500rpm for 2 hours in 14 ml ultracentrifuge 
tubes (Beckman) using the SW40Ti rotor.  The tissue culture supernatant was removed and 
discarded and the resulting fragile pellet was resuspended in 250 µl NK medium and added to 
1x106 cells in one well of a 24 well plate.  The cells were incubated with the concentrated virus 
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for 18 hours, then 1 ml fresh NK medium was added.  The cells were sorted after 48 hours by 
GFP expression by fluorescence-activated cell sorting (see below). 
 
Transduction of SNK10 and SNT16 cell lines with lentivirus 
SNK10 and SNT16 cells were transduced with concentrated lentivirus as described above.  
However, in order to obtain a stable population with high expression of the viral gene we 
performed 4 serial transductions, each a week apart, before sorting the highest GFP-expressing 
population. 
 
2.6  Fluorescence-activated cell sorting  
Fluorescence-activated cell sorting (FACS) was used to isolate either cells expressing green 
fluorescent protein (GFP) or to sort cells which had been prestained with fluorophore-
conjugated primary antibodies.  The FACS was performed using the MoFlo cell sorter (Beckman 
Coulter), and was provided as a service by the Institute for Biomedical Research at the 
University of Birmingham. 
The PBMC were resuspended at 20x106 cells per ml in cold MACS buffer (PBS with 2 mM EDTA 
and 0.5% v/v bovine serum albumin) then incubated with the appropriate isotype controls, 
single antibodies and combination of antibodies for 30 minutes at 4°C.  The stained cells were 
then washed in 10 ml sterile MACS buffer by centrifugation in a Hereaus™ Megafuge™ at 1200 
rpm, and resuspended in 1 ml sterile MACS buffer then filtered through a CellTrics° 50 µm filter 
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(Partec, Germany).  Isotype controls and single colour stains were performed on 0.5x106 cells in 
25 l MACS buffer.  Antibodies used are shown in table 2-4. 
 
Table 2-4 - Antibodies used for FACS cell sorting 
Target antigen Fluorophore Manufacturer Concentration used 
CD4 APC AbD (MCA1267APC) 1:20 
CD8 FITC AbD (MCA1226FT) 1:20 
CD19 PE-Cy5 AbD (MCA1235C) 1:20 
CD56 RPE Invitrogen (MHCD5604) 1:20 
 
Cells were sorted into 1 ml sterile PBS (for immediate harvest) or 1 ml sterile medium with 
added gentamicin at 50 mg/L to inhibit the growth of bacterial contaminants (for culture). 
 
2.7  Real-time quantitative PCR 
Real time qPCR is a method whereby quantification of a specific gene’s expression can take 
place during PCR amplification.  This relies on a fluorescent probe which hybridises to the DNA 
sequence of the gene of interest; by measuring the change in fluorescence as the reaction 
proceeds it is possible to determine the number of transcripts present at any particular PCR 
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cycle over 40 cycles.  To calculate the number of DNA/transcripts, a threshold is set at mid-
exponential phase of PCR amplification when the primers, probes and dNTPs are non-limiting to 
ensure the qPCR is truly quantitative. 
A total of 25 ng of cDNA was subjected to each multiplexed PCR reaction in a 25 µl reaction 
volume, comprising the gene of interest plus a house-keeping gene for normalisation, usually 
GAPDH.  Each PCR reaction comprised of 1 x TaqMan™ MasterMix (Invitrogen); 25 pmol gene-
specific forward and reverse PCR primers; 5 pmol gene-specific FAM-labelled PCR probe; 25 
pmol GAPDH-specific primers; 5 pmol VIC-labelled probe and DEPC-treated water.  The PCR was 
performed in a 7500 Real-Time PCR System (Applied Biosystems) machine, where the samples 
were heated to 95°C for 10 minutes to activate the polymerase enzyme, followed by 40 cycles 
of denaturation at 95°C for 15 seconds and primer annealing and extension at 60°C for 60 
seconds.  The resulting data were analysed using the 7500 system software. 
 
Absolute quantitation using the AQ-plasmid 
 
A plasmid was commercially synthesized to encode EBV DNA sequences corresponding to qPCR 
amplicons of 45 latent and lytic EBV genes, and 3 cellular “housekeeping” genes (B2M, GAPDH 
and PGK).  Details of the AQ-plasmid have been published (38).  The sequence was inserted into 
the pUC57 plasmid vector (GenScript).  The plasmid was quantified as plasmid copies per l, 
then a 10-fold serial dilution series was set up from 1x105 copies/l to 1 copy/l and was 
subsequently used to generate standard curves for absolute qPCR of EBV mRNA transcripts and 
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B2M, GAPDH and PGK.  Prior to the development of the AQ plasmid, cDNA from well-
characterised cell lines was used as a standard. 
 
Fluidigm specific target amplification and 48:48 Dynamic Array integrated fluidic circuit 
(IFC) analysis 
Amplification of the specific mRNA transcripts of interest from the cDNA was achieved by 
specific target amplification (STA) using the new Fluidigm technology as described in (38).  Each 
STA reaction comprised of 25 ng of cDNA or AQ plasmid, 2.5 μl of 2x TaqMan PreAmp Master 
Mix (Life Technologies) and 1.25 μl of 20x TaqMan assays.  The reactions were incubated at 
95C for 10 minutes, followed by 12 cycles of 95C for 15 seconds and 60C for 4 minutes.  The 
pre-amplified samples were then diluted 1:5 with DNA Suspension Buffer. 
 The 48:48 Dynamic Array IFC was prepared and run in a Biomark HD instrument as per the 
manufacturer's instructions; the data were analyzed using Biomark Real-Time PCR Analysis 
Software Version 2.0 (Fluidigm). 
 
2.8  Western Blotting 
Sample preparation 
Each cell sample was initially washed in PBS, then resuspended at 1x106 cells per 100 µl urea 
buffer (9 M urea, 50 mM Tris, pH 7.5).  The disrupted cells were then sonicated for 20 seconds 
using an ultrasonic cell disrupter (Misonix) to reduce viscosity before protein determination 
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using the Bio-Rad DC assay kit according to manufacturer’s instructions.  The quantified samples 
were diluted to 1-2 mg/ml in urea gel sample buffer (4% SDS (sodium docecyl sulphate), 62.5 
mM Tris pH 6.8, 5% β-mercaptoethanol, 5 M urea, 10% glycerol, 0.01% bromophenol blue) then 
heated to 100°C for 5 minutes to denature the proteins.   
 
Protein electrophoresis 
A 20 μg aliquot of each protein sample was loaded into each well of a Criterion™ TGX™ Precast 
gel. SeeBlue° Plus2 prestained ladder (Invitrogen) was pre-diluted (10 µl SeeBlue plus 15 µl gel 
sample buffer) and run alongside the samples to estimate the molecular weight of the proteins 
of interest.  The gels were run in Tris-Glycine running buffer at 120 V for 60 minutes, or until 
visual examination showed completion of protein separation. 
 
Blotting 
Transfer of the proteins from the gel to PVDF membranes was achieved using the TurboBlot 
system (BioRad), using a preset 7 minute protocol at 25 V, 2.5 A.  Trans-Blot transfer packs, 
which include 2 presoaked ion reservoir stacks with a prewetted PVDF membrane were used.  
Examination of the transfer of the SeeBlue size markers from the gel to the membrane 
confirmed complete transfer of protein to the membrane. 
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Immunostaining 
The PVDF membranes were blocked in 5% skimmed milk powder in PBST (phosphate-buffered 
saline with 0.1% V/V Tween 20) at room temperature for 1 hour to prevent non-specific 
antibody binding.  The membranes were then incubated with appropriately-diluted primary 
antibodies in 5% milk-PBST (see table 2-5).  The membranes were washed 4 times for 5 minutes 
with PBST then incubated for 1 hour at room temperature with the appropriate secondary 
antibodies conjugated to horseradish peroxidise (Sigma).  The blots were then washed 6 times 
with PBST over a minimum of 1 hour.  The proteins were visualised by Amersham ECL Western 
Blotting Detection Reagent (GE Healthcare) with the ChemiDoc documentation system (BioRad). 
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Table 2-5 - Antibodies used in Western blotting. 
Antigen Antibody Stock 
concentration 
Dilution 
used 
Incubation 
conditions 
Secondary 
antibody 
Secondary 
antibody 
concentration 
LMP1 CS1-4 
(357) 
1 mg/ml 1:1000 Overnight 
at 4°C 
Mouse 1:1,000 
LMP2a 14B7 
(Abcam) 
 
1 mg/ml 1:1000 Overnight 
at 4°C 
Rat 1:1,000 
Haemagglutinin 
(HA) 
3F10 
(Sigma)  
50 µg/ml 1:1000 Overnight 
at 4°C 
Rat 1:1,000 
EBNA-1 “AM” sera 1:1 1:200 Overnight 
at 4°C 
Human 1:1,000 
EBNA-2 PE2 
(Abcam) 
1 mg/ml 1:25 Overnight 
at 4°C 
Mouse 1:1,000 
Calregulin H-170 
(Santa 
Cruz) 
200 µg/ml 1:1000 1 hour at 
18°C 
Rabbit 1:5,000 
BAD D24A9 
(Cell 
Signaling) 
Not provided 1:1000 Overnight 
at 4°C 
Rabbit 1:1,000 
BAX D2E11 
(Cell 
Signaling
  
Not provided 1:1000 Overnight 
at 4°C 
Rabbit 1:1,000 
BID #2002 
(Cell 
Signaling 
Not provided 1:1000 Overnight 
at 4°C 
Rabbit 1:1,000 
BIM #2993 
(Cell 
Signaling 
Not provided 1:1000 Overnight 
at 4°C 
Rabbit 1:1,000 
BCL2 50E3 (Cell 
Signaling 
Not provided 1:1000 Overnight 
at 4°C 
Rabbit 1:1,000 
BCL-XL 54H6 (Cell 
Signaling 
Not provided 1:1000 Overnight 
at 4°C 
Rabbit 1:1,000 
MCL1 5453 (Cell 
Signaling 
Not provided 1:1000 Overnight 
at 4°C 
Rabbit 1:1,000 
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2.9  EBER-ISH in solution 
Freshly isolated PBMCs or control cell lines were washed in MACS buffer prior to staining for 30 
minutes at 4°C with the antibodies described in table 2.6.  The cells were then washed a further 
two times in PBS before fixation for 20 minutes at room temperature in 4% Paraformaldehyde 
in DEPC H2O.  They were then permeabilised in permeabilisation solution (250 l Tween 20 in 50 
ml PBS) for 10 minutes at room temperature.  Formamide buffer was made by adding 75 µl of 
100% formamide and 25 µl hybridisation buffer (100 mM NaCl, 50 mM Na2EDTA, 500 mM Tris-
HCl pH 7.5) to 100 l DEPC H2O; this was added to the sample then immediately centrifuged off.  
The cells were resuspended in EBER PNA probe (Dako) and incubated for 60 minutes at 56C 
before adding permeabilisation solution and incubating for 10 minutes at 56C.  The cells were 
centrifuged, the supernatant discarded and the pellet resuspended in permeabilisation solution 
and incubated for 10 minutes at 56C.  They were then centrifuged, the supernatant discarded 
and the cells resuspended in permeabilisation solution before analysis by flow cytometry.  If 
amplification of the EBER signal was required, the cells were then incubated at 4˚C for 30 
minutes with an anti-FITC antibody; this was then washed off before analysis.  
 
2.10  Human PrimeFlow™ RNA Assay 
The Human PrimeFlow™ RNA Assay (eBioscences) is a technique whereby in situ hybridisation 
to an mRNA sequence is performed in conjunction with conventional cell surface or intracellular 
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staining and analysed by flow cytometry, summarised in figure 2-4.  Briefly, a dual-probe set is 
hybridised to the mRNA of interest; the probe set is subjected to pre-amplification, 
amplification then labelling with up to 400 molecules of fluorophore.  Only when both probes of 
the probe set are bound will signal amplification occur, giving the assay its specificity.  The large 
number of fluorescent molecules loaded onto each probe makes the assay highly sensitive.  
Each mRNA will have at least 10 probe sets, thereby increasing sensitivity of mRNA detection. 
Together, the assay is able to identify one copy of mRNA in a specific cell type identifiable by 
flow cytometry.   
 
Figure 2-4 - Schematic of the PrimeFlow workflow.  Firstly, cell surface staining is carried out.  Next, specific probesets are 
hybridised to RNA.  Firstly a preamplifier, then an amplifier are hybridised to the probesets, then multiple copies of a fluorescent 
label probe are attached to the amplifier molecules.  The resulting cells can be examined by flow cytometry and gene expression 
within different cells can be examined. 
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Two probe-sets were designed to the EBER non-translated EBV RNA and to cellular β2-
microglobin mRNA as a positive control.  All hybridisation steps were carried out at exactly 40°C 
in a temperature-calibrated hybridisation oven.  The cells were initially stained for cell surface 
markers using the antibodies shown in table 2-6.  Staining was performed in MACS Buffer for 30 
minutes at 4°C; the cells were then washed in the same buffer. 
Table 2-6 - Antibodies used for cell surface staining in the Human PrimeFlow™ RNA assay. 
Cell surface 
marker 
Fluorophore Clone name Manufacturer Concentration 
CD3 AF700 OKT3 eBiosciences 1:20 
CD4 ECD SFCI12T4D11 Beckman Coulter 1:50 
CD8 AF488 SK1 Biolegend 1:20 
CD14 Pacific Blue HCD14 Biolegend 1:20 
CD19 PeCy7 HIB19 eBiosciences 1:20 
CD56 PE MEM-188 Invitrogen 1:20 
 
The cells were then fixed in Fixation Buffer 1 for 30 minutes at 4°C, permeabilised by washing 
twice in Permeabilization Buffer and fixed with Fixation Buffer 2 for 60 minutes at 14°C.  The 
cells were again washed twice in Wash Buffer. 
The Target Probes were diluted 1:20 in pre-warmed Target Probe Diluent, then the cells were 
incubated in 100 μl of the diluted target probes in a 1.5 ml tube at 40°C for 2 hours.  The cells 
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were then washed twice in Wash Buffer and stored overnight suspended in Wash Buffer 
containing RNAse inhibitor. 
Signal amplification was achieved by incubating the cells with pre-warmed PreAmp Mix for 90 
minutes at 40°C, washing 3 times with Wash Buffer, incubating with pre-warmed Amp Mix for 
90 minutes at 40°C, then washing twice with Wash Buffer.  Finally, the cells were incubated with 
the Label Probes diluted 1:100 in pre-warmed Label Probe Diluent for 1 hour at 40°C, before 
washing twice with Wash Buffer and once with storage buffer.  The samples were then analysed 
using the BD™ LSRII Flow Cytometer. 
 
  
93 
 
CHAPTER 3 – MICROARRAY ANALYSIS OF THE EFFECTS OF 
LMP1 ON NK CELLS 
3.1  Introduction 
ENKTL is almost universally EBV-positive, with expression of a latency 2 pattern of gene 
expression – EBNA-1, LMP1, LMP2, EBERs and miRNAs (see chapter 1).  Clonality of EBV 
episomes indicates that viral infection occurs early in the process of malignant transformation.  
This strongly suggests that the virus plays an important role in lymphomagenesis, and yet the 
role of these EBV gene products is still obscure. 
The roles of LMP1 and LMP2 are well-characterised in B- and epithelial cell malignancies.  LMP1 
acts as an oncogene in rodent fibroblast models and is critical for human B-cell transformation 
by the virus (6).  It induces the expression of anti-apoptotic proteins (81, 82).  In ENKTL, 
however, the role is much less clear and in two NK lymphoma cell lines, reducing LMP1 levels 
does not seem to impact on cell proliferation to the same extent as in B-cells (58). 
LMP2A is relatively well characterised in B-cells as it acts as a surrogate B-cell receptor (103).  
However, LMP2A expression in ENKTL is low to absent (52, 284) and it is only recently that 
LMP2B-TR, whose function is much more obscure even in B-cells, was shown to be expressed at 
significant levels in ENKTL (306). 
There is very little published work to date using primary NK cells that is relevant to the role of 
EBV in ENTKL. 
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As a first step to investigating the role of EBV in the pathogenesis of ENKTL, we sought to 
identify the transcriptional effects of LMP1 and LMP2 in primary NK cells.  Our experimental 
approach was to establish cultures of normal NK cells then transduce them with lentiviral 
vectors expressing LMP1, LMP2B or LMP2A, and then perform microarray analysis to examine 
changes in gene expression profile as a result of the expression of the viral protein. 
 
3.2  Methods 
The design and cloning strategy of the lentiviruses is described in detail in chapter 2.  In brief, 
the relevant gene was amplified from the transcriptome of an EBV-positive cell line for insertion 
into the lentiviral plasmid.  ENKTL, although rare, is proportionally much more common in Asia 
and South America (233, 234, 236).  EBV strains also show geographical variation, the 
significance of which is not always clear (6); for this reason SNK6, a Japanese ENKTL line (354), 
was used as the source of the viral sequence for the LMP1 and LMP2B-TR.  As the majority of 
previous LMP2A functional studies have been performed with the prototypic B95.8 sequence, 
and LMP2A is poorly expressed if at all in ENKTL lines, we cloned the B95.8 LMP2A sequence for 
comparison with the SNK6 LMP2B-TR sequence in these array experiments.  As there is no 
reliable antibody to LMP2B, a haemagglutinin (HA) sequence was included in the LMP2B-TR and 
2A vectors to enable detection of the protein with an anti-HA antibody. 
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Figure 3-1 - Schematic of microarray sample preparation. A: Primary NK cells were transduced with the "empty" lentivirus or 
one expressing LMP1, LMP2B-TR or LMP2A.  B: Cells were sorted for GFP positivity. C: RNA was extracted from sorted cells. D: 
cDNA was generated from the RNA. 
 
Figure 3-1 summarises the workflow for generation of the samples for the microarray.  NK cells 
were isolated from three different laboratory donors using the Miltenyi Human NK Cell Isolation 
Kit, as described in chapter 2.  After one week in culture they were transduced with 
concentrated lentivirus - either LMP1, LMP2A or LMP2B.  Samples of primary NK cells harvested 
with no lentiviral transduction and those transduced with an “empty” lentiviral construct with 
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no EBV gene expression (although GFP was constitutively expressed) were also included.  
Matched samples transduced with each of the lentiviruses permitted pair wise analysis using 
the “empty” lentivirus-transduced population as a control sample, thus minimizing detection of 
non-specific genetic changes as a result of in vitro culture or as a result of lentiviral 
transduction.  More importantly, pairwise analysis gets around biological variation in NK cells 
from different donors.   
In cell lines it is possible to generate stable cultures with lasting expression of the viral protein.  
However, ex vivo NK cells have a finite lifespan in culture so it is more appropriate to 
experiment on fresh, actively-replicating NK cells before they begin to senesce.  In view of this 
we exploited the burst of unregulated viral protein expression seen on first transducing the cells 
to examine the effects of the viral protein in untransformed NK cells, harvesting at 72 hours.  
This has the advantage that the cells are freshly isolated and can be presumed to more closely 
resemble their in vivo counterparts.  Figures 3-2 – 3-4 show the expression of the viral proteins 
in primary NK cells by qPCR and Western blot analysis.  The limitations of the sample size meant 
that we were unable to perform protein analysis on the same samples sent for microarray 
analysis; we could, however, using a tiny amount of RNA perform RT-Q-PCR using the Fluidigm 
system (38). 
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B 
Figure 3-2 - Expression of LMP1 in primary NK cells, compared to an LCL (Western blot, panel A) and SNK6 (qPCR, figure B). As 
can be seen, early on following transduction the lentivirus is promiscuously expressed at a high level and is not inducible by 
doxycycline as the vector has not fully integrated.  We took advantage of this early burst of gene expression in order to examine 
the effects of viral proteins on freshly-isolated NK cells.  The molecular weight of the SNK6 sequence transduced into the NK 
cells is less than that of the B95.8 from which the LCL was derived. 
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A 
B 
Figure 3-3 - Expression of LMP2A in primary NK cells  Again showing non-inducible early expression, by Western blot (panel A) 
and by qPCR (panel B) in relation to SNK6. 
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A 
  B  
Figure 3-4 - LMP2B in primary NK cells.LMP2B in primary NK cells from 3 different donors.  As there is no reliable antibody to 
LMP2B, the Western blot (panel A) uses an antibody to the HA tag engineered into the plasmid, and so a control with 
endogenous levels of expression cannot be shown.  However, in the qPCR figure (panel B) it can be seen that levels of 
expression are significantly higher than in SNK6.  Again, the expression is not inducible at this early stage after transduction.   
 
The lentivirus constitutively expresses green fluorescent protein (GFP), enabling successfully 
transduced cells to be sorted after 3 days by FACS and then harvested immediately.  RNA was 
extracted using the RNAEasy kit (Qiagen, UK) as per the manufacturer’s protocol, and stored at -
80°C until needed.  Analysis of RNA quality and quantity was undertaken using the Eukaryote 
Total RNA Pico Series II Bioanalyser chip (Agilent). 
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The Affymetrix U133 Plus 2 array was performed at the University of Manchester as a Cancer 
Research UK service.  Briefly, cDNA was generated from the sample RNA by reverse 
transcription, and then a second strand was produced.  Fluorescently-labelled cRNA was then 
made from the double-stranded cDNA, fragmented and hybridised to the array chip.  By 
analysing which array probe hybridises to a fluorescent RNA fragment it is possible to quantify 
gene expression by the cells studied. 
 
3.3  Data analysis 
Initially, the probesets were matched to their corresponding genes using the Affymetrix chip 
definition file.  Array chips are designed with multiple probe sets running forwards and 
backwards across the genome.  These are not limited to known genes as this would mean that 
as new genes are identified the chips would become obsolete.  However, the existing situation 
means that any probe set not, as yet, associated with a known gene is impossible to interpret in 
the context of a gene expression array.  Thus, Affymetrix-defined probe sets that have not yet 
been matched to a corresponding gene were discarded in this analysis.  This left 42450 probe 
sets matching to 21014 gene symbols. 
A LIMMA pair wise analysis was then performed on the resulting data by Dr Wenbin Wei.  The 
expression of each probe set was compared between the control sample and the sample of 
interest.  This allowed detection of any significant change of expression between the two 
populations.  Due to biological variability, small changes in gene expression are inevitable, and 
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difficulties may arise when trying to determine when these approach biological significance.  In 
order to minimise the possibility of a type I error, rigorous statistical methods are used.  We set 
a significance limit of P<0.01 – i.e., there is a probability of less than 1% that the observed 
change in gene expression is due to chance rather than to a biological effect of the newly 
expressed gene.  We also defined a significant fold-change (FC) as >1.5 for upregulated and <-
1.5 for downregulated genes.  The selected genes can then be categorised depending on 
whether they are up- or down-regulated, and lists compiled accordingly. 
 
3.4  Results 
Firstly, gene expression was compared between cells expressing the latent membrane proteins 
and those expressing the empty lentivirus.  This gives us a core set of genes which, by this 
analysis, are significantly up- or down-regulated by the expression of the gene of interest (Table 
3-1). 
Table 3-1 - Genes differentially regulated by viral proteins in primary NK cells (FC>1.5 or <-1.5, P<0.01) 
 LMP1 LMP2B LMP2A 
Number of genes 
upregulated 
109 84 115 
Number of genes 
downregulated 
146 154 189 
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DAVID analysis 
The Database for Annotation, Visualization and Integrated Discovery (DAVID) provides a means 
by which lists of differentially altered genes can be compared to those involved in known 
cellular pathways.  This allows the identification of areas of enrichment within an expression 
profile (358, 359).  The lists of differentially regulated probesets, as defined by the above 
LIMMA analysis, were entered into the database (DAVID 6.7) (360).  Pathways significantly 
overrepresented (modified Fisher’s exact test, P<0.05) are summarised in Table 3-2. 
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Table 3-2 – Pathways significantly overrepresented by expression of LMP1, LMP2B-TR and LMP2A in primary NK cells 
 Pathway Fold 
enrichment 
P value 
 
LMP1 Transcription (GO:0006351) 
 
2.4 
 
0.00000041 
 
 Mitochondrion organisation (GO:0007005) 
 
6.2 0.008 
 
 Response to nutrient levels (GO:0031667) 
 
4.4 0.011 
 
 Cellular response to stress (GO:0033554) 2.7 0.016 
 
 Regulation of cell death (GO:0010941) 
 
2.3 0.017 
 
 Response to extracellular-stimulus (GO:0009991) 
 
4.0 0.017 
 Negative regulation of cell death (GO0060548) 
 
3.3 0.018 
 Cell proliferation  (GO:0008283) 
 
2.7 0.029 
 Cell cycle arrest (GO:0007050) 
 
5.6 0.033 
 Cellular amino acid biosynthetic process (GO:0008652) 
 
10.1 0.035 
 Negative regulation of gene-specific transcription 
(GO:0045892) 
 
9.1 0.042 
 ncRNA metabolic process (GO:0034660) 
 
3.7 0.044 
 Anion transport (GO:0006820) 
 
4.8 0.05 
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 Pathway Fold 
enrichment 
P value 
 
LMP2B 
 
Transcription (GO:0006351) 
 
1.7 0.002 
 Transcription initiation from RNA polymerase II promoter 
(GO:0006367) 
 
8.6 0.0026 
 Amine catabolic processes (GO:0009310) 
 
12.0 0.0029 
 Cellular macromolecule catabolic process (GO:0044265) 
 
2.4 0.0031 
 Mitochondrion organisation (GO:0007005) 
 
5.1 0.0062 
 Cellular macromolecule localisation (GO:0070727) 
 
2.6 0.024 
 Protein localisation in mitochondrion (GO:0070585) 
 
10.4 0.033 
 Nitrogen compound biosynthetic process (GO:0044271) 
 
3.6 0.048 
 Histidine metabolic process (GO:0006547) 
 
38.9 0.049 
 G-protein signalling coupled to cAMP second messenger 
(GO:0007188) 
 
8.2 0.05 
LMP2A 
 
Organelle localisation (GO:0051640) 
 
6.8 0.0021 
 Endoplasmic reticulum calcium ion homeostasis 
(GO:0032469) 
 
38.9 0.005 
 Interphase (GO:0031525) 
 
5.3 0.015 
 Positive regulation of cell differentiation (GO:0045597) 
 
3.4 0.016 
 Negative regulation of cell activation (GO:0050866) 
 
7.3 0.017 
 Regulation of cellular protein metabolic process 
(GO:0032268) 
 
2.4 0.025 
 Positive regulation of developmental process (GO:0051094) 
 
2.8 0.037 
 RNA splicing (GO:0008380) 
 
2.8 0.041 
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As can be seen, the 255 genes differentially regulated by LMP1 are significantly enriched for 
pathways involved in cell cycle and cellular responses to stress.  This is consistent with the 
previously reported effects of LMP1 in other cell types, and suggests that LMP1 may have an 
oncogenic effect in the NK cell.  However, the 255 genes with significantly altered expression by 
LMP1 in NK cells is fewer than the number of genes changed in most studies where LMP1 was 
expressed in other cell types, e.g. 1926 genes in germinal centre B-cells (361).  The reason for 
this difference is not clear.   
It is possible that this reflects a technical issue with the microarray itself.  However if that is the 
case the DAVID analysis suggests that, whilst there may be a reduced sensitivity in detecting 
significant changes, qualitatively the range of altered genes represents changes consistent with 
known LMP1 functions.  It is also possible that the difference between the two arrays reflects 
the fact that we used a lentiviral expression vector whereas in the B cell array, electroporation 
of the plasmid was used.  This may affect the way in which the cell responds to the foreign 
molecules.  Despite the fact that adequate controls were used in both cases, it is theoretically 
possible that the two different strategies might result in different thresholds for detecting 
LMP1-specific effects. 
It is also important to note here that the number of genes significantly altered is affected by the 
starting transcriptome as well as the final transcriptome.  Consider the situation with B-cells – 
GC B-cells and naive B-cells are transcriptionally very different but LCLs generated from either 
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background are identical.  As the data are analysed in a pairwise fashion, this will affect the 
number of genes identified as significantly altered by the expression of the protein of interest;    
I will show later that data from the Murray group (361) indicate that expression of LMP1 in 
naive B-cells results in a much smaller number of changes than that resulting from its expression 
in GCB-cells. 
 The case with LMP2A is less clear-cut.  We do not know how LMP2A functions in NK cells as its 
most well-characterised functions depend on the ITAM signalling motifs that modulate the B cell 
receptor signalling pathways - these may not be operational in NK cells.  However, apoptotic 
pathways seem to be significantly affected, which is in keeping with what we know about the 
function of the protein in B-cells.  It is important to remember, however, that there is little 
evidence that LMP2A is expressed in ENKTL and so the significance of these effects is unclear.  
LMP2B, in contrast, is known to be expressed in ENKTL samples and cell lines, but the cellular 
pathways enriched do not include those classically associated with oncogenesis, further 
highlighting how little is understood about the function of this protein.  Yet another important 
consideration is that relatively few genes are significantly altered using our stringent statistical 
limits – this inevitably results in fewer pathways being identified.  However we know that 
LMP2B-TR is expressed in ENKTL, and the LMP2B molecule lacks the ITAM signalling sequences, 
suggesting that the LMP2A and LMP2B may have similar effects in an NK cell background.  As 
can be seen in figure 3-5 and Table 3-3, there is a significant overlap in the genes up- and 
downregulated by LMP2B and LMP2A. 
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Figure 3-5 - Venn diagram showing overlap between differentially regulated genes by LMP2B-TR-TR and LMP2A in primary NK 
cells. 
 
Table 3-3 - Comparison of genes differentially expressed by LMP2B-TR or LMP2A in NK cells (FC>1.5 or <-1.5, P<0.01). 
Denominator: 21,014 
NK LMP2B NK LMP2A  Overlap OR Chi sq P 
Up (84) Up (115) 
 
13 
 
37.36 342.10 <0.0001 
Down 
(189) 
 
2 2.71 2.05 0.15 
Down 
(154) 
Down 
(189) 
 
27 27.12 473.71 <0.0001 
Up (115) 
 
2 2.41 1.59 0.21 
 
Comparing to other arrays 
We have access to data from similar arrays performed by past and present colleagues in our 
department, and we used the same array platform.  This allowed us to examine and compare 
the effects of LMP1 and LMP2 in different cell backgrounds.  The most comprehensive set of 
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array data is for LMP1 in different B cell and epithelial cell backgrounds.  As both LMP1 and 
LMP2A arrays have been performed on germinal centre (GC) B-cells, in the first instance, we 
compared our data on these two EBV genes in NK cells with corresponding array results in GC-B-
cells ((361), M. Vockerodt, unpublished data).  Raw data were obtained from the authors and 
analysed exactly in the same way as our own data; this means that the final dataset we used is 
slightly different to that published by the authors, but means that our comparisons are fairer.  
When the affected genes in this array were compared with those in one using a GC B-cell 
background, there was a significant overlap in the genes both up- and down-regulated by LMP1 
(Table 3-4, figure 3-6).  Reassuringly, there was no significant overlap in genes upregulated by 
LMP1 in one background and downregulated in the other. 
Table 3-4– Comparison of genes differentially expressed by LMP1 in NK or germinal centre B (GCB) cells (FC>1.5 or <-1.5, 
P<0.01). 
Denominator: 21,014 
NK LMP1 GCB LMP1 Overlap OR Chi sq P 
Up (109) Up (952) 
 
19 
 
4.51 
 
40.04 
 
<0.0001 
 
Down 
(1732) 
 
6 0.65 0.99 0.609 
Down 
(146) 
Down 
(1732) 
 
22 
 
1.98 8.25 0.0162 
Up (952) 
 
10 1.55 1.733 0.424 
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Figure 3-6 – Venn diagram of genes altered by LMP1 in NK and germinal centre B (GCB) cells. (362) 
 
This is very reassuring as it suggests that the actions of LMP1 in NK cells are similar to those in a 
related lymphocyte background. 
Next we compared the effects of LMP2A on NK and GCB-cells (Table 3-5). 
Table 3-5 - Comparison of genes differentially expressed by LMP2A in NK or germinal centre B (GCB) cells (FC>1.5 or <-1.5, 
P<0.01). 
Denominator: 21,014  
NK LMP2A GCB 
LMP2A 
Overlap OR Chi sq P 
Up (115) Up (79) 
 
1 
 
2.34 
 
0.75 
 
0.69 
 
Down 
(112) 
 
2 3.34 3.14 0.208 
Down 
(188) 
Down 
(112) 
4 
 
4.15 
 
8.89 
 
0.0117 
 
 
Up (79) 
 
2 2.88 2.34 0.31 
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Interestingly there was very little overlap between the genes differentially regulated by LMP2A 
in the GCB and NK cells.  The only sub-group where this became significant was in genes 
downregulated by LMP2A, and it must be emphasised that the number of genes involved is very 
small, so this result should be interpreted cautiously. 
In B-cells, LMP2A is known to act as a surrogate B-cell receptor (BCR), and is capable of 
“rescuing” germinal centre B-cells with crippling mutations of their BCRs from apoptosis (103), 
and to modulate BCR-mediated signalling in B-cells with a functional BCR (see (106) for review).  
NK cells do not express a BCR, and so it is difficult to predict with any confidence firstly how the 
expression of LMP2A will affect the cell, and secondly whether there is any physiological 
relevance to the changes that are seen.  This may explain why the degree of overlap between 
the differentially regulated genes in the two cell backgrounds is so small compared to that seen 
with LMP1.   
There are no data available on the effects of LMP2B in other cell backgrounds, and so we are 
unable to compare the effects in NK cells with, for example, B-cells. 
What genes are altered? 
Next we focused our attention on single genes identified by the microarray findings.  Beginning 
with LMP1, we examined the 10 genes upregulated (or downregulated) with the smallest P 
values.  We excluded genes with no published function, and genes with very low levels of 
expression.  When microarray data are analysed at the single gene level, care must be taken not 
to rely on fold-change alone as a marker of significance, as when expression of a gene is very 
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low a small absolute change can lead to a large fold change which seems less likely to be 
biologically significant.  Results are shown in Table 3-6 and 3-7. 
Table 3-6 – Ten genes increased by LMP1  (FC>1.5, P<0.01) 
Gene name Proposed function 
MEF2C (myocyte enhancer 
factor 2C) 
 
Seen in B- but not T-cells, thought to regulate differentiation 
and function. (363) 
 
BCAT1 (branched chain 
amino-acid transaminase 
1) 
 
Overexpressed in NPC probably by c-Myc and thought to be 
involved in cell proliferation, migration and invasion (364, 
365) 
SNCA (synuclein, alpha 
(non A4 component of 
amyloid precursor)) 
 
Highly expressed in the brain; involved in the pathogenesis of 
Parkinson disease. (366) 
SCD (stearoyl-CoA 
desaturase (delta-9-
desaturase)) 
 
Enzyme involved in the synthesis of fatty acids; upregulated in 
many cancers and a possible target for novel 
chemotherapeutic agents (367) 
 
PHGDH (phosphoglycerate 
dehydrogenase) 
 
Enzyme involved in the synthesis of L-serine; contributes to 
oncogenesis in some cancers (368) 
 
ARID1B (AT rich interactive 
domain 1B) 
Subunit of the human ATP-dependent SWItch/sucrose 
nonfermentable (SWI/SNF) complex; important in ontogeny 
and possibly functions as a tumour suppressor gene in 
pancreatic cancer (369) 
ORAI2 (calcium release-
activated calcium 
modulator 2) 
 
Calcium channel important in mast cell mediator release (370) 
KLHL23 (kelch-like family 
member 23) 
 
Novel gene, may be some association with cancer (371) 
MAGI3 (membrane 
associated guanylate 
kinase, WW and PDZ 
domain containing 3) 
Ubiquitously expressed in all tissues; involved in intracellular 
signalling (372) 
NFRKB (nuclear factor 
related to kappa-B-binding 
protein) 
 
Involved in DNA replication and repair, chromatin remodelling 
and transcription regulation (373). 
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Table 3-7- Ten genes downregulated by LMP1 (FC <-1.5, P<0.01) 
AKAP13 (A kinase (PRKA) 
anchor protein 13) 
Binds to protein kinase A (PKA) and localises it within the cell; 
may be increased in some cancers (374) 
CUL3 (cullin 3) Involved in ubiquitination and degradation of proteins, may be 
significant in bladder cancer invasiveness (375). 
TNFSF4 (tumour necrosis 
factor (ligand) superfamily, 
member 4) 
 
Cytokine belonging to the tumour necrosis factor (TNF) family; 
involved in T-cell:antigen-presenting cell interactions.  This 
protein and its receptor are reported to directly mediate 
adhesion of activated T cells to vascular endothelial cells. 
[provided by RefSeq, Jul 2008] 
CDK19 (cyclin-dependent 
kinase 19) 
Member of the mediator complex involved in regulation of 
transcription (376) 
ZFP28 (zinc finger protein 
28) 
Zinc finger protein thought to have some association with 
melanoma (377) 
ITGA1 (integrin, alpha-1, 
CD49a) 
Upregulated in T- and NK-cells in response to viral infection 
leading to T-cell inflammatory cytokine production(378) 
CLNK (cytokine-dependent 
hematopoietic cell linker) 
Expressed in cytokine-stimulated haematopoietic cells and 
involved in immunoreceptor signalling (379) 
CCND3 (Cyclin D3) Necessary for cell division 
MPZL2 (myelin protein 
zero-like 2) 
A member of the immunoglobulin superfamily, expressed in 
thymus epithelium , important in T-cell maturation (380) 
LHX9 (Lim-homobox 9) Transcription factor important in neural cell differentiation; 
reduced expression in paediatric gliomas associated with 
migration and invasiveness (381) 
 
With the intriguing exception of genes associated with neural tissue, the others identified here 
fit well with the pathways demonstrated by the DAVID analysis; most interestingly, they are 
biologically plausible for the predicted role of LMP1 in ENKTL.   
 
3.5  Validating the array 
Conventionally, gene expression arrays are validated using qPCR.  Assays are made (either by 
the user or by a commercial company) by designing primers and probesets predicted to react 
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specifically with the major transcripts(s) of the gene of interest.  By simultaneously including an 
assay for a ubiquitously expressed “housekeeping” gene we can control for variability in the 
RNA.  
Whilst qPCR assays are reliable, one of the limitations of this technique is that realistically only a 
few genes can be validated at a time.  To improve our validation, therefore, we utilised a new 
high-throughput chip system.  This has been designed for use on small amounts of RNA (382).  
The Fluidigm Dynamic Array™ integrated fluidic circuit uses a chip containing a system of 
channels, valves and chambers to enable automatic assembly of multiple simultaneous qPCR 
reactions.  The advantage in our case is that the amount of cDNA required is small and so a 
portion of the identical sample used for the microarray could be used rather than simply a 
biological replicate.  Briefly, qPCR assays containing forward and reverse primers and a labelled 
probe, are made or purchased (TaqMan® Gene Expression Assays, Applied Biosystems, USA) for 
each gene of interest.  These are pooled, combined with cDNA from the sample and subjected 
to a pre-amplification stage to selectively amplify the cDNA of transcripts of interest.  The 
amplified cDNA is loaded on to the chip with the single assays and the chip is subjected to qPCR 
analysis.  The combination of each sample with each qPCR assay is automated and takes place in 
a chamber within the chip. 
When choosing which genes to validate, several factors must be borne in mind.  Firstly, in order 
to maximise the biological relevance, genes with a statistically significant change in expression 
should be used.  Secondly, the absolute level of expression must be sufficiently high to be 
detected by qPCR.  Finally, to minimise the problem of genomic DNA contamination, a qPCR 
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assay spanning more than one exon must be available.  Of course it is also relevant and 
important to validate the expression patterns seen in unchanged genes, or indeed in non-
expressed genes, and the nature of the Fluidigm process, where every sample is tested with 
every assay, allowed us to use genes that were not altered by one protein as controls in this 
way.  Bearing these factors in mind, we chose 25 genes for analysis by Fluidigm (see table 3-8).  
We were surprised to find that only about half of our chosen genes seemed to show similar 
changes with Fluidigm qPCR analysis as were seen in the original microarray.  Similar results 
were obtained for all 3 EBV genes studied.  There are little available data in the literature on 
array validation.  It is often difficult to tell from published work exactly how validation was 
undertaken and what were the results; commonly, validation data are only shown for individual 
“interesting” genes.  However, the proportion of genes that validated in our NK cell arrays was 
consistent with the experience of colleagues in this department who have used the Affymetrix 
U133 Plus 2 array platform extensively (personal communications). 
Possible reasons for the discrepancies between the array results and the qPCR validations that 
were experienced by ourselves and others include: 1) selective amplification of some transcripts 
in the Fluidigm Specific Target Amplification (STA) step, 2) low gene expression initially leading 
to potentially large fold change variation with small absolute changes or 3) detection by array 
and qPCR of different subsets of alternative transcripts for a particular gene.  However, a 
recurring theme in the literature concerned the complexity and reliability of annotation of the 
Affymetrix array probesets, which we explored further.  
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On average, every gene in the Affymetrix Human Genome U133 Plus 2.0 array is represented by 
2.8 probesets, so called “sibling probesets” (383).  However, we noticed that where several 
probesets map to a single gene, not all of them are necessarily altered in the same way by the 
expression of the viral protein.  For example, BHLHB9 has 3 probesets in the array of which one 
was significantly upregulated by the expression of LMP1 in the NK cells and the other 2 were 
downregulated, although this change did not reach statistical significance.   
The Affymetrix probe sets were generated with the intention of covering the entire genome, 
rather than just targeting known genes.  This concept was intended to allow the array chips, and 
indeed array data, to be interrogated for the presence of novel gene transcripts as they were 
defined, and thus prolong the useful life of the technology.  Affymetrix provides updated 
annotations to try and deal with this but does not address the situation where a subset of 
probes within the probeset maps to another gene, either instead of, or as well as, the one to 
which it is attributed.  It therefore appears that some probes have been misattributed to the 
relevant gene, with incorrect directions of reading of the genome and sequences.  As a result, 
relying on the Affymetrix annotation system alone may produce erroneous conclusions.  For 
example, ISG20L2 has 3 probesets attributed to it by the Affymetrix chip definition file (CDF).  Of 
these, one was significantly upregulated by LMP2A; on further analysis, this probeset is for the 
non-coding direction (see Figure 3-7). 
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Figure 3-7- Location of the probesets attributed to ISG20L2.  Black bars indicate coding exons, grey bars non-coding exons, 
dashed lines introns and green lines Affymetrix probes.  Genes and probesets above the solid line are read left-to-right; below 
the line right-to-left.  Note that of the 3 probesets shown, only 2 are in the same direction as the gene coding.  From the 
Annmap Genome Browser (384, 385) 
When this is compared to MYC, which has only 2 probesets attributed to it, we can see that they 
are both directed to the correct strand (Figure 3-8).   
 
  
Figure 3-8 - Location of the probesets attributed to MYC.  Black bars indicate coding exons, grey bars non-coding exons and  
dashed lines introns.  Genes and probesets above the solid line are read left-to-right; below the line right-to-left.  The green 
lines represent probesets attributed to MYC; the blue lines represent probesets not attributed to MYC.  Note that both MYC 
probesets are in the same transcriptional direction as the gene.  From the Annmap Genome Browser (384, 385) 
 
Bearing this in mind, we returned to our Fluidigm validation and this time compared the results 
with those of every probeset annotated with the name of the relevant gene (Table 3-8).   
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Table 3-8 – Fold change of selected genes by microarray and by Fluidigm validation.  Note that where there is more than one 
probeset labelled for a gene, the results for each probeset are shown individually.  DNA indicates that the PCR reaction did 
not amplify.  Green shades indicate upregulation and red shades downregulation. 
  LMP1 Fold Change         LMP2B-TR Fold Change       
Gene Array       Fluidigm   Array       Fluidigm 
              
 
            
MEF2C 3.09 1.95 1.81     -1.18 
 
1.48 1.36 1.14     1.05 
SNCA 2.46 1.54 1.29 1.24 1.00 1.63 
 
-1.20 1.15 1.05 1.05 1.02 1.26 
PHGDH 2.35         2.05 
 
1.36         -1.16 
ITGA1 -2.29 -2.21       -2.00 
 
1.12 1.27       1.38 
RSAD2 -1.59 -1.50       1.07 
 
-2.01 -1.49       1.12 
HOXA5 1.14         1.70 
 
2.12         -1.68 
RAP1GAP2 1.18         1.00 
 
1.18         4.19 
DIAPH2 1.51 1.60 -1.06     -1.33 
 
-1.24 1.99 -1.12     -1.84 
HBEGF 1.19 1.08 1.08 1.08   2.35 
 
1.19 -2.49 -1.62 -1.00   -1.00 
PDE8B -1.49 1.26 -1.05      DNA 
 
1.31 -2.44 1.15     DNA 
HLA-A 1.08 1.02       -1.28 
 
1.17 1.07       -1.30 
BIRC5 1.33 1.23 1.25     1.69 
 
-1.09 1.08 1.04     2.01 
CD74 1.21 1.15 1.23     -1.51 
 
1.03 1.13 -1.00     -1.78 
DUSP6 1.21 1.36 1.01     1.19 
 
-1.03 -1.41 -1.07     -1.32 
MYC 1.66 1.12       1.31 
 
-1.10 -1.05       -1.47 
SOCS1 1.43 1.34 1.22 1.17   -1.57 
 
-1.21 -1.15 -1.14 -1.09   -2.56 
ZEB2 -1.50 1.23 -1.34 -1.46   -1.57 
 
-1.20 -1.26 -1.20 1.12 1.11 -1.54 
BCL2 -1.29 -1.09 1.07 1.04   -1.19 
 
-1.12 -1.20 1.29 -1.18 1.00 -1.28 
CXCR3 1.59 -1.11       -1.06 
 
1.55 -1.14       -1.49 
EGR1 -1.12 1.13 1.01     -1.05 
 
-1.07 -1.04 -1.03     -2.13 
TBX21 -1.00         -1.05 
 
-1.18         -1.20 
CIITA -1.70 -1.17 -1.05     -1.85 
 
-1.36 -1.12 -1.18     -1.47 
PMAIP1 1.04 -1.02       1.12 
 
-1.56 -1.47       -1.56 
DICER 1.42 1.25 -1.07 -1.10 -1.02 1.12 
 
-1.47 -1.38 1.38 -1.12 -1.06 -1.15 
GLT8D2 2.71 1.53       DNA 
 
-1.12 1.12       DNA 
IFT74 1.97 1.18       -1.74 
 
1.64 -1.09       -2.78 
PHGDH 2.35         1.77 
 
          -1.69 
SCD 2.39 2.00 1.91 1.39 1.43 1.28 
 
1.42 1.40 1.23 1.07 1.03 -1.57 
C17orf66 -2.14         -1.28 
 
          2.64 
FCHO2 -2.07 1.03       DNA 
 
1.22 1.17       -2.71 
MRC2 -2.20 1.04       -2.56 
 
-1.30 1.18       -1.87 
TGFB1T1 -2.08         -2.26 
 
-1.55         -2.48 
TNFSF4 -2.68         -2.51 
 
-1.16         -2.32 
ZNF383 -2.16         -2.13 
 
-1.08         -1.74 
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ZNF527 -2.63 1.21       -2.95 
 
-1.64 1.15       -3.12 
ZNF565 -2.04         -3.76 
 
-2.01         -4.26 
RAD9B 2.24 1.11       -3.30 
 
2.62 1.29       DNA 
GSTM4 1.48 1.00       -1.41 
 
2.13 1.54       -2.08 
KCNMB4 1.31 1.39       -1.32 
 
1.91 1.37       -1.06 
SYNGR3 1.24         1.03 
 
1.85         1.35 
ARG1 -1.29 -1.29 1.01 -1.00   DNA 
 
1.78 1.39 1.17 -1.05   DNA 
ALDOC 1.30         -1.32 
 
1.73         -1.32 
HCN3 -1.74         -1.15 
 
-2.20         1.14 
SRFBP1 -1.42         -1.65 
 
-2.41         -3.15 
ZNF573 -1.74 1.10       -2.95 
 
-2.35 1.03       -4.03 
NID2 -1.38         1.80 
 
-2.28         1.32 
SCG5 -1.05         -1.89 
 
-1.72         -2.03 
BEX1 1.09         DNA   1.71         DNA 
 
As can be seen here, there are several genes where the different probesets show a lack of 
conformity in their response to either LMP1 or LMP2B.  The situation with LMP2A was similar 
(data not shown). 
There are two important conclusions which can be drawn at this stage.  Firstly, the lack of 
agreement between the Fluidigm data and the original microarray can be explained at least in 
part by the dissimilarity between expression patterns of probesets attributed to the same gene.  
Secondly, and more worryingly, this suggests that relying on the Affymetrix probeset annotation 
for analysis of the microarray data to identify interesting genes is likely to be inaccurate. 
In order to overcome this, we next performed our comparison analyses using the Affymetrix 
probe set identifiers rather than the gene names.  Any probeset without a named gene was 
discarded from the analysis even if the resulting change in expression appeared significant.  
Results are shown in Table 3-9. 
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Table 3-9 - Genes differentially regulated by viral proteins in primary NK cells when analysed at the probeset level (FC>1.5 or 
<-1.5, P<0.01). 
 LMP1 LMP2B LMP2A 
Number of probesets 
upregulated 
113 88 122 
Number of probesets 
downregulated 
148 160 199 
 
When compared to the analysis performed at the gene level using the Affymetrix gene labels 
(Table 3-1), the results are similar.  This suggests that although we know that some genes have 
several allocated probes on the Affymetrix chip, in our analysis there do not appear to be many 
genes with multiple probes altered by the viral proteins.  This is concerning as we know that 
many genes do have multiple probesets in the array; our results suggest that possibly only one 
of these is being altered by the EBV gene, which raises questions about the reliability of the 
data, as if a gene’s expression is truly being altered then we would expect to see this reflected in 
all of the probesets attributed to that gene. 
The preceding analyses comparing the effects of LMP1 in NK- and GC-B-cells were repeated at 
the probeset level (Table 3-10).   
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Table 3-10 – Analysis of LMP1 effects on NK and GCB-cells at the probeset level (FC>1.5 or <-1.5, P<0.01). 
Denominator: 42,450 
NK LMP1 GCB LMP1 Overlap OR Chi sq P 
Up (113) Up (953) 
 
11 
 
4.74 
 
28.23 
 
<0.0001 
 
Down 
(1656) 
 
1 0.22 2.64 0.27 
NK LMP1 
down 
(148) 
Down 
(1656) 
 
6 
 
1.04 
 
0.0089 
 
0.9956 
 
Up (113) 
 
1 0.22 2.64 0.27 
 
 
When compared to table 3-4 (analysis of the effect of LMP1 using Affymetrix gene annotation), 
although there was significant overlap in the probesets upregulated by LMP1 in NK and GCB-
cells, those downregulated were not statistically similar.  Also, the number of overlapping 
probes is much lower than the number of genes.  This suggests that some of the overlapping 
genes as defined by the Affymetrix notation were, in actual fact, represented by different probe 
sequences, and that not all of the probesets purported to represent a given gene were altered 
by the same magnitude and direction by the viral protein – due to multiple mRNA isoforms 
cross-hybridising to different probes, probesets that target more than one gene and mislabelled 
probesets.  These issues with Affymetrix microarray analysis are well described (383, 386), albeit 
usually ignored. To illustrate the scale of the problem, when the ambiguous cross-hybridising 
and incorrectly orientated probesets are removed, only 11,837 genes remain identified from an 
original number of 20,932 (Dr Wenbin Wei, personal communication). 
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The analysis is further complicated by the fact that genes are represented by different numbers 
of probesets – some as many as 20, some as few as 1; and genes with more probesets are more 
likely to appear in the lists of significantly altered genes purely by chance.  Therefore, although 
the denominator for this analysis is 42,450, these are not actually 42,450 independent 
probesets.  Correcting for this statistically is complex.  One method is to group all the probesets 
by the number of probesets per gene and analyse them separately – for example, all the 
probesets where there is only one probeset per gene in one group, where there are 2 probesets 
per gene in a second group, and so on.  However, not only is this particularly time-consuming, 
the denominators of some of the groups become so small as to be unreliable.  Furthermore, 
even this doesn’t resolve the problem where multiple probesets against the same gene do not 
change in the same way.  This situation, in combination with the low rate of qPCR validation, 
caused us to consider carefully the appropriateness of the Affymetrix annotation in this case. 
There have been several strategies reported in the literature to try to correct for this problem.  
The problems with a probeset analysis are discussed above.  Choosing one probeset to 
represent a certain gene and discarding the others has been suggested (see (383)) but means 
discarding potentially useful data.  Li et al (387) proposed a method whereby probesets to the 
same gene which behave in the same manner for a certain array (as determined by statistical 
analysis) are grouped together whereas other probesets to the same gene are not.  The 
disadvantages here are that these groupings will vary from dataset to dataset, making 
comparison between datasets difficult, again, data are lost by the analysis.  A more 
sophisticated approach is to combine statistical analysis of sibling probesets with sequence 
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analysis of the probesets as described by Schneider et al (383), but the drawbacks of this 
method are similar. 
The other reported solution to the problem is the use of custom chip definition files (CDFs) as 
discussed by Dai et al (386).  A CDF can be considered as a “key” to the microarray chip; it is a 
file which matches probe sequences to that of known genes.  Affymetrix provide a CDF as a 
matter of course, but the problems with this have been discussed above.  Custom CDFs 
generate an entirely new set of probe labels matching stringent criteria.  For example, Dai et al 
demanded that firstly the probe sequence should match the gene sequence exactly.  Secondly, 
each probe in a probe set should have only one perfect match within the genomic sequence.  
Thirdly, the probe should match a genomic region corresponding to a transcribed mRNA, not 
just an expressed sequence tag (EST), as these have high rates of error.  Fourthly, the probe 
must not match another gene.  Fifthly, the probes within a set should all match to the same 
genomic sequence.  Finally, each probe set must contain at least 3 probes (386).  The authors 
suggest that with their custom CDF there can be as much as a 40% difference in the final list of 
differentially regulated genes when compared to conventional analysis.  Drawbacks include the 
need to reanalyse the raw data with the custom CDF file (which may be problematic in 
comparing to historical arrays if only processed data are available), and, again, the discarding of 
some potentially accurate data due to the stringent entry criteria.  Finally, the CDF file must be 
constantly updated as new sequence information becomes available, and care must be taken to 
use the most recent version in analysis (see (388) for file downloads).  This last point also applies 
to the Affymetrix CDF, although it is updated less frequently and, apparently, with less rigour. 
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We therefore repeated our analysis using the Entrez custom CDF file (388), with interesting 
results (Table 3-11). 
Table 3-11 - Comparison of genes differentially expressed by LMP1 in NK or germinal centre B (GCB) cells using the Entrez CDF 
gene labels (FC>1.5 or <-1.5, P<0.01).   
Denominator: 18,718 
NK LMP1 GCB LMP1 Overlap OR Chi sq P 
Up (44) Up (492) 3 2.72 2.94 0.0864 
Down 
(753) 
2 0.23 0.030 0.863 
Down (78) Down 
(753) 
 
5 
 
1.64 1.11 0.292 
Up (496) 2 
 
0.97 0.00217 0.962 
 
Unlike the previous analyses (Table 3-3 and Table 3-9), the overlap between genes upregulated 
by LMP1 in the two cell backgrounds (NK cells vs. GC B-cells) is no longer significant.  When, 
using the custom CDF file, the effect of LMP1 in NK- and naive B-cells (M. Vockerodt, 
unpublished data) is compared the results are even more striking (Table 3-12) 
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Table 3-12 - Comparison of genes differentially expressed by LMP1 in NK or naive B-cells using the Entrez CDF gene labels 
(FC>1.5 or <-1.5, P<0.01). 
Denominator: 18,718 
NK LMP1 Naive B Overlap OR Chi sq P 
Up (44) Up (27) 
 
0 
 
0 
 
0.063 
 
0.969 
 
Down (54) 
 
0 0 0.13 0.9371 
Down (78) Down (54) 
 
0 
 
0 
 
0.23 
 
0.89 
 
Up (27) 
 
0 0 0.11 0.95 
 
As discussed above, the usual host cells for EBV are B-lymphocytes and epithelial cells; it could 
be expected that the virus would have evolved to have a stereotyped and coherent strategy for 
infection of these cells whereas that in NK cells may be less well developed.  With this in mind, 
we then compared the effects of LMP1 in NK cells with AdAH (an epithelial hybrid 
nasopharyngeal cell line (389)) and SCC12F (a squamous epithelial cell line (75, 390)) (Table 3-13 
and Table 3-14).  As can be seen there is no significant overlap between genes upregulated or 
downregulated by LMP1 in these cell backgrounds.  The significant result for LMP1 upregulated 
genes in NK cells and downregulated in AdAH cells highlights the fact that, in these very 
different cell backgrounds, LMP1 appears to be having very different effects. 
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Table 3-13 - Comparison of genes differentially expressed by LMP1 in NK or AdAH nasopharyngeal carcinoma cells using the 
Entrez CDF gene labels (FC>1.5 or <-1.5, P<0.01). 
Denominator: 18,718 
NK LMP1 AdAH 
LMP1 
Overlap OR Chi sq P 
Up (44) Up (461) 1 0.92 0.00646 0.94 
Down 
(494) 
4 3.71 6.94 0.008 
Down (78) Down 
(494) 
 
3 1.48 0.43 0.512 
Up (461) 1 0.513 0.44 0.507 
 
Table 3-14 - Comparison of genes differentially expressed by LMP1 in NK or SCC12F squamous epithelial cells using the Entrez 
CDF gene labels (FC>1.5 or <-1.5, P<0.01). 
Denominator: 18,718 
NK LMP1 SCC12F 
LMP1 
Overlap OR Chi sq P 
Up (44) Up (45) 0 0 0.106 0.74 
Down (40) 0 0 0.094 0.76 
Down (78) Down (40) 
 
0 0 0.167 0.68 
Up (45) 0 0 0.188 0.66 
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We next compared the effects of LMP1 in naive and germinal centre B-cells (Table 3-15).  As 
expected, there was a significant degree of overlap between genes upregulated and 
downregulated by LMP1 in these very similar cellular backgrounds. 
Table 3-15 - Comparison of genes differentially expressed by LMP1 in GCB or naive B-cells using the Entrez CDF gene labels 
(FC>1.5 or <-1.5, P<0.01). 
Denominator: 18,718 
GCB Naive B Overlap OR Chi sq P 
Up (492) Up (27) 
 
5 8.49 25.94 <0.0001 
Down (54) 
 
2 1.42 0.238 0.626 
Down (753) Down (54) 
 
10 5.48 28.21 <0.0001 
Up (27) 
 
2 1.91 0.77 0.38 
 
We next compared the effects of LMP1 on the two epithelial cell lines (Table 3-16).  Again, there 
is a marked and significant degree of overlap between differentially regulated genes within 
these cells. 
Table 3-16 - Comparison of genes differentially expressed by LMP1 in AdAH nasopharyngeal carcinoma cells or SCC12F 
squamous epithelial cells using the Entrez CDF gene labels (FC>1.5 or <-1.5, P<0.01). 
Denominator: 18,718 
AdAH LMP1 SCC12F 
LMP1 
Overlap OR Chi sq P 
Up (461) Up (45) 6 6.15 21.59 <0.0001 
Down (40) 1 1.02 0.00022 0.99 
Down (494) Down (40) 
 
15 22.78 184.19 <0.0001 
Up (45) 9 9.37 51.39 <0.0001 
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Finally, we compared the effects of LMP1 on epithelial cells and B-cells (table 3-17), and showed 
that there was no significant overlap in gene expression.  This corroborates our findings when 
epithelial cells were compared with NK cells, and suggests that the pattern of gene expression 
imposed by the viral gene may be different in different cell backgrounds. 
Table 3-17 - Comparison of genes differentially expressed by LMP1 in AdAH nasopharyngeal carcinoma cells or naive B-cells 
using the Entrez CDF gene labels (FC>1.5 or <-1.5, P<0.01). 
Denominator: 18,718 
AdAH LMP1 Naive B 
LMP1 
Overlap OR Chi sq P 
Up (461) Up (27) 0 0 0.66 0.42 
Down (54) 0 0 1.33 0.25 
Down (494) Down (54) 
 
2 1.42 0.23 0.63 
Up (27) 1 1.42 0.12 0.73 
 
 
In conclusion, we can see that LMP1, whose function is well-characterised in B- and epithelial 
cells, also causes differential expression of several cellular genes in an NK cell background, 
although not necessarily the same ones.   
There are no published microarrays looking at LMP1 in NK cells with which to compare our data, 
but we do have access to data from a series of ENKTL samples (391).  We analysed these by 
comparison to uninfected NK cells rather than to those transduced with the empty lentivirus.  
The repeat analysis was necessary as the published array data did not include relevant controls 
that would have allowed direct comparison with our array.  When this was compared with the 
effects of LMP1 and 2B on primary NK cells (table 3-18 and Table 3-19) we can see that the 
genes differentially regulated by LMP1 are significantly similar to those seen when the gene 
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expression profile of the ENKTL is compared to that of our uninfected primary NK cells.  LMP2A 
shows an overlap with downregulated but not upregulated genes (data not shown).  However, 
LMP2B shows no significant overlap with ENKTL samples (table 3-19). 
 
Table 3-18 -  Comparison of genes differentially expressed by LMP1 in NK cells with those expressed in ENKTL biopsies 
compared to uninfected NK cells using the Entrez CDF gene labels
Denominator: 18,718 
NK LMP1 ENKTL Overlap OR Chi sq P 
Up (44) Up (2869) 14 2.58 7.81 0.0052 
Down 
(2769) 
2 0.27 3.12 0.0773 
Down (78) Down 
(2769) 
 
21 2.12 
 
7.76 0.0053 
Up (2869) 11 0.91 0.076 0.7828 
 
 
Table 3-19 - Comparison of genes differentially expressed by LMP2B in NK cells with those expressed in ENKTL biopsies 
compared to uninfected NK cells using the Entrez CDF gene labels 
Denominator: 18,718 
NK LMP2B ENKTL Overlap OR Chi sq P 
Up (42) Up (2869) 6 0.92 0.0297 0.8632 
Down 
(2769) 
2 0.29 2.86 0.0908 
Down (54) Down 
(2769) 
 
12 1.65 2.01 0.1563 
 
Up (2869) 7 0.822 0.197 0.6572 
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3.6  Discussion 
 
There are two main conclusions to be drawn from these results.  Firstly, the data are consistent 
with LMP1 exerting a significant oncogenic effect on the primary NK cells – this is perhaps 
unsurprising given its known function as an oncogene in other cell backgrounds, but given the 
lack of any significant overlap with the gene expression in B- and epithelial cells suggests that it 
may have a different mechanism of action in NK tumours.  Secondly, there is no significant 
overlap in genes differentially expressed in ENKTL and as a result of LMP2B-TR expression, 
suggesting that LMP1 makes a greater contribution to the transcription profile of ENKTL than 
LMP2B does.   
With this in mind, it is perhaps surprising that LMP2B does not show more overlap with the 
ENKTL data set.  There are several possible explanations for this.  Firstly, it must be considered 
that the number of differentially regulated genes in the primary NK arrays is relatively small.  
This is, to some extent, a reflection of our stringent statistical criteria.  It is possible that longer 
term expression of the viral protein might have led to more striking changes in gene expression, 
but in view of the short lifespan of primary NK cells in vitro, this is likely to introduce significant 
inaccuracies.  The existence of the stereotyped latency patterns of EBV gene expression 
suggests that the EBV proteins may act co-operatively to produce a phenotype; if this is the case 
then LMP2B may be unable to exert a significant effect without LMP1 co-expression.  Finally, 
when considering ENKTL primary tissue, it is necessary to bear in mind that the tumours are 
characteristically necrotic, with the resultant changes in gene expression as well as infiltration 
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by inflammatory cells.  For this reason, gene expression profiling of biopsy material in this case 
is inevitably somewhat inaccurate when trying to obtain a picture of the cancer cells per se, and 
is one of the reasons why so many of such studies rely upon established cell lines. 
In summary, we expressed the EBV proteins LMP1, LMP2A and LMP2B in primary NK cells using 
a lentiviral vector, and examined the resultant changes in gene expression profiling using an 
Affymetrix U133 Human Genome microarray.  Differentially regulated genes included those 
involved in cell cycle and apoptosis.  Using a custom CDF to avoid inaccuracies due to probeset 
misannotation we compared our results with those seen with the same proteins in B and 
epithelial cells, and showed that although there was limited overlap between those seen in NK 
cells, the results seen when compared to ENKTL were strikingly similar.  LMP1 in particular 
shows a marked overlap with the ENKTL samples, and the role of this protein in NK cells needs 
further elucidation. 
Further work which could be performed in this area includes a thorough analysis of the genes 
either up- or down-regulated by both LMP1 and in the ENKTL samples.  This was limited by lack 
of time (the issues with the interpretation of the microarray results arose late in the course of 
this study), but also by an understandable reluctance on the part of the researchers to commit 
further time and money to this somewhat flawed data set.  Although we are fortunate to have 
access to the ENKTL data, there are various issues with it: firstly, the controls used (fresh and IL-
2-stimulated NK cells, in culture for a maximum of 24 hours (297)) seem inadequate as we know 
that NK cells are dependent upon IL-2 to grow in vitro and the cytokine-induced changes to the 
cells will not be complete at 24 hours.  Secondly, the ENKTL data included a subgroup of γδ T 
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cell malignancies and EBV-negative tumours (391), and despite appeals to the authors we have 
been unable to determine which these are in order to remove them from the analysis.  In 
summary, we feel that the above results, although intriguing, should be followed up in a 
different manner. 
RNA sequencing involves sequencing the entire RNA transcriptome, or just a selected section of 
it (for example, coding mRNA, miRNA, etc).  RNA is isolated and reverse transcribed into cDNA.  
The transcriptome is then constructed either by de novo assembly or by comparison to a 
reference genome.  This technique allows analysis of gene expression without any of the probe 
issues discussed above, and has the advantage of providing the actual RNA sequence, so 
permitting the detection of mutations or polymorphisms.  Excitingly, it can also be used to 
simultaneously analyse viral RNA if required (392).  The technology is relatively new, and not 
without problems (393), but it would seem that the next logical step in this situation is to repeat 
the experiment using RNA sequencing, including well-characterised tumour samples with 
appropriate controls. 
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CHAPTER 4 - CHARACTERISING THE APOPTOSIS 
RESISTANCE PHENOTYPE IN ENKTL 
4.1  Introduction 
 
Many investigations have been performed over the last 50 years to try to elucidate how EBV 
contributes to lymphomagenesis.  The majority of these studies have been performed on B cell 
derived lymphomas; to date the role played by EBV in T cell and NK cell lymphomas has been 
largely neglected primarily due to the rarity of these diseases and the access to lymphoma 
tissue before treatment.  The contribution of the virus is better understood in Burkitt lymphoma 
(BL), where it is thought that it can contribute to tumour maintenance via anti-apoptotic effects 
as well as a likely role in tumour initiation (reviewed in (394)).  Recent studies have shown that 
EBV provides BL with an apoptosis-resistance phenotype, which is significantly enhanced if the 
cells exhibit the Wp-restricted viral gene expression profile (132, 395).  We therefore sought to 
determine if EBV contributes towards the apoptosis-resistance phenotype commonly observed 
in ENKTL compared to the non-malignant and apoptosis-sensitive CAEBV.  
Apoptosis is vital not only for the maintenance of normal tissues but also provides a means 
whereby the body can protect itself from cancer.  Upon detecting potentially oncogenic 
damage, for example double-stranded DNA breaks, the cell can initiate an apoptotic cascade 
and effectively commit suicide before it can divide and form a tumour.  Many of the currently-
used chemotherapy agents exploit these apoptotic pathways, either by causing sufficient 
damage to the cell that it initiates apoptosis itself, or, increasingly, by directly feeding in to the 
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cascades.  ENKTL in particular is resistant to many conventional chemotherapeutic agents, 
which may suggest that the tumours have an apoptosis-resistance phenotype similar to that 
seen in BL. 
The rarity and clinical behaviour of ENKTL and other EBV-positive T- and NK-cell disorders means 
that we rely heavily upon cell lines in order to examine cell behaviour.  The cell lines we used in 
this study are summarised in table 2-1.  These have been created by careful and methodical 
culture of patient samples, and represent both the malignant ENKTL and non-malignant CAEBV.  
We first examined the EBV gene expression by both the levels of EBV mRNA transcripts and 
protein and compared these between a panel of ‘malignant’ cell lines with ‘non-malignant’ cell 
lines.  
4.2 - Characterising the EBV gene expression profile of ENKTL and CAEBV cell 
lines. 
Analysis of the EBV gene expression profile has only previously been performed on a very 
limited subset of the ENKTL cell lines.  We have since collected further ENKTL cell lines and 
analysed the EBV gene expression profile using an extensive panel of viral qPCR assays using the 
Fluidigm Specific Target Amplification system for viral mRNA expression.  The EBV qPCR assays 
used were developed and validated by Dr A Bell, and have all been published (38, 50, 396). 
Representative results from these experiments are shown in figures 4-1 to 4-5.  Sequence 
variations in EBV strains have been noted particularly in LMP1; the LMP1 Cao assay has been 
designed specifically to detect the sequence variant prevalent in SE Asia and Japan, and 
therefore seen in the ENKTL cell lines, whereas the B95.8 assay detects the gene first sequenced 
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from a Caucasian IM patient and prevalent outside SE Asia including African BL samples.  The TR 
assays for LMP1 and LMP2 detect transcripts initiated from the terminal repeat region of the 
genome; LMP2 exon 6 assay was developed to detect both LMP2A and LMP2B via their common 
region.  For each individual assay, the viral gene expression was normalised to the input of cDNA 
to control for any differences in the amount of cDNA added to each assay. 
Surprisingly we noted that the levels of EBV gene expression not only varied between the ENKTL 
and the CAEBV cell lines, but also varied significantly between the ENKTL cell lines.  LMP1 
transcription can be initiated from either the EBNA-2-regulated promoter which is usually active 
in B-cells, or else from one located in the terminal repeat region (TR).  Figure 4-1 shows that in 
the ENKTL and CAEBV lines, the vast majority of the transcripts are from the B-cell promoter, 
and there is significant variation in levels between the cell lines, with SNK6, SNT8 and SNT13 
showing higher expression (note the different scales used to demonstrate expression of the less 
abundant transcripts).  LMP1 expression is variable both between and within ENKTL samples, 
and so this variability is plausible and intriguing (52, 57). 
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Figure 4-1 – LMP1 expression in ENKTL and CAEBV cell lines analysed by Fluidigm Specific Target Amplification.  Four sets of 
primers were used to detect the conventional (EBNA-2 regulated promoter) and terminal repeat promoter (TR) alternative 
transcripts, and the B95.8 and Cao sequences.  Conventional LMP1 with the Cao sequence is the only transcript significantly 
expressed in the lines studied, and its expression is significantly higher in SNK6, SNT8 and SNT13 
  
Figure 4-2 shows LMP2 expression.  The exon 6 assay was designed to detect all LMP2 
transcripts; however, even when LMP2A, 2B and 2B-TR are accounted for there is still an excess 
of exon 6 detected in most of the cell lines.  It is possible that this represents a sequence 
variation, or may be the result of transcription from an as-yet unknown promoter.  Of note, 
both LMP1 and LMP2A levels are comparable to that seen in an LCL (approximately 1 and 0.1 
copies per PGK respectively (38). 
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Figure 4-2 – LMP2 expression in ENKTL and CAEBV cell lines by Fluidigm Specific Target Amplification.  Four sets of primers 
were used.  The LMP2 exon 6 primers will detect both LMP2A and LMP2B.  Absolute expression of LMP2 transcripts is much 
lower than that of LMP1 (figure 4-1), and the predominant form is the LMP2-TR transcript.  The differences in expression 
between the ENKTL cell lines is not as apparent as the levels of transcripts observed for LMP1. 
 
Figure 4-3 shows EBNA-1 expression.  This about ten times lower than that seen in an LCL (38) 
and is more consistent across the class than the latent membrane proteins.   
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Figure 4-3 - EBNA-1 expression in T and NK cell lines by Fluidigm Specific Target Amplification.  The Q-U-K probe set detects 
EBNA-1 initiated from the Q promoter.  Expression is low however it is much less varied across the cell lines.  Expression from 
the C and W promoters was absent, as shown by the lack of expression by the Y-U-K probe set. 
Figure 4-4 shows EBER expression – again, EBER1 and EBER2 are shown on different scales to 
demonstrate the variability between cell lines.  SNK13 and SNT15 show greatly elevated levels 
compared to the other cell lines; for comparison, EBER1 expression in LCLs is approximately 2-8 
copies per PGK (38). 
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Figure 4-4 - EBER expression in T- and NK-cell lines by Fluidigm Specific Target Amplification.  EBER1 expression is generally 
higher than EBER2 expression across all the cell lines.  However, EBER1 expression is remarkably high in both SNT13 and 
SNT15.  The significance of this is not clear. 
Figure 4-5 shows that levels of BZLF1 are low across the cell lines, suggesting that little lytic 
replication is taking place.  For comparison, in lytic cycle in an Akata cell the levels of BZLF1 peak 
at around 35 copies per PGK (38).  EBNA-2 levels are low, as expected. 
 
Figure 4-5 - Expression of EBNA-2 and BZLF1 in ENTKL and CAEBV lines by Fluidigm Specific Target Amplification. Expression of 
EBNA-2 is extremely low as would be expected in these cell lines given the usage of the Wp and Cp promoters are B cell 
specific. The very small levels of EBNA-2 can probably be accounted for by the low levels of lytic cycle observed and 
represented here by BZLF1.  
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Characterising protein expression in ENKTL and CAEBV cell lines. 
 
Quantitative PCR to examine the relative levels of viral mRNA transcripts is a convenient tool to 
examine which viral genes are being expressed.  However, gene expression does not always 
correlate with translation of the message or indeed the final levels of protein.  We therefore 
also characterised the viral gene expression at the protein level by Western blot for all the cell 
lines used.  Western blots were performed for the proteins reported to be expressed in T/NK 
cell lymphomas including EBNA-1, LMP1 and LMP2A, shown in figure 4-6.  As an EBV-negative 
control we used Jurkat and as an EBV-positive control we used an LCL which expresses high 
levels of LMP2A.  EBNA-1 was expressed in every cell line albeit at lower levels than those 
observed in an LCL, consistent with the RT-Q-PCR findings.  However, the LMP1 levels observed 
in SNK1, SNK6 and SNT8 were significantly higher than that observed in an LCL.  The protein 
expression for SNK1 is in contrast with the relatively low mRNA levels detected by Q-RT-PCR, 
suggesting a polymorphism in the LMP1 primer/probe sequence.  As previously observed, we 
could not detect LMP2A in either the ENKTL or the CAEBV cell lines.  Unfortunately an antibody 
does not exist for LMP2B meaning we could not verify the Q-RT-PCR results for the LMP2B and 
LMP2B-TR transcripts. 
Neither BZLF1 or EBNA-2 were detected by Western blot, consistent with the very low levels of 
mRNA transcripts. 
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Figure 4-6. Viral proteins expressed in the ENKTL and CAEBV cell lines.  Western blots confirming EBNA-1 and LMP1 protein 
expression in the ENKTL and CAEBV cell lines. The Western blots for LMP1 were exposed for 3 minutes (short exposure) or 10 
minutes to confirm the low level of expression of LMP1 in the ENKTL cell lines SNT13, 15 and Mec04, and the CAEBV cell lines 
SNK10 and SNT16. 
4.3  Examination of the impact of high level EBV gene expression on the growth 
of ENKTL. 
The significant differences in EBV gene expression, particularly LMP1 and LMP2, between the 
ENKTL cell lines prompted us to question the role of these proteins in T/NK lymphomagenesis.  
Previous work examining the role of LMP1 in the absence of EBNA-2 expression (397-399) 
showed that LMP1 expression may be cytokine dependent.  LMP1 levels fall following IL-2 
removal, and this is quickly followed by apoptosis of the cells.  However, given the individual cell 
lines express both high levels or extremely low levels of LMP1, we wanted to examine if, in very 
low levels of LMP1, the ENKTL cell lines responded to IL-2 withdrawal in the same manner as the 
cells expressing high levels of LMP1.  All the ENKTL cells and CAEBV cells are IL-2 dependent for 
proliferation.  We therefore first reproduced the loss of LMP1 following IL-2 withdrawal by Q-
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RT-PCR for the cell lines expressing high levels of LMP1 (figure 4-7).  We performed all 
experiments on the cells expressing high levels of LMP1 by Western blot and Q-RT-PCR, SNK1, 
SNK6 and SNT8, plus SNT13 as the higher intermediate level of LMP1.  The cells were removed 
from their culture medium, washed three times in medium without IL-2 and re-plated in 
medium without IL-2 for 1 hour.  To ensure the IL-2 was completely washed off, the cells were 
once more re-plated in fresh medium without IL-2.  The Q-PCR results indicate LMP1 mRNA was 
significantly reduced over the first 24 hours following IL-2 withdrawal and was maintained at a 
similar low or reducing level over the following 4 days (figure 4-7). 
 
Figure 4-7  Analysis of LMP1 mRNA transcripts following IL-2 withdrawal.  Although the initial level of LMP1 expression is 
variable between cell lines, it invariably falls after 24 hours of IL-2 withdrawal and remains low for the duration of the 
cytokine deprivation. 
 
Given the levels of LMP1 significantly reduced within 24 hours following IL-2 withdrawal, we 
wanted to determine what effect the IL-2 withdrawal would have upon the survival of the cells 
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which originally expressed LMP1 at high levels, compared to intermediate levels and 
low/negative LMP1 expression.  We therefore performed viability assays on the ENKTL cell lines 
expressing high levels of LMP1 and compared them to ENKTL expressing intermediate levels of 
LMP1 and no LMP1.  We also wanted to determine if cell lineage (T cell or NK cell) or ENKTL or 
CAEBV diagnosis induced a differential sensitivity to IL-2 withdrawal.   
As above, the cells were washed three times to remove IL-2 and re-plated in fresh medium 
without the cytokine at a density of 1x105cells/ml.  The cells were then harvested every day, 
stained with propidium iodide, analysed by flow cytometry and the total number of live cells 
recorded.  All assays were performed three times, each in triplicate.  The results are 
represented as % of cells alive after IL-2 withdrawal and are shown in figures 4-8 and 4-9.  
Statistical analysis was performed using a one-way analysis of variance (ANOVA) analysis. 
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Figure 4-8 - The effect of IL-2 withdrawal in the LMP1 high, intermediate and low/negative cell lines.  IL-2 withdrawal caused 
a significant decline in cell survival over the subsequent 5 days. Each assay was performed three times in triplicate.  
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Figure 4-9 - Analysis of cell survival at day 5 following IL-2 withdrawal according to LMP1 expression, disease and cell type. 
Further analysis was performed on the ENKTL and CAEBV cell lines to determine if cell survival following IL-2 withdrawal 
could be accounted for by LMP1 expression, disease or cell lineage. 
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The cells expressing the highest initial levels of LMP1 (SNK1, SNK6 and SNT8) appeared to show 
the poorest survival following IL-2 withdrawal, with the average survival by day 5 of between 
only 18 and 28% (figure 4-9, top panel).  This suggests that the coincident loss of LMP1 in these 
cells following removal of IL-2 may be responsible for the loss of survival.  The cells expressing 
the intermediate level of LMP1 (SNT13, SNK10 and SNT16) appeared to show better survival 
following IL-2 withdrawal, with survival rates between 37 and 52% (figure 4-9, top panel).  The 
difference between these two groups was statistically significant (p=0.02) by ANOVA analysis.  
Interestingly the MEC04 cells not expressing LMP1 showed a poor survival of 20% and the 
SNT15 expressing a very low level of LMP1 showed 35% survival (figure 4-9, top panel).  When 
all three groups were compared (p=0.059), or when the high LMP1 group was compared to the 
combined intermediate and low group (p=0.07) there was a trend towards different survival 
although this did not reach statistical significance.  
When ENKTL-derived lines were compared to CAEBV, there was a trend towards cells of CAEBV 
origin surviving better than ENKTL following IL-2 withdrawal (figure 4-9, middle panel); but this 
did not reach statistical significance (p=0.053).  There was no difference between cells of T- and 
NK-origin (figure 4-9, bottom panel, p=0.56). 
Both the ENKTL and CAEBV cell lines are dependent upon growth factors such as IL-2 for their 
survival.  This dependence is variable between cell lines, and infected cell type, and may show 
some association with LMP1 expression.     
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In order to further investigate apoptosis susceptibility in these cells we next examined the cells 
for differences in expression of the pro- and anti-apoptotic members of the intrinsic apoptosis 
pathway (figures 4-10, 4-11 and 4-12).  As a control, the IL-2 independent T cell leukaemia line 
Jurkat (400) was treated with camptothecin at 5 mM concentration for 18 hours to induce the 
expression of the pro-apoptotic proteins.  NKL, an NK line derived from NK leukaemia (401) and 
Mutu, a BL line (402), were included as controls. 
 
Figure 4-10 - Expression of proapoptotic BCL2 family members in the ENKTL and CAEBV cell lines.  BAD is seen at high levels in 
the CAEBV lines only.  BAX is interestingly expressed at very similar levels across the cell lines with the exception of MEC04.  
Two BID isoforms, full-length (FL) and truncated (T) are seen although expression is only significantly detected in SNK1 and 
the CAEBV lines.  3 BIM isoforms – extra long (EL), long (L) and short (S) – are generated by alternative splicing of the 
transcript.  There is only very weak BIM expression in the CAEBV lines. 
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Figure 4-11 - Analysis of BID and BIM mRNA transcripts in the ENKTL and CAEBV cell lines. The mRNA transcripts of the ENKTL 
and CAEBV cell lines were compared to mRNA transcripts detected in the control Jurkat cell line. The Jurkat transcripts were 
given an arbitrary value of 1, so the mRNA transcripts of BID (upper panel) and BIM (lower panel) could be compared to the 
control Jurkat cell line. 
 
The expression of the pro-apoptotic proteins in the ENKTL and CAEBV lines (figure 4-10) was 
significantly different to that in the control cell lines, which included an EBV-negative NK 
lymphoma (NKL), an EBV-negative T cell lymphoma (Jurkat), an EBV-positive Burkitt lymphoma 
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and a lymphoblastoid cell line.  Of particular note, the expression levels of the pro-apoptotic BID 
were significantly decreased in ENKTL and CAEBV compared to relevant controls.  Furthermore, 
the two cell lines SNK6 and SNT8 which express the highest levels of LMP1 were completely 
negative for BID, both when assayed for protein by Western blot (figure 4-10) and for mRNA by 
RT-Q-PCR (figure 4-11).  This could potentially have significant impact on susceptibility to 
mitochondrial apoptosis and interestingly could have an impact on extrinsic apoptosis given BID 
is one intersect between both pathways. 
BIM can be present in three isoforms formed by alternative splicing; BIMEL, BIML and BIMS, with 
BIMS being recognised as the most potent pro-apoptotic isoform (403, 404).  Surprisingly the 
majority of ENKTL cells express the BIML isoform, which again is unusual as most untreated cells 
will express the BIMEL isoform, as demonstrated by the controls assayed in parallel which 
included NK-cells (NKL), T-cells (Jurkat) and B-cells (Mutu1 and LCL).  By Q-RT-PCR we 
demonstrated that the levels of BIM transcripts were similar in all the cell lines, with the 
exception of MEC04, which had at least 6-fold higher levels of transcripts than the Jurkat control 
cell line.  This does not correspond to a higher level of protein by Western blot, but BIM is 
subject to post-transcriptional regulation (reviewed in (405)).  Also, our BIM assay did not 
differentiate between the different isoforms, so could not confirm or refute the finding that 
BIMEL is expressed in these cell lines.  
Furthermore, the proapoptotic BAD protein is expressed at higher levels in the CAEBV lines 
compared to the ENKTL cell lines or controls.  BAX protein expression is also significantly higher 
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in all the ENKTL and CAEBV cell lines compared to the control cells, with the exception again of 
MEC04, which was significantly lower (figure 4-10). 
 
 
Figure 4-12 - Expression of protein levels of antiapoptotic BCL2 family members in the ENKTL and CAEBV cell lines by Western 
blot.  In general, the expression of BCL2 and BCL-XL is increased in these cells compared to controls, and the level of MCL1 
was low in the CAEBV lines.  MEC04 has no expression of BCL-XL. 
 
The expression level of anti-apoptotic BCL2 family members is shown in figure 4-12.  Expression 
of BCL2 was increased in SNK1, SNK6, SNT8 and SNT13 compared to controls (except NKL); 
interestingly, these cell lines also show the highest levels of LMP1 expression (figure 4-6).  
However, the SNT15, MEC04, SNK10 and SNT16 also appear to have increased levels of BCL2 
which cannot be accounted for by LMP1 , particularly in SNT15 and MEC04 which have very 
little or no LMP1 expression.  BCL-XL was increased in all the ENKTL and CAEBV lines compared 
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to relevant controls, with the notable exception again of MEC04, which shows no BCL-XL 
expression.  Little difference can be observed in expression of MCL1 between the cell lines. 
 
4.4  Examination of the impact of BCL2 family and EBV gene expression on 
apoptosis 
 
ENKTL is a remarkably chemo-resistant tumour, resulting in poor outcomes with conventional 
treatment.  We wished to examine the sensitivity of the cell lines to apoptosis in order to see if 
there was an association between EBV or BCL2 family gene expression and cell death in 
response to apoptotic agents, which could have important therapeutic implications.  The 
expression data above were taken from proliferating cell lines with no IL-2 depletion. 
We treated them with a variety of apoptosis-inducing agents.  Etoposide acts by forming a 
complex with DNA and the topoisomerase II enzyme, which is necessary for the cleavage and 
religation of both DNA strands during transcription and replication (406).  In contrast, 
camptothecin affects DNA topoisomerase I (407).  Both drugs prevent DNA religation; the 
resulting double-stranded DNA breaks trigger apoptosis.  Ionomycin acts as a calcium 
ionophore.  In lung cancer cells it triggers apoptosis by activating calpains, and results in 
activation of the intrinsic pathway of apoptosis (408).   
The apoptosis assays were carried out as described in chapter 2.  Cells were stained for Annexin 
V and propidium iodide (PI), and analysed by flow cytometry.  Live cells were gated as PI and 
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Annexin V negative, apoptotic as Annexin V positive, and necrotic as PI positive (see figure 4-
13); the latter two gates were combined for analysis.  All assays were performed three times, 
each in triplicate. Standard deviations for all assays are shown. 
 
Figure 4-13 - Flow cytometric analysis of apoptosis assay showing SNT16 either with no drug or treated with etoposide.  The 
flow cytometry dot plots are shown to highlight the gating strategy for the apoptosis assays.  
Initially we titrated the chemotherapy agents on EBV-negative control Jurkat and MOLT4 (T 
lymphoblast (409) cells), measuring response at 24 hours.  The results are shown in figure 4-14.  
For ease of comparison to similar studies, the cell death induced by the drug was calculated as 
follows:  (total cell death - spontaneous cell death)/(100 – spontaneous cell death) (343).  This is 
particularly important as the ENKTL cell lines in particular have a relatively high rate of 
spontaneous apoptosis. 
Both cell lines show good dose-response apoptosis in response to ionomycin and etoposide, and 
time-dependent apoptosis in response to camptothecin at 5 µM concentration.     
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Figure 4-14 - Treatment of the control cell lines Jurkat and MOLT4 with apoptosis-inducing drugs.  The cell lines were either 
treated with increasing concentrations of etoposide (A), Ionomycin (B), or with 5µM Camptothecin over 18 hours (C). The % 
apoptosis was determined with Annexin V and PI staining and the results plotted against drug concentration.  
As can be seen in figure 4-14, the Jurkat and MOLT4 cell lines are equally susceptible to 
induction of apoptosis by the drugs etoposide (A), ionomycin (B) and camptothecin (C), making 
these cell lines good controls for the efficacy of the apoptosis-inducing drugs.  
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The ENKTL and CAEBV cells were treated in parallel with the apoptosis-inducing drugs (figures 4-
15 – 4-18).  Statistical analysis was performed on results from a representative drug 
concentration.  ANOVA analysis was used to compare the cell lines (grouped by LMP1 
expression) to the control cell lines. 
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Figure 4-15 - Analysis of apoptosis induced by increasing concentrations of etoposide on ENKTL and CAEBV cell lines.  The cell 
lines were treated with increasing concentrations of etoposide for 48 hours. The % apoptosis was determined with Annexin V 
and PI staining and the results plotted against drug concentration. Assays were performed three times in triplicate. 
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Figure 4-15 shows apoptosis in response to etoposide.  There is a significant difference between 
the control cells (figure 4-14) and the LMP1 high group (p=0.0007) in their sensitivity to the drug 
at 5µM concentration.  This is also the case when the controls are compared to the LMP1 
intermediate group (p=0.003).  However, when the control and LMP1 low groups were 
compared there was no significant difference (p=0.14).  This suggests that LMP1 expression may 
be associated with resistance to apoptosis associated with etoposide.  
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Figure 4-16 - Analysis of the apoptosis induced by increasing concentrations of ionomycin in the ENKTL and CAEBV cell lines.  
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The cell lines were treated with increasing concentrations of Ionomycin for 48 hours. The % 
apoptosis was determined with Annexin V and PI staining and the results plotted against drug 
concentration. Assays were performed three times in triplicate. 
Responses to ionomycin showed a similar pattern to etoposide, with the LMP1 high group 
(p=0.0005) and the LMP1 intermediate group (p=0.0003) showing significantly less apoptosis 
than the control cells at 5µM, but the LMP1 low group showing no significant difference 
(p=0.31).  Again, this suggests that LMP1 may contribute to the ENKTL resistance to ionomycin. 
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Figure 4-17 - Analysis of the induction of apoptosis over 18 hours by camptothecin. The cell lines were treated with 5µM 
camptothecin over 18 hours. The % apoptosis was determined with Annexin V and PI staining and the results plotted against 
drug concentration. Assays were performed three times in triplicate. 
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Again, camptothecin sensitivity was reduced in the LMP1 high group by 18 hours (p=0.005), 
although the intermediate (p=0.16) and low (0.81) were not different.   
These data are interesting as they show that LMP1 expression may be associated with some 
degree of protection from apoptosis induced by chemotherapeutic agents, and suggests that 
high levels of the protein may confer chemoresistance.  Given that LMP1 is expressed in ENKTL, 
and that the tumours are particularly difficult to treat with conventional agents, this is a 
plausible and important finding. 
Whilst the MEC04 line both lacks LMP1 and is the most sensitive to etoposide-induced 
apoptosis, this line is noticeably different from all the other ENKTL and CAEBV lines with respect 
to its pattern of  expression of the BCL2 family of proteins.  When taking into account the lack of 
expression of BAX and BCL-XL and the low levels of BAD in MEC04, the picture is more 
complicated than can be explained simply through LMP1 expression.  
 
4.5  The effect of BH3 mimetics in inducing apoptosis in ENKTL and CAEBV 
lines 
 
Small molecules engineered to interact with the BH3 pathway, the BH3 mimetics, are currently 
in clinical trials in the treatment of lymphoid malignancies including CLL, lymphoma and 
myeloma (reviewed in (347)).  ABT-737, a “BAD-like” BH3 mimetic, binds to and inhibits BCL2, 
BCL-XL and BCL-w in cells (350).  ABT-199 is a specific BCL2 inhibitor (351).  Given the apparent 
inherent chemo-resistance of ENKTL and CAEBV, plus the in vitro resistance demonstrated 
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herein, we decided to examine the sensitivity of the ENKTL and CAEBV cell lines to the currently 
available members of this class.  We titrated the BH3 mimetics alone onto the cell lines and 
examined the induction of apoptosis following 48 hours incubation.  Similar to the assays above, 
we performed apoptosis assays on the treated cells and plotted the percentage apoptosis over 
the increasing concentrations of drugs (figure 4-18). 
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Figure 4-18 - Analysis of BH3 mimetic mediated apoptosis. The ENKTL and CAEBV cells were treated with increasing 
concentrations of the BH3 mimetics ABT199 (left hand graphs) or ABT737 (right hand graphs) for 48 hours. The percentage cell 
death was plotted against drug concentration. Each assay was performed 3 times in triplicate. 
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Every cell line treated showed remarkable resistance to ABT199 – this is surprising as BCL2 was  
expressed in each cell line, and raises issues about the efficacy of the drug in our system.  In 
contrast, every cell line, except for MEC04, was similarly sensitive to ABT737 (figure 4-18).  
MEC04 is completely resistant to the tested doses of ABT737; it may be pertinent that this line 
does not express BCL-XL, and it may be that this is the major way in which ABT737 is acting upon 
the other cell lines (figure 4-19).   
In summary, despite their similar backgrounds, the ENKTL cell lines show a remarkable 
heterogeneity in their expression of intrinsic pathway proteins and their sensitivity to 
chemotherapeutic agents.  This is likely to be reflected in their parent clinical diseases, and 
makes a strong case for considering profiling of individual tumours when planning treatment.  
BH3 profiling (reviewed in (410)) involves subjecting cells to different BH3 mimetics and 
measuring mitochondrial outer membrane permeabilisation; this is quickly becoming the gold 
standard for pre-treatment analysis where BH3 mimetic use is being considered. 
 
4.6  The role of LMP1 and LMP2 in protection from apoptosis. 
 
The expression of EBV genes has been shown to protect B-cells from apoptosis (411).  BHRF1 
(128) and BALF1 (129) are viral homologues of the anti-apoptotic cellular protein BCL2.  LMP1 
also has a well-defined anti-apoptotic role – its effects in B-cells are complex but include 
upregulation of the anti-apoptotic BCL2 (81, 412), although it is important to note that this may 
not be the case in non-B-cells.  There is little currently known about the role of LMP2B in 
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apoptosis, but LMP2A expression results in constitutive activation of the Ras/PI3K/Akt pathway 
which in turn induces the expression of BCL2 and BCL-XL (102). 
With this in mind, we repeated the earlier apoptosis assays using cell lines stably transduced 
with an LMP1 or LMP2B lentivirus.  The creation of the lentiviral vector and cell transduction 
strategies are described in chapter 2.   
We first wanted to ensure the transduced cell lines expressed the LMP1 and LMP2B from the 
integrated lentiviruses.  We transduced 293 cells as a positive control as they produce good 
levels of protein from lentivirus transductions.  We also transduced SNK10 as it has low levels of 
endogenous LMP1 expression.  Following transduction, the cells were sorted for GFP expression 
to ensure every cell was capable of making LMP1 or LMP2B.  We titrated doxycycline onto the 
cells to ascertain the optimal lowest concentration to induce expression of the viral proteins.  
Expression was compared to an average LCL.  Figure 4-19 shows the induction of LMP1 in the 
SNK10 cells.  Expression was induced maximally at 100 ng/ml doxycycline and levels of LMP1 
expression in the SNK10 cells were significantly higher than that of the LCL.  
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Figure 4-19 - Induction of LMP1 expression in transduced 293 cells and SNK10 cells by Western blot.  LMP1 expression was 
induced by increasing concentrations of doxycycline (DOX). Maximal expression was achieved with 100 ng/ml.  Expression in 
the transduced cells was significantly higher than in the LCL control; LMP1 expression in the transduced 293 cell shows 
supranormal levels. 
We then sought to quantitate the mRNA transcripts of LMP1 following doxycycline induction of 
the 293 cells and SNK10 cells compared to the LCL.  As controls, empty lentiviruses were 
employed and subjected to the same doxycycline-induction.  The mRNA transcripts were 
normalised against PGK and shown in figure 4-20.  
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Figure 4-20 - Analysis of LMP1 mRNA transcripts by Q-RT-PCR in 293 cells and SNK10 cells transduced with LMP-1 expressing 
lentivirus. 293 cells and SNK10 cells were transduced with either empty lentiviruses or LMP1 lentiviruses then expression of 
LMP1 was induced with either 500ng/μl or 1μg/μl of doxycycline.  The mRNA was analysed by Q-RT-PCR for levels of LMP1 
mRNA transcripts.  All experiments were performed in triplicate. An LCL is shown as a control.    
The results represented in figure 4-20 confirm the Western blot data shown in figure 4-19 
Induction of LMP1 expression was performed at 500 ng/ml for all future experiments. 
The same set of experiments was performed following LMP2B lentivirus transduction into 293 
cells and SNK10 cells.  Unfortunately no antibody to LMP2B is available, so natural levels of 
LMP2B in control cells such as SNK6 or SNT8 could not be performed by Western Blot.  
However, the LMP2B lentiviruses were constructed with an HA-tag to enable analysis of 
expression (figure 4-21).  Similarly to the LMP1 experiments above, LMP2B protein in 
transduced 293 cells was expressed at a higher level than in transduced SNK10 cells.  However, 
this is not entirely surprising given that LMP2B transcript levels in SNK6 and SNT8 are naturally 
significantly lower than those of LMP1. 
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Figure 4-21 - Analysis of induction of LMP2B expression in transduced 293 cells and SNK10 cells by Western blot.  Top panel: 
LMP2B-TR expression was induced by 500ng/l or 1g/l of doxycycline and expression was detected by anti-HA antibody. 
Bottom panel shows the calregulin loading control of the proteins examined. 
 
Similar to the LMP1 lentivirus, we also examined the levels of LMP2B-TR transcripts in the 
transduced cells by qPCR and compared them to a positive control, shown in figure 4-22.  
Transcript levels in the transduced SNK10 cells are detected at higher levels than the naturally 
expressed transcripts in SNK6 cells. 
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Figure 4-22 - Analysis of LMP2B expression in transduced 293 and SNK10 cells by qPCR.  293 cells and SNK10 cells were 
transduced with either empty lentiviruses or LMP2B lentiviruses.  Expression of LMP2B was induced with either 500ng/μl or 
1μg/μl of doxycycline.  The mRNA was analysed by qPCR for levels of LMP1 mRNA transcripts.  SNK6 is shown as a control.  
All experiments were performed in triplicate. 
 
Given our findings on the apparent LMP1-mediated reliance upon the growth factor IL-2, we 
performed IL-2 withdrawal assays on SNK10 and SNT16 cell lines transduced with the LMP1 and 
LMP2B lentiviruses.  After doxycycline induction we subjected the cells to 5 days of IL-2 
deprivation in culture to see if the viral protein could protect them from the apoptotic stimulus 
of cytokine withdrawal (figure 4-23).  These assays were performed three times in triplicate and 
statistical analysis was performed on the results at day 5 using a Student t test. 
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Figure 4-23 - Analysis of IL-2 withdrawal on cells expressing high levels of LMP1 and LMP2B.  The CAEBV cell lines were 
transduced with lentiviruses encoding LMP1 and LMP2B.  Expression was induced and IL-2 was withdrawn from the culture 
medium.  The cells were stained with PI and the % alive cells plotted against days post IL-2 withdrawal.  Statistical analysis by 
paired t-test showed significant differences between the empty and viral protein-expressing cells in the absence of IL2. 
**indicates p<0.05 
 
Overexpression of LMP1 compared to cells transduced with empty lentivirus resulted in a small 
increase in survival following IL-2 withdrawal in SNT16 cells (p=0.09 for SNK10, p=0.003 for 
SNT16). This confirmed our early experiments when we stratified the cells according to the level 
of expression of LMP1. However, following over-expression of the LMP2B in the SNK10 and 
SNT16 cell lines, the LMP2B also appeared to provide a small but reproducible survival 
advantage (p= 0.009 for SNK10, p=0.009 for SNT16).  In the presence of IL-2, the proteins had no 
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effect on survival (SNK10 p=0.67 for LMP1, 0.07 for LMP2B; SNT16 p=0.06 for LMP1, 0.09 for 
LMP2B). 
LMP1 has previously been shown to have anti-apoptotic activity in B-cells, for example, by 
inducing the expression of BCL2 (81); it also increases the expression of BCL3 in Jurkat cells 
(304).  Following stratification of our cell lines into high-, intermediate- and low/negative LMP1 
protein expression (figure 4-6), we saw a significant protection from drug-induced apoptosis in 
cells expressing high endogenous levels. 
We therefore decided to repeat the apoptosis assays using stably transduced cells which can be 
induced to express LMP1 and LMP2B.  We used Jurkat lines transduced with the same 
lentiviruses as a control (figure 4-24), and showed that LMP1 increased susceptibility to 
ionomycin-induced apoptosis. 
170 
 
 
Figure 4-24 - Analysis of apoptosis-inducing drug titrations on Jurkat cells expressing LMP1 or LMP2B-TR.  Jurkat cells were 
transduced with either empty, LMP1- or LMP2B-TR expressing lentiviruses. The gene expression was induced and the cells 
were then treated with increasing concentrations of (A) Etoposide or (B) Ionomycin. The % apoptosis was determined by 
annexin V and PI staining. The % apoptosis was plotted against drug concentration.  
 
We then repeated the experiments using stably transduced SNK10 and SNT16 cells (figure 4-25). 
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Figure 4-25 - Analysis of apoptosis in response to etoposide, ionomycin and camptothecin in SNK10 and SNT16 cells 
expressing either LMP1 or LMP2-TR. Apoptosis was measured with Annexin V and PI, and apoptosis plotted against the top 
drug concentration previously used. The assays were performed three times in triplicate.  
 
Interestingly, LMP1 significantly increased the susceptibility of SNK10 cells to ionomycin and to 
camptothecin, and the SNT16 cells to camptothecin.  Also, LMP2B led to an increased 
susceptibility of SNK10 to etoposide and ionomycin, and of the SNK16 cells to all 3 agents. 
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These assays were performed three times in triplicate, therefore the results are robust.  
However these assays were performed on just the two cell lines so before any firm conclusions 
can be drawn, the assays need to be repeated on a greater range of cells including both T cell 
lines and NK cell lines.  Also, both viral proteins are usually expressed at low levels in both of 
these cell lines (see figures 4-1 and 4-2) and our lentiviral system resulted in expression levels 
that were probably supraphysiological (see figures 4-19 – 4-22).  However in the cells 
transduced by the LMP1 and the LMP2B lentiviruses, the transcripts were significantly higher 
than the SNK6 cell line, which exhibited one of the highest levels of these proteins.  Although 
these results are intriguing, it is necessary to address these issues with further investigation 
before any kind of extrapolation to an in vivo situation can be considered. 
We then sought to determine if we saw the same picture by inducing apoptosis with the BH3 
mimetics as previously performed in the ENKTL and CAEBV cell lines.  The SNK10 and SNT16 cell 
lines transduced with the empty, LMP1 or LMP2B were treated with 10 µM of the BH3 mimetic 
ABT199 and 1 µM of ABT737, stained for Annexin V and PI after 48 hours and analysed for 
induction of apoptosis.  The results are represented in figure 4-26.  Statistical analysis was 
performed using the Student t-test.   
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Figure 4-26 - Analysis of apoptosis in response to the BH3 mimetics ABT199 and ABT737 in SNK10 and SNT16 cells expressing 
either LMP1 or LMP2-TR.  Apoptosis was measured with Annexin V and PI, and apoptosis plotted in response to the drugs.  
The assays were performed three times in triplicate.  The results were compared by Student t-test. 
 
Aside from LMP2B, which resulted in increased susceptibility to apoptosis induced by ABT737 in 
SNK10 cells, there were no significant effects of the viral proteins in the cell lines in their 
response to BH3 mimetics.  However, there were trends towards an increased susceptibility to 
apoptosis from ABT199 in both cell lines expressing LMP2B, although given the extraordinary 
resistance shown, this may not be biologically significant.   
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4.7  Discussion 
 
Most EBV-positive T- and NK-cell lines are derived from either ENKTL or CAEBV, and vary in their 
expression of viral proteins.  They are all dependent upon IL-2 for proliferation and survival 
(276, 353-355), but neither this dependence nor their sensitivity to apoptosis seems to correlate 
with viral expression.  However, they also vary in their expression of the BCL2 family members, 
and it is likely that this can explain, at least to some extent, the patterns of drug sensitivity seen. 
In our hands, IL-2 withdrawal resulted in a fall in LMP1 expression, in keeping with the literature 
(397, 398).  It has been demonstrated that EBV-positive cell lines require less IL-2 to proliferate 
than EBV-negative lines (398); given that LMP1 is an oncogene, we would expect cells with a 
high endogenous level of LMP1 to show a particular sensitivity to IL-2, and thus LMP1, 
withdrawal – and this is the case.  However, cells with low levels of LMP1 were similarly 
affected, suggesting that the effects of IL-2 withdrawal are not purely mediated by a fall in 
LMP1.  Most intriguingly, cells with an intermediate level of LMP1 expression were significantly 
less susceptible to IL-2 deprivation. 
The role of LMP1 in non-B-cell infections is not straightforward.  Its expression in ENKTL samples 
and cell lines is variable (52, 57), but may correlate with an improved prognosis (51) – this may 
correspond to the high sensitivity of the LMP1-high group of cell lines to cytokine withdrawal in 
our results.  However, reducing LMP1 expression in ENKTL lines does not have the dramatic 
effects on proliferation that are seen in B-cells (58). 
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It seems likely that the JAK/STAT pathway is involved in the interaction between IL-2 and LMP1 
effects in NK cells.  IL-2 can act via the JAK/STAT pathway in NK cells (297) and STAT-binding 
elements are seen in both of the LMP1 promoters (300).  STAT has also been shown to be 
constitutively activated in at least one ENKTL cell line (276).  Interestingly, LMP1 has also been 
shown to induce CD95 expression in B-cells thus rendering them more vulnerable to T-cell (or 
CD95-ligand) killing; this effect is mediated by NFκB and STAT pathways (413). 
It is important to bear in mind that these are malignant, transformed cells with complex 
cytogenetic changes, and although it is tempting to conclude that LMP1 must be a factor, there 
are many possible overlaps in what is a very small sample.  This having been said, there is an 
interesting overlap in the pathways by which LMP1 and cytokines can signal within a cell.  IL-10 
exposure results in an increase in LMP1, CD25 and CD54 in EBV-positive but not EBV-negative 
NK cell lines (397, 398); this suggests that the virus may in some way mediate the effects of 
cytokines upon the cells, maybe amplifying the cytokine signal to maximise the proliferative 
advantage of the infected cells.  Overexpression of LMP1 using a lentiviral vector shows 
protection from the effects of IL-2 withdrawal in SNT16, a CAEBV line, but increased the 
susceptibility of the cells to apoptosis induced by ionomycin and camptothecin.  In SNK10 cells it 
did not show a protective effect from cytokine withdrawal, but also increased susceptibility to 
ionomycin and camptothecin.  It is plausible that the CAEBV lines are more sensitive to the 
effects of the EBV proteins as they lack the other oncogenic mutations accumulated by the 
cancer lines, but the effects of artificial overexpression of a protein may not mirror those seen 
with endogenous expression. 
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LMP2B, interestingly, also showed a protective effect on apoptosis associated with cytokine 
withdrawal in both SNK10 and SNK16; it also increased the susceptibility of both cell lines to 
ionomycin, etoposide and camptothecin.  Expression is very low in untransduced SNK10 cells 
although slightly higher in SNT16; the significance of these findings is not yet clear, particularly 
as very little is known about LMP2 in T- and NK-cell backgrounds. 
The role of EBV proteins in the expression of members of the BH3 families is also unclear, but 
interesting.  LMP1 can increase levels of BCL2, BFL1 (301), A20 (302) and MCL1 (303) in B-cells, 
and in a T-cell line was able to induce BCL3 expression (304), although reducing LMP1 levels in 
ENKTL cells did not reduce BCL2 expression (58), suggesting a more complex interaction.  
Interestingly, BCL2 levels are particularly high in the “LMP1-high” group (SNK1, SNK6 and SNT8) 
which were particularly susceptible to IL-2 withdrawal – this may suggest a mechanism whereby 
these cells rely upon a high level of BCL2 for their survival, and IL-2 withdrawal and the resulting 
fall in LMP1 removes this prop. 
Proapoptotic BH3 family members also vary between the cell lines.  BID levels are low and are 
absent from SNK6 and SNT8.  BAD expression is higher in the CAEBV cell lines and BAX is high in 
all of the cell lines compared to the controls.  There is evidence that, contrary to the accepted 
model, BID may be primarily responsible for BAK activation and BIM for BAX (414).  Based upon 
our observation, this would suggest that the ENKTL and CAEBV cells are more reliant upon the 
BIM-BAX pathway.  In keeping with this, BIM is associated with cell death in response to growth 
factor withdrawal (415) and BID is implicated in cell death in response to topoisomerase 
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inhibitors (416).  A lack of BID could explain some of the resistance seen to etoposide and 
camptothecin. 
Another possible factor to take into account is the viral homologues of the BH3 family.  BHRF1 
and BALF1 act in the same way as BCL2 to protect cells from apoptosis (128, 129) and BHRF1 is 
expressed in ENKTL, albeit at low levels (417).  It would be interesting to examine expression of 
these proteins in the cell lines and see if they provide some of the answers to the questions 
posed above. 
ENKTL in particular is notoriously difficult to treat with conventional chemotherapy, and novel 
strategies are badly needed.  BH3 profiling is a technique whereby the expression of the BCL2 
family proteins can be examined and suitable chemotherapeutic agents trialled within a short 
space of time – our results here would support this strategy in clinical practice.  Newer BH3 
mimetics are under investigation – MCL1 and BCL-XL in particular are favoured targets – and it 
will be interesting to see how they affect this varied panel of cells (418).  
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CHAPTER 5 - THE CLINICAL IMPACT OF EBV-INFECTION OF 
NON-B-CELLS 
 
5.1  Introduction 
 
EBV-associated T- and NK-cell disorders are rare in the UK, and, particularly in the case of HLH, 
often diagnosed late in the condition or even after death.  This means that data regarding the 
incidence, clinical course and biological characteristics of the diseases are limited, and we are 
often reduced to extrapolating from case series from Asia, where these conditions are more 
common.  The extent of the resemblance between Western and Asian pathology remains 
unknown and it is important to systematically examine cases in the UK in order to determine 
whether it is appropriate to consider them as similar entities.  As a result, our group has set up a 
network of 17 UK sites, with ethical approval to obtain blood, biopsy and bone marrow samples 
from cases of ENKTL, HLH, CAEBV and ANKL. 
Despite the wide range of our network, recruitment to the study is predictably slow due to the 
reasons stated above.  However, we have recruited some interesting patients over the lifetime 
of the study, and some of the recent recruits with a variety of pathologies will be shown here. 
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5.2  Materials and methods 
 
Ethical approval for this work was provided from the West Midlands Research Ethics Committee 
(REC: 07/H1208/62). 
Patients thought to have non-B-cell EBV-associated disorders were recruited by local clinicians.  
Upon obtaining informed consent, samples of 60 ml of peripheral blood were obtained in 
lithium heparin-containing Vacutainer® tubes (BD, USA).  Samples were sent to us by courier, 
arriving within 24 hours. 
PBMCs were obtained from the blood samples as described in chapter 2.  Briefly, after dilution 
with sterile PBS the sample was layered onto LymphoPrep (Axis Shield, Oslo, Norway) and 
centrifuged; PBMCs form a layer at the interface between the LymphoPrep and the plasma and 
can be retrieved using a transfer pipette. 
The mononuclear cells were sorted into lymphocyte subsets (T cells, B-cells and NK cells) by 
fluorescence-activated cell sorting following staining for the cell surface expression of anti-CD4 
(APC) and -CD8 (FITC), anti-CD19 (PE-Cy7) and anti-CD56 (PE).  Once sorted, the DNA was 
extracted from each subset using the DNeasy Blood & Tissue Kit (Qiagen) and analysed for viral 
load per cell by qPCR.  The Burkitt cell line Namalwa was used as a standard – it is known that 
each Namalwa cell harbours 2 integrated copies of the EBV genome(419).  Quantitative PCR for 
the single copy EBV DNA polymerase gene BALF5 (Pol) was performed and normalised to β-2-
microglobin to give copies of virus per cell (see table 5-1 for primers and probe sequences). 
180 
 
Table 5-1 - Sequences of EBV pol primers and probe used for DNA quantification by qPCR 
EBV pol forward primer 5’-AGTCCTTCTTGGCTAGTCTGTTGAC-3’ 
EBV pol reverse primer 5’-CTTTGGCGCGGATCCTC-3’ 
EBV pol probe 5’(FAM)CATCAAGAAGCTGCTGGCGGCCT(TAMRA)-3’ 
 
Using this technique we were able to demonstrate which lymphocyte population was infected 
with EBV and what the mean virus load was in each lymphocyte subset in a range of EBV-
positive disorders.  To determine the range of virus loads in the B-cells of healthy virus carriers, 
we first performed the analysis on six healthy laboratory donors.  Figure 5-1 shows the 
lymphocyte distribution and EBV load of six healthy laboratory donors.  In general the virus load 
in PBMC of healthy virus carriers is low at less than 3,000 copies per million cells.  One donor 
had a load of nearly 9000 - this is a surprisingly high load, but the range of virus loads seen in 
healthy carriers (0-3,000 copies per million cells) and of IM (5,000 – 50,000 copies per million 
cells) is very wide(420, 421).  EBV infection was confined to the CD19-positive B-cells, with none 
of the other lymphoid subsets showing any evidence of EBV infection.  
 
181 
 
 
Figure 5-1 - Distribution of EBV in the PBMCs of healthy laboratory donors. In all cases the virus was only seen in B-cells.  Viral 
loads vary somewhat but are all within the normal range for latent infection. 
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5.3  Patient Samples 
 
We then performed the same set of experiments on a small number of patients with different 
EBV-associated T/NK cell lymphoproliferations or malignancies.  Patient 1 was a young male 
patient who had been treated for nasal ENKTL in 2007 with combined chemo-radiotherapy.  He 
had relapsed locally after one year and was treated with further radiotherapy and palliative 
chemotherapy, then developed skin and bladder lesions in 2010, when we received our sample.  
As above, we isolated the lymphocyte subsets by FACS, extracted the DNA and performed Q-
PCR for mean EBV load (figure 5-2).  In contrast to the healthy EBV carriers, we observed two 
clear differences: (i) the virus load was significantly higher in the B cell subset, at 81427 
genomes per million B-cells, (ii) the virus was not restricted to the B lymphocytes, but was 
instead also observed in the CD56 NK cells and the CD8 T cells.  The virus load observed in the 
CD8 cells was within the range of the EBV load in healthy carrier B-cells, but the load in the 
CD56 cells was considerably higher at 47883 genome copies per million cells.  The cell 
populations were reported as 99% pure after sorting, which would suggest that neither of the 
virus loads present in the T- or NK cells could be explained by any B cell contamination during 
the FACS procedure.  Unfortunately, the follow-up sample contained insufficient PBMC for this 
analysis; the patient subsequently underwent a sibling allograft and died during conditioning. 
These results are interesting for a number of reasons.  EBV infection of NK cells, as discussed in 
the introduction, is likely to be a rare and possibly dangerous event, thus it is reasonable to 
suggest that the EBV-positive, CD56-positive cells seen here represented the malignancy 
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entering a leukaemic phase, although without demonstrating clonality this can’t be confirmed.  
Pre-treatment serum EBV levels have been shown to be an independent prognostic marker in 
ENKTL, although the cell in which the virus exists in these cases has not been systematically 
studied.  The high viral titres in the B-cells are also interesting – this may represent EBV 
reactivation as a result of treatment- or disease-induced immunosuppression.  Finally, the CD8 
results are intriguing – this is unlikely to represent contamination as the purity of the sorted 
populations was excellent.  It is possible that, in the conditions of high EBV, occasional CD8 cells 
have become infected as is speculated to occur in IM. 
 
Figure 5-2 - Distribution of EBV load in the lymphocyte subsets of a patient 1 with nasal ENKTL. The majority of the viral 
copies were observed in CD19-positive B-cells. However a significant virus load was observed in the CD56-high NK cells and a 
smaller amount in CD8-positive T-cells. 
 
Patient 2 was a young female who had had a combined heart-lung transplant in childhood for 
primary pulmonary hypertension.  She developed clinical manifestations of HLH with a high EBV 
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load in her peripheral blood 6 months after transplant.  Lymphocyte subsets were sorted by 
FACS and qPCR performed as described above (see figure 5-3).   
 
 
Figure 5-3 – Distribution of EBV load in the lymphocyte subsets from patient 2 with HLH and PTLD. There is a very high overall 
viral load, and the majority of this represents CD19-positive B-cells, but there is also a very high level of infection in CD8
+
 T-
cells. 
 
In contrast to what has previously been published on EBV-associated HLH, we unexpectedly 
demonstrated an extremely high viral load in the CD19-positive B-cells at 8,572,663 EBV 
genomes per million B-cells (figure 5-3).  Additionally we also found high viral loads in all the 
CD4+ T cells (716,847), the CD8+ T cells (3,392,236) and the CD56 cells (482,582). Again, these 
virus loads cannot be explained by a possible contamination of the sorted subsets.  The B-cell 
population was found to be clonal by immunoglobulin gene rearrangement studies (performed 
at her clinical centre), suggesting a B-cell malignancy. A subsequent diagnosis of EBV-driven 
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PTLD suggested that this malignancy was probably contributing to the concurrent HLH.  She was 
initially treated with IVIg, methylprednisolone and etoposide as per the HLH 2004 guidelines; 
rituximab was added upon the diagnosis of PTLD and she obtained a rapid reduction in EBV 
loads.  A significant population of EBV-positive T-cells remained after her initial treatment 
(figure 5-4) and she continued with HLH 2004 chemotherapy; at this stage she had no 
detectable B-cell population as a result of the Rituximab treatment.  EBV became undetectable 
in her peripheral blood by six months after treatment and she has continued to make good 
clinical progress. 
 
 
Figure 5-4 – Distribution of the EBV load in lymphocyte subsets from patient 2 with HLH following treatment with 
chemotherapy including rituximab. As can be seen, the viral load fell dramatically.  No CD19 cells were sorted due to 
rituximab-induced cell clearance.  There is still a significant viral load remaining in the CD8
+
 T-cells. 
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Patient 3 was a paediatric patient with XLP, who had received a matched, unrelated donor 
allograft for lymphocytic vasculitis 2 years previously.  Although EBV reactivation at the time of 
transplant had been treated successfully with Rituximab, he subsequently became persistently 
EBV positive, with no response to further Rituximab, but with no clinical symptoms.  Our 
investigations (Figure 5-5) showed that the virus was predominantly restricted to the CD56-high 
NK-cells (110,496); furthermore, EBV was also detected in the CD8 T cells at a significant level 
(40,082).  The patient’s family refused further treatment and his viral titres have remained 
stable. 
 
 
Figure 5-5 - Distribution of EBV load in lymphocyte subsets from patient 3 with persistent EBV reactivation after BMT for XLP.  
The majority of the virus is seen in the CD56-bright NK cells; there is also a significant viral load in the CD8
+
 T-cells. 
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Patient 4 was a middle-aged male patient with HLH and moderate viral titres.  Blood was 
obtained after induction chemotherapy with steroid and etoposide.  Here, in keeping with the 
current UK data on HLH (218) the virus was restricted predominantly to the CD56-bright NK cells 
(figure 5-6) but the viral load in these was much lower (2,366 copies per million cells) than is 
usually seen.  This may reflect the effects of the chemotherapy.  The low levels seen in the CD4+ 
and CD8+ cells may represent contamination.  Unfortunately the patient died before further 
sampling could take place. 
 
 
Figure 5-6 – Distribution of EBV load in lymphocyte subsets from patient 4 with HLH.  The majority of the viral genomes are 
located in the CD56-bright NK cells. 
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was sent for us to investigate for the possibility of a non-B-cell infection.  His results are shown 
in figure 5-7 – here the vast majority of the virus is seen within the CD19-positive B-cells.   Due 
to the exceptionally high levels, it is likely that the values seen in the other cell populations 
represent minor B-cell contamination.  He was treated for PTLD with rituximab and 
chemotherapy. 
 
 
Figure 5-7 – Distribution of EBV load in the lymphocyte subsets from patient 5 with PTLD. The vast majority of EBV was 
restricted to the B cell subset, with what appears to be minor contamination with B-cells in the remaining subsets. 
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5.4 The PrimeFlow RNA system 
 
All of the patient samples above were sorted into lymphocyte subsets by fluorescence-activated 
cell sorting and subsequently analysed for the EBV load by Q-PCR performed on DNA extracted 
from sorted cell subsets.  This has several limitations.  Firstly, from 60 ml of whole blood it is 
usual to obtain approximately 20x106 PBMCs; this number of cells is only just adequate to 
obtain sufficient purified cells from each lymphocyte subset following FACS and to extract 
sufficient DNA for the qPCR analysis.  Unfortunately, all the cells are used for this one parameter 
and it is impossible to obtain further data, for example, virus and cellular gene expression, from 
the sample.  It is not usually possible to obtain repeat samples due to the high early mortality in 
these patients.  Secondly, although we can determine which lymphocyte population is infected 
and the average amount of virus present within the total subset, we cannot determine what 
percentage of cells are infected within the individual subsets.  Thirdly, we cannot perform these 
types of analyses on paediatric patients as it is not possible to obtain sufficient volumes of 
blood.  Finally, there is little consensus as to which of the EBV genes is actually expressed in HLH 
– in the experience of our group, only the EBERs have been reliably seen which cannot be 
detected using conventional flow cytometry.  The inability to detect expression of other EBV 
genes may be due to a lack of sensitivity of our assays.  If only a small percentage of cells are 
actually infected, the number of viral mRNA transcripts may be below the threshold of 
detection by qPCR assays.  We therefore need an assay which is sensitive and specific enough to 
identify EBV infected lymphocyte subsets from a very small amount of blood to be of use in 
paediatric diagnosis. 
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To this end, we first investigated the use of a previously published method of analysing EBV-
infected cells using a combination of cell-surface staining and fluorescent in-situ hybridisation 
for EBER RNA (FLOW-FISH) (422) in the context of T and NK cell disorders (423).  However, we 
encountered several problems, the most pressing of which were (i) an insufficient separation of 
the EBER positive and negative populations, and (ii) an insufficient separation of the lymphocyte 
subsets following cell surface staining.  This made identification of the infected lymphocyte 
subset unacceptably subjective.  We therefore tried to reproduce the results of the original 
authors to examine both the sensitivity and specificity of the FLOW-FISH technique (422).  Firstly 
we examined the sensitivity of the technique to determine if it could identify low levels of EBER 
expression.  We previously demonstrated that when primary resting B-cells are infected with 
EBV, the expression levels of the EBERs remain low until the infected cells begin to replicate at 
day 3 post-infection.  We therefore infected primary resting B-cells at a range of multiplicities of 
infection (MOI) 1, 10 and 100, then examined the expression levels of the EBERs at day 3 post 
infection by Q-RT-PCR.  As a control, we also examined EBER transcripts from the EBV-positive 
Burkitt lymphoma cell line Akata to highlight the low level of EBER expression in the primary B-
cells.  
Assays were performed on 3 independent sets of infected B-cells and Q-RT-PCR assays were 
performed in duplicate.  The results were normalised against GAPDH and plotted in figure 5-8.  
The first thing of note was the number of EBER1 transcripts were significantly higher than EBER2 
transcripts in the newly infected B-cells (Fig 5-8 A).  However, the number of EBER transcripts in 
the newly infected B-cells were at least 300-fold less than those observed in the Akata cells (Fig 
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5-8 B).  As controls for EBV infection of the B-cells, we also performed Q-RT-PCR assays and 
immunofluorescence for EBNA-2 to ensure that the levels of EBER1 & 2 expression reflected the 
expected levels of EBV infection.  
 
Figure 5-8 – Analysis of EBER 1 & 2 expression in newly-infected primary resting B-cells and Akata Burkitt lymphoma.EBER 1 & 
2 RNA transcripts were quantitated by Q-RT-PCR and plotted against GAPDH.  Panel A shows the timecourse of EBER 
expression during primary infection.  EBER1 levels rise quickly after infection whereas EBER2 remain low; however, on day 3 
both are low.  Panel B shows EBER1 and 2 expression in Akata BL cell lines.  
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We then performed FLOW-FISH on the newly-infected B-cells at day 3 post infection.  As above, 
we infected primary resting B-cells with EBV at an MOI of 1, 10 and 100.  For this assay we 
limited the number of B-cells tested to 1x106 for each time point.  The cells were analysed by 
flow cytometry and plotted as histograms in figure 5-9.  Although we achieved good signals for 
the MOI of 10 and 100, applying gates to accurately identify the positive and negative 
populations was still subjective.  
 
 
Figure 5-9 - FLOW-FISH analysis of EBER RNA transcripts in newly-infected B-cells. Primary resting B-cells were infected with 
EBV at increasing MOI. Cells were analysed by FLOW-FISH for EBER transcripts on day 3 post infection.  The results of one 
such experiment is shown. 
 
In order to improve the separation, the authors of the original publication performed an 
additional amplification step using an anti-FITC AF488-conjugated antibody, which bound to the 
FITC on the FISH probe to amplify the FITC signal.  AF488 and FITC both fluoresce in FL1 on the 
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flow cytometer (excitation 490, emission 519), so this second antibody effectively doubled the 
fluorescent signal. 
We therefore performed the B cell infection experiments and performed the FLOW-FISH with 
this additional amplification step, shown in figure 5-10.  Interestingly the FLOW-FISH now picked 
up EBER RNA in the MOI 1 infected B-cells and, as predicted, doubled the fluorescence in the 
MOI 10 infected B-cells.  However, the separation between the positive and negative 
populations would still have been subjective, even at high MOIs.  This could be envisaged as a 
significant problem when using clinical samples as the levels of EBER expression are not 
predictable before starting the experiment, and the technique does not appear to be sufficiently 
sensitive to identify cells with low levels of EBER expression. 
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Figure 5-10 - Amplification of the EBER signal in the FLOW-FISH analysis of newly-infected primary B-cells.  B-cells were 
infected with EBV at an MOI of 1 or 10, and were either subjected to an amplification step to improve separation between 
the populations or processed by the traditional method.  As can be seen, amplification improved separation of the 
populations but where the MOI was low there is still significant overlap. 
 
Given we had previously identified it as the only viral transcript which appeared to be present in 
the T- or NK cells of HLH patients, in situ hybridisation for EBERs appeared to be the only 
technique that we could use to identify the EBV-infected lymphocyte subset in small numbers of 
patient cells.  We therefore decided to use another newly-marketed fluorescence ISH kit 
(eBioscience PrimeFlow RNA) to identify the EBERs with simultaneous cell surface staining.  This 
kit is marketed as being both highly specific and highly sensitive. The specificity is achieved by 
using two 20-mer probes which anneal to the RNA adjacent to each other. The absence of one 
195 
 
probe results in the loss of the downstream amplification and no fluorescent signal. However, 
importantly the single biggest difference between the two techniques is the high level of signal 
amplification of the EBER probes in the PrimeFlow kit.  The PrimeFlow RNA method is described 
in detail in chapter 2, but briefly involves the hybridisation of the two adjacent probes to the 
EBER RNA, then the attachment of a branched, amplifier molecule which captures up to 400 
fluorescent molecules per probe.  This results in significantly-amplified fluorescence of the 
hybridised probe thereby giving excellent separation between the EBV-positive and negative 
populations.  This technique can be performed with cell surface staining to identify the 
lymphoid subsets and we have performed the technique on as few as 1x106 cells. 
In order to be useful in a clinical context, the PrimeFlow RNA technique needed to be both 
sensitive and specific.  As shown earlier in this chapter, EBER expression is low in the first week 
following primary B cell infection and levels at day 3 post infection are approximately 300-fold 
lower than those of Akata BL.  We therefore used the primary B-cells and Akata BL cells as 
models for testing the PrimeFlow RNA. 
First we applied the PrimeFlow RNA assay to the infected B-cells at day 3 post-infection to 
determine the sensitivity of the assay to detect the low levels of EBER transcripts.  The forward-
scatter/side-scatter plots (Figure 5-11, top panel) identified that at day 3 post infection the B-
cells were activated and beginning to increase in size, consistent with the growth 
transformation into LCLs.  We gated on the live population of cells as shown and analysed the 
levels of EBER RNA transcripts in uninfected B-cells (figure 5-11, lower left panel), in infected B-
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cells at day 3 post infection (lower middle panel) and we substituted the EBER probe for a 
house-keeping probe beta-2-microglobulin (B2M) (lower right panel).  
We can clearly see a very small population of EBER-positive cells in the uninfected B-cells. This 
might indicate one of two things: either the healthy donor from which the B-cells were isolated 
were already infected with a natural isolate of EBV, or the EBER probe may be non-specifically 
labelling cells and this needed to be examined.  The second observation was that EBER 
expression could be detected over a two-log range, indicating that the cells expressed from low 
levels to high levels of EBERs even at this early stage of infection.  The third observation is that 
the housekeeping B2M probe did not appear to label all the cells.  Again, this needed further 
examination, but suggested that we needed to rule out contaminating dead cells. 
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Figure 5-11  – Analysis of EBER expression following infection of primary resting B-cells by the PrimeFlow RNA technique.  
Gates were drawn around the live cells on the FS/SS plots (Top panel). The bottom panel left shows a very small percentage 
of cells expressing EBERs, suggestive of endogenous virus.  Bottom middle shows a two-log spread of EBER transcripts in 
newly-infected B-cells.  Bottom right is a positive control for the ISH using the housekeeping B2M as a control.  
 
In order to demonstrate that the EBER signal detected in the primary infected B-cells was truly 
specific, we also performed immunofluorescence on the B-cells to determine the percentage of 
cells expressing EBNA-2 as a marker of EBV infection, using the PE2 mAb.  EBNA-2 is one of the 
first proteins expressed following B cell infection, and every infected B cell expresses EBNA-2, 
making it an ideal marker for infection.  The percentage of EBNA-2-expressing B-cells was 
measured by flow cytometry and plotted against the percentage of cells positive for EBER 
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transcripts measured by PrimeFlow RNA.  The results are shown in figure 5-12, and highlight 
that both assays detect an equivalent percentage of infection of the B-cells at 3 days following 
infection. 
 
 
Figure 5-12 - EBNA-2 expression and PrimeFlow RNA measurement of EBER RNA.  Primary resting B-cells were infected with 
EBV for 3 days, then either stained for EBNA-2 expression or subjected to PrimeFlow RNA for EBER analysis.  Both assays were 
measured by flow cytometry and show equivalent percentage of infection whether determined by EBNA-2 staining or by 
PrimeFlow RNA for EBERs. 
 
We then focussed on the specificity of the PrimeFlow RNA assay.  Firstly, we performed the 
PrimeFlow RNA assay on EBV-negative Akata BL cells (158) and showed no signal with the EBER 
probe set (Figure 5-13).  As a control for the ISH, we also performed the assay using the B2M 
probe set.  As we saw in the primary B cell infection experiment, we found the B2M probe set 
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did not bind to all the cells  as would be expected (approximately 10% were unstained) and 
again we suspected that this might be due to dead cells within the culture.  
 
 
Figure 5-13 – Analysis of EBER and B2M transcripts in EBV-negative Akata BL cells using the PrimeFlow RNA assay.  The 
PrimeFlow assay was performed on EBV negative Akata BL cells to determine how specific the EBER and B2M probe sets were 
for EBV infection.  No signal was detected for EBERs as would be expected, and a good signal was detected for the house-
keeping gene B2M.  However a small number of cells did not stain with the B2M probe, suggesting the presence of dead cells.  
 
We then made use of a fortuitous set of EBV-positive and EBV-negative Akata BL cultures, 
established in our laboratory as part of an unrelated project.  The EBV-positive Akata BL cells 
contain a recombinant GFP-expressing EBV.  The EBV-negative Akata BL cells are a matching 
EBV-loss clone and are GFP-negative.  This provided an excellent internal control for the 
following set of experiments.  We “spiked” the GFP-negative Akata BL cells with 5% and 1% of 
the EBV/GFP-positive Akata BL and performed the PrimeFlow RNA assay (Figure 5-14).  All the 
EBER-positive cells were also GFP-positive and provided a double-positive population, thereby 
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demonstrating the specificity of the assay (upper panel).  The assay was again performed with 
the B2M probe set as a positive control for the assay.  All cells were positive for B2M.  
 
 
Figure 5-14 – PrimeFlow-RNA analysis of Akata cells.  EBV-negative Akata cells, which are GFP-negative, were mixed with 
GFP-positive EBV-positive Akata cells.  The top panel shows the correlation between GFP expression and detection of EBERs 
by PrimeFlow-RNA at different concentrations of test cells.  The bottom panel shows the B2M housekeeping gene, with a 
small population of negative cells.  In both panels the sensitivity to GFP is excellent and is not affected by the ISH signal. 
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5. 5  Validation of PrimeFlow RNA in the UK 
 
In the meantime, recruitment of our UK patients has continued.  Most recently, a patient with 
EBV-associated HLH was identified.  The patient was thought to have a primary EBV infection 
which triggered the HLH and was initially treated according to the HLH-2004 protocol 
(dexamethasone, etoposide, cyclosporine)(193), whereupon the clinical syndrome appeared to 
resolve.  PBMCs from this patient were subjected to this new technique to determine the 
sensitivity and specificity of PrimeFlow-RNA in the patient setting.  
Healthy donor PBMCs were initially subjected to several controls critical for setting up a 
multicolour cell surface staining panel for the LSR-II flow cytometer.  The cells were first stained 
using isotype controls to set the negative populations, shown in figure 5-15.  Isotype controls for 
CD3 (AF700), CD4 (PE-Texas red), CD8 (AF488), CD19 (PeCy7) and CD56 (PE) were used. 
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Figure 5-15 - PrimeFlow-RNA assay isotype controls.  The PBMC were subjected to the PrimeFlow-RNA protocol using specific 
appropriate isotype controls for the cell-surface staining and without RNA ISH probes to ensure adequate gating for the 
negative control cells. 
 
The cells were then stained using the individual lymphoid markers (CD3, CD4, CD8, CD19, CD56) 
to ensure that following the RNA-ISH technique the fluorescent markers were still fluorescent 
and showed sufficient separation between the positive and negative populations.  The cells 
were also stained using a dead cell marker, vital dye conjugated to pacific blue, and a marker for 
monocytes, CD14-pacific blue.  All cells staining for either of these parameters were excluded 
from the analysis.  
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Finally, the cells were stained using the appropriate isotype controls together with the positive 
RNA-ISH control, B2M to ensure the B2M probe worked in the presence of antibodies on 1x106 
cells (figure 5-16). 
 
 
Figure 5-16 -PrimeFlow-RNA assay for B2M positive control. All lymphocyte subsets were stained with isotype controls 
together with the positive control for the mRNA ISH, B2M.  
 
Having established an appropriate set of cell surface fluorophores on healthy donor PBMCs, and 
given the healthy donor PBMCs showed a very small EBV load (<500 EBV copies per million B-
cells), it was inappropriate to test the EBER probe set directly on donor PBMCs.  We therefore 
went ahead and performed the cell surface staining and the EBER-ISH on the patient’s PBMCs. 
Figure 5-17 shows the results of the combined analysis of EBER expression by ISH with cell 
surface staining.  The top panel shows lymphocyte gating by forward and side scatter.  As with 
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all HLH cases we have previously observed, the percentage of monocytes in the peripheral 
blood had increased significantly.  The bottom panel shows the results of the dual staining, and 
demonstrates that the EBV-positive population in this case is the CD4+ T-cells, and that there is 
no significant EBER expression in any of the other lymphocyte subsets, including CD19+ B-cells.  
Importantly, the EBER-positive population and the EBER negative populations are separated by 
approximately one log of fluorescence, eradicating the worry about assay sensitivity and 
subjective interpretation of results.  One small issue remains to be resolved.  There are minor 
compensation issues with the CD3-AF700 and EBER-APC as seen in figure 5-18, bottom right-
hand panel.  When taking this assay forward, it will be preferable to substitute the AF-700 for an 
alternative, more suitable fluorophore. 
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Figure 5-17 - PrimeFlow-RNA assay on PBMC from an EBV-associated HLH patient.  (a) PBMC were analysed by FSC and SSC to 
identify the lymphocyte subsets and to provide the appropriate gating strategy. (b) The lymphocyte subsets were stained for 
specific subset markers and subjected to the PrimeFlow-RNA protocol to detect the presence of EBERs. The lymphocyte 
subset infected with EBV was the CD4
+
 cells. 
 
Finally, figure 5-18 shows the results of ISH for B2M and cell surface staining.  All cell subtypes 
are positive for B2M, as expected. 
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Figure 5-18 - PrimeFlow-RNA assay on PBMC from an EBV-associated HLH patient.  The lymphocyte subsets were stained for 
specific subset markers and subjected to the PrimeFlow protocol to detect the presence of the positive control mRNA B2M.  
As shown, all the subsets were positive for B2M. 
 
Interestingly we were able to follow the progress of this patient after HLH-2004 treatment.  
Figure 5-19 shows the results of the PrimeFlow RNA performed on PBMCs from the same 
patient 2 months following HLH-2004 treatment.  This shows that although the patient 
remained symptom-free, EBV-positive CD4+-T cells remained in the blood of the patient and 
furthermore, the number of EBV-positive cells appeared to be expanding from 52% of CD4+ cells 
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2 weeks following treatment, to 72% at 2 months following treatment.  The patient had, in the 
meantime, received a diagnosis of CAEBV, which can be presumed to be the trigger for the HLH.  
 
Figure 5-19 - PrimeFlow-RNA assay on PBMC from an EBV-associated HLH patient 2 months following HLH-2004 treatment. 
PBMC from the HLH patient were subjected to PrimeFlow-RNA to determine the % of EBER-positive CD4
+
-T cells following 
HLH-2004 treatment.  
We re-analysed the patient PBMC sampled prior to treatment using an antibody panel 
employing a PE-Cy5-conjugated CD4 antibody that unfortunately did not work.  However, we 
were able to ascertain from the CD3 and CD8 staining that the percentage of EBER-positive 
CD4+-T cells was 12%.  Table 5-2 gives a breakdown of the expansion of the EBV-positive CD4+-T 
cells and indicated an expansion of the CD4+ cells as a percentage of total lymphocytes.  
Unexpectedly, we observed that instead of reducing the number of EBV-positive CD4 T cells in 
the PBMC, treatment with the HLH-2004 protocol was associated with an expansion of the EBV-
infected CD4+ T cells. 
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 PRE-HLH 2004 2 WEEKS 
POST HLH 2004 
2 MONTHS 
POST HLH 2004 
% EBER positive CD4 12% CD4 52% CD4 72% CD4 
% CD4 total 30% 50% 82% 
Table 5-2 – Expansion of the CD4
+
, EBV-positive T-cell population in the patient after HLH-2004 treatment.  The percentage of 
CD4
+
 cells infected with EBV rose from 12% to 72% over this period, and CD4
+
 cells represented 82% of the total PBMCs by 2 
months after treatment. 
We have previously demonstrated that EBV-infected T cells or NK cells present in the PBMC of 
HLH patients only express the viral EBERs.  However, now that we have developed an assay to 
identify the EBV-infected subset directly from patient PBMC, we were able to purify the EBV-
positive cells and examine the viral gene expression.  We therefore isolated RNA from the CD4+ 
T-cells from the pre-treatment, the 2 weeks post treatment and the 2 months post treatment 
samples.  We performed Q-RT-PCR for the viral mRNA transcripts EBNA-1 from the Q-promoter 
(Qp), LMP1, LMP2A, LMP2-TR, EBNA-2 and BZLF1.  Figure 5-20 shows the results of these 
analyses.  Similarly to that previously demonstrated, we did not detect EBV transcripts in the 
pre-treatment cells other than the EBERs.  However, in both post-treatment samples we were 
able to detect reliable levels of EBNA-1 from the Q-promoter (Qp), LMP1, LMP2A and the novel 
LMP2B-TR transcript.  These levels are small, and by comparison with published work (38) this 
suggests that they may be expressed in only a subset of the EBER-positive cells.  Not 
surprisingly, we were unable to detect EBNA-2 transcripts, given they are B cell-specific.  
Additionally, we were only able to detect vanishingly small levels of BZLF2 transcripts, indicating 
the infected cells are not entering lytic replication.  This is important in the context of the 
expansion of the infected cells following treatment.  
209 
 
 
 
 
 
Figure 5-20 - Analysis of EBV transcripts in the HLH case before, 2 weeks post and 2 months post treatment.  Viral transcripts 
were measured by Q-RT-PCR and are represented as absolute viral transcripts per cell.  Given there was only one sample for 
each time point, the assays were performed in triplicate resulting in no standard deviation.  
  
When the CD4+ T-cell receptors were analysed by the clinical team, there was a significant 
population with identical rearrangements, indicating that the disease represents a clonal 
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expansion of a single EBV-infected cell.  This reinforces the hypothesis that EBV infection in non-
B-cell disorders is an early event. 
5.7 Discussion 
 
The total number of patient PBMCs used in this final experiment was only 2x106, compared to 
20x106 for conventional cell sorting and QPCR.  This technique has the potential to revolutionise 
the way in which EBV-associated disorders are diagnosed.  As discussed earlier, the clinical 
criteria for EBV-associated HLH are ill-defined, and the analysis of which lymphocyte subset is 
infected is vital for the correct diagnosis as well as management; anti-B-cell antibodies, as used 
in PTLD, will not be effective if the offending population is CD20 negative.  We propose a 
strategy by which we are able to offer quick and reliable testing on small numbers of cells, 
foreseeing a future in which it is used routinely in a clinical setting. 
The combination of ISH and cell surface staining can also be exploited for further therapeutic 
purposes.  The presence or absence of druggable targets on the infected cell population can be 
quickly determined, allowing the rapid deduction of an appropriate personalised regimen.  For 
example, CCR4, a chemokine receptor, has been detected on the surface of ENKTL cells(424); a 
monoclonal antibody to it, Mogamulizumab, has shown promising results when used to treat 
cutaneous T-cell lymphoma (425) and is a potentially useful agent.  Another example is the 
Programmed Death Ligand (PD1) pathway (reviewed in (426)).  Ligation of PD-1, a molecule 
found on the surface of effector T-cells (as well as other immune cells), results in suppression of 
their action and contributes to a “tumour-permissive” environment (427); PD1 ligand 1 (PD1-L1) 
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is upregulated by LMP1 (428) and is expressed on NKTL (429).  This pathway is the subject of 
intense scrutiny and it is likely that it will become a major target for pharmaceutical 
intervention; by analysing the expression of the relevant proteins on the EBV-infected cell, the 
suitability of this could be determined for each patient. 
In summary, I have described a new technique for quickly and reliably performing simultaneous 
ISH and cell surface staining for analysis by flow cytometry.  Unlike previous techniques, this is 
accurate using only 1x106 PBMCs, making it appropriate for use in the paediatric population.  
Not only does this permit the rapid deduction of which lymphocyte subset is infected with EBV, 
it also allows further analysis of the characteristics of the infected cells and could contribute 
significantly to the speedy selection of appropriate treatment regimens. 
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CHAPTER 6 - CONCLUSIONS AND FURTHER WORK 
 
Despite the wealth of information about EBV in B-cell conditions, its role in T- and NK-cell 
disorders remains remarkably enigmatic.  This can be attributed to several factors – the relative 
rarity of these diseases, their geographic distribution outside the West, and, perhaps most of all, 
the difficulty in reproducing them in vitro.  I have demonstrated three approaches to studying 
these conditions – at a molecular level, by using cell lines, and by systematically recruiting and 
effectively investigating the clinical cases that are encountered. 
LMP1 is the most obvious candidate for a pathogenic protein in ENKTL.  It has well-described 
oncogenic functions (6, 42, 73) and is expressed (although to variable degrees) in ENKTL 
specimens (51, 52, 57).  When microarray analysis of the effects of its expression in primary NK 
cells was undertaken, 109 genes were significantly upregulated and 146 downregulated.  
Further analysis of these genes revealed that pathways involved in response to cellular stress 
and cell cycle were significantly enriched, which is in keeping with the known effects of LMP1 on 
epithelial and B-cells. 
However, when the specific genes altered were compared with published data, there was no 
significant overlap between the gene expression profile induced by LMP1 in NK cells, B-cells and 
epithelial cells.  This is not altogether surprising as the cell backgrounds are very different, and 
on further analysis of the published data we have shown that the gene expression profiles 
engendered by LMP1 are not similar when B-cells and epithelial cells are compared, suggesting 
a very specific, cell-type dependent, role for the protein in these malignancies. 
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Most interestingly, there is a significant overlap in genes differentially regulated by LMP1 in 
primary NK cells and those expressed in ENKTL samples compared to uninfected NK cells.  This is 
encouraging evidence that LMP1 is important in NK lymphomagenesis and/or maintenance of 
the established tumour phenotype.  The evidence may be even more convincing if we are able 
to ascertain which of the ENKTL samples were expressing LMP1; information that we have as 
yet been unable to extract from the authors of the original ENKTL study. 
LMP1 can also be seen to be important when cell lines are examined.  It is expressed, at varying 
levels, in most of the currently available ENKTL and CAEBV cell lines.  Endogenous LMP1 
expression correlates with survival upon IL-2 withdrawal – when cell lines were considered by 
LMP1 expression, intermediate levels of the protein were associated with a significant 
protection, despite the fact that LMP1 itself falls in the absence of the cytokine.  Cells expressing 
high levels of endogenous LMP1 were also less susceptible to apoptosis in response to 
etoposide, ionomycin and camptothecin.  Overexpression of LMP1 in one of the cell lines again 
resulted in protection from apoptosis as a result of IL-2 withdrawal.  This suggests an 
overlapping survival and proliferation pathway between the cytokine and the protein, which is 
in keeping with what is known about LMP1 function in B-cells.  However, overexpression of 
LMP1 was also associated with increased sensitivity to ionomycin and camptothecin, although 
interestingly not etoposide, in the cell lines examined. 
LMP2B is much less well-understood, even in the B- and epithelial cell contexts.  It is expressed 
in ENKTL tumours and cell lines (306) and, we can speculate, is likely to be important in 
lymphomagenesis.  However, upon microarray analysis, although the expression of 238 genes 
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was significantly altered by LMP2B expression in primary NK cells, this did not show significant 
overlap with the gene expression profile of ENKTL.  Overexpression in SNK10 and SNT16 
increased susceptibility to apoptosis in response to etoposide (although not significantly in 
SNK10), ionomycin and camptothecin; yet it provided some protection to both cell lines from 
apoptosis in response to cytokine withdrawal. 
Exploitation of the intrinsic pathway to induce apoptosis in malignant cells is an exciting field of 
pharmacological research.  This intricate web of interconnecting processes is disrupted in 
cancers, and by identifying the key proteins for a particular cell’s immortality, specific 
therapeutic regimens can be devised.  I have demonstrated the variability between expression 
of the BH3 protein family, even within the same diagnosis, giving further weight to the 
argument for BH3 profiling on clinical cases in order to be able to deliver targeted, appropriate 
and effective chemotherapy.   
Clinical cases of EBV-associated non-B-cell disorders are rare in the UK, and as a result it is 
difficult to systematically study their features.  We have an ongoing network of UK centres and 
have recruited several interesting patients as a result.  We have also set up a collaboration with 
the largest children’s hospital in Ho Chi Minh City to consider HLH in a cohort of patients with 
similar backgrounds and comorbidities.  In order to effectively use what can be very small 
samples, we have developed a technique of simultaneous in-situ hybridisation to the EBER 
transcript and cell surface staining; suitable for use on as few as 1x106 PBMCs.  This technique is 
capable of revolutionising the way in which these conditions are studied and treated. 
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The work in this field is ongoing.  Immediate challenges are to subject further patient samples to 
the PrimeFlow RNA technique and validate it with more conventional methods.  Other cell 
surface markers must be worked up in order to investigate the targeting of novel molecules and 
pathways in these conditions.  Further investment in the Vietnamese laboratories should enable 
this study to be restarted, and this collaboration is a promising one for both sides of the 
agreement.  The PrimeFlow technique will be particularly appropriate for these tiny samples.  
Furthermore, we have applied to extend our UK study to include paediatric cases, which will 
allow direct comparison with the Vietnamese samples. 
The study of non-B-cell EBV infections is fascinating, offering as it does a unique opportunity to 
study the virus outside of its natural habitat.  It has the potential to answer many questions 
about the role of the viral proteins and how, and why, these cells get infected in the first place.  
The conditions discussed here are rare but devastating, and the clinical impact of work in this 
field is potentially life-saving.  
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